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SUMMARY
Seven proteins encoded by herpes simplex virus have been shown to be essential for 
the replication of virus DNA and for virus growth. This study is concerned with two 
of these proteins: Pol and UL42. Pol is the catalytic subunit of DNA polymerase 
and is encoded by gene UL30; UL42 is an accessory protein which serves to 
increase polymerase processivity and is encoded by gene UL42. Together these two 
proteins form the polymerase holoenzyme, and evidence suggests that the interaction 
between them is an essential one and hence a potential target for antiviral drugs.
To identify regions of the UL42 protein of herpes simplex virus type 1 which may 
affect viral DNA polymerase activity, a series of 96 overlapping pentadecapeptides 
spanning the entire 488 amino acid residues of the UL42 protein were synthesised 
and tested for their ability to inhibit polymerase activity on a primed single-stranded 
M l3 DNA template. Two assays were used: (i) formation of full length double­
stranded M13 molecules; (ii) rate of incorporation of deoxyribonucleoside 
triphosphates. Both of the assays were optimised to ensure that any inhibition by the 
peptides would be detected.
Peptides from five non-contiguous regions of the UL42 protein were found to inhibit 
polymerase activity in both the presence and absence of the UL42 protein. The most 
active peptides from each region correspond to amino acid residues 23 to38 (peptide 
6), 64 to 78 (peptide 14), 89 to 102 (peptide 19), 229 to 243 (peptide 47), and 279 
to 293 (peptide 57). By two different methods (DNA mobility shift and DNA 
precipitation), peptides 14, 19, 47 and 57 were found to bind DNA; they most 
probably inhibit enzyme activity by this mechanism. Peptide 6 did not bind DNA 
and must act by some mechanism other than competing for DNA.
The inhibitory peptides were also tested for activity against mammalian polymerase a  
and the Klenow fragment of Escherichia coli polymerase. Although some limited 
specificity was demonstrated (up to 10-fold for peptide 6), all the peptides showed 
significant activity against both polymerase a  and E. coli polymerase.
UL42 peptides other than those which inhibited polymerase were also found to bind 
DNA. Twenty-six peptides were shown to have DNA-binding properties by gel 
mobility shift assay. Twenty-two of these were positively charged, suggesting that
non-specific electrostatic interactions were largely responsible for the observed 
binding.
There is evidence that the carboxy-terminus of Pol is required for the formation of a 
functional complex with UL42. Two peptides spanning the carboxy-terminal 42 
amino acid residues of Pol were tested for their ability to inhibit the processivity of 
the Pol-UL42 holoenzyme. They had no detectable effect.
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INTRODUCTION
1. The Herpesviruses
1.1 Description and classification
Herpesviruses are found in a wide variety of host species, ranging from fish to 
humans (reviewed by Roizman, 1990). Membership of the family Herpesviridae is 
based on the structure of the virion. A herpes virion consists of a double stranded 
DNA genome contained in an icosahedral capsid 100-1 lOnm in diameter; the capsid 
is surrounded by an amorphous proteinaceous layer of tegument which in turn is 
enveloped in a lipid membrane containing glycoprotein spikes.
Although they differ widely in their pathogenic potential, herpesviruses share several 
important biological properties. Their most notable feature is the ability to persist in 
a latent form in an infected individual; following an initial infection the viral DNA 
remains in a quiescent state in specific tissues of the host organism, from which it 
can be re-activated to produce a lytic infection. Most studies on latency have been 
carried out on herpes simplex virus type 1 (reviewed by Stevens, 1989; Ho, 1992). 
Other biological features common to all herpesviruses are as follows:
1) They encode many virus-specific enzymes, particularly those involved in nucleic 
acid metabolism and DNA replication.
2) Synthesis of viral DNA and assembly of capsids takes place in the nucleus.
3) Production of infectious virus always results in death of the infected cell.
Members of the family Herpesviridae are divided, mainly on the basis of their 
differing biological properties, into three sub-families:
Alphaherpesvirinae  are neurotropic viruses which establish latent infections 
primarily in sensory ganglia. They are relatively fast-growing and have a variable 
host range in tissue culture and experimental animal systems. Members of this sub­
family include herpes simplex virus type 1 and type 2 (HSV-1, HSV-2), varicella-
1
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zoster virus (VZV), pseudorabies virus (PRV) and equine herpes virus type 1 (EHV- 
1).
Betaherpesvirinae are slow-growing viruses with a restricted experimental host 
range. Infected cells in culture may fuse to form giant cells or cytomegalia. They 
can establish latency in secretory glands, lymphoreticular cells, kidneys and other 
tissues. Members of this class include human cytomegalovirus (HCMV) and murine 
cytomegalovirus (MCMV).
Gammaherpesvirinae are lymphotropic viruses which infect and establish latency 
in T or B lymphocytes. They have a very restricted host range in experimental 
animals. Members of this sub-family include Epstein-Barr virus (EBV) and 
herpesvirus saimiri (HVS).
The complete sequences have been published of EBV (Baer et al, 1984), VZV 
(Davison & Scott, 1986), HSV-1 (McGeoch et al 1985, 1986, 1988b; Perry & 
McGeoch 1988), HCMV (Chee et al, 1990), EHV-l(Telford et al, 1992), HVS 
(Albrecht et al, 1992), and channel catfish virus (Davison, 1992). Partial sequence 
data are available for many others. These data allow a re-evaluation, based on 
conservation of gene arrangement and coding content, of the original classification. 
On the whole, a high degree of genetic relatedness is found to be reflected in similar 
biological characteristics, confirming the original groupings, but there are 
exceptions. The sequence of Marek's disease virus places it in the 
alphaherpesvirinae, but its biological properties more closely resemble those of the 
gammaherpesvirinae (Buckmaster et al, 1988). Human herpesvirus 6 (HHV-6), 
being a lymphotropic virus, would also appear to belong in the gammaherpesvirinae, 
but in fact its genome structure and sequence is closely related to HCMV, the 
prototype betaherpesvirus. The sequencing of channel catfish virus (CCV), 
classified on the basis of morphology and biology as an alphaherpesvirus (Roizman, 
1982), showed it to be completely unrelated to the herpesviruses of higher 
verterbrates (Davison, 1992). Thus, on the basis of the genetic data, CCV 
constitutes a new subfamily, or possibly a new virus family altogether.
1.2 Pathology and epidemiology of human 
herpesviruses
Seven herpesviruses which infect man have been identified to date: HSV-1, HSV-2, 
VZV, EBV, HCMV, HHV-6 and human herpesvirus 7 (HHV-7). They appear to be 
ubiquitous, and serological studies show that a large proportion of people throughout
2
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the. world have been exposed to and may be latently infected with one or more 
herpesviruses.
HSV-1 and HSV-2 (reviewed by Whitley, 1990), usually cause cold sores and 
genital lesions, respectively. Primary infection can be asymptomatic or result in 
virus replicating at the site of infection to form a localised lesion. Virions are 
transported via the axons to the sensory ganglia that innervate the site of infection. 
The virus thereafter remains in a latent state in the ganglia, and can reactivate 
spontaneously to produce recurrent infection. The frequency of reactivation is 
increased by physical or emotional stress, fever, exposure to bright sunlight or UV 
light, tissue damage or immune |suppression. The virus can occasionally cause 
encephalitis or disseminated disease in newborn infants. HSV-2 has long been 
suspected of an association with cervical carcinoma but, despite numerous studies, 
its role as a causative agent of transformation is not clear.
VZV infection (reviewed by Gelb, 1990) has two distinct clinical manifestations: 
chickenpox (varicella) and shingles (zoster). Varicella represents the primary 
infection, usually in childhood; zoster is caused by reactivation later in life of virus 
from sensory ganglia, and is limited to the skin innervated by a single sensory 
ganglion. The most common complication of herpes zoster is postherpetic neuralgia 
(pain lasting over a month).
EBV (reviewed by Miller, 1990) infects B lymphocytes in the peripheral blood and 
lymphoid organs, causing infectious mononucleosis or 'glandular fever’. EBV is 
also associated with two specific cancers: Burkitt’s lymphoma, a tumour affecting 
children in East Africa, and nasopharyngeal carcinoma, which has a high incidence 
in southern China.
HCMV infections (reviewed by Alford & Britt, 1990) are most often asymptomatic, 
and latency is established in the absence of any associated disease. Virulence is seen 
only in the absence of a competent immune system. The virus is a threat in utero, 
since it has the ability to cross the placenta and cause congenital infection which can 
lead to birth defects. It is frequently reactivated after organ transplants. It is one of 
the more common opportunistic infections associated with AIDS, and acts as a co­
factor in AIDS progression.
HHV-6 (reviewed by Lopez & Honess, 1990) is a lymphotropic virus acquired by 
most individuals during their first two years of life. It can cause exanthem subitum, 
a mild fever and rash, but in most cases seroconversion is asymptomatic.
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HHV-7 was recently isolated from the T lymphocytes of a healthy individual 
(Frenkel et al, 1990). The virus has not yet been associated with a known disease.
The virulence of all these viruses is generally controlled by an intact immune system, 
but they are able to cause serious disease in immunocompromised individuals. 
Therefore, with the use of immunosuppressive drugs for the control of malignant 
disease, the increase in organ transplants, and the advent of AIDS, they pose a 
growing problem.
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2. Herpes Simplex Virus Type 1
2.1 The structure and content of the HSV-1 
genome
The HSV-1 genome is a linear DNA molecule about 152kbp in length and comprises 
a long (L) and a short (S) region, which are covalently linked. The long region 
consists of a unique sequence (U l) flanked by a repeat element (Rl); the terminal 
(TR l) and internal (IRl) copies of the repeat are oriented in oppos ite directions 
(Sheldrick & Berthelot, 1974). The short region similarly consists of IRs, Us and 
TRs (Figure la). The sequences of R l and Rs are distinct, and contain short tandem 
reiterations which vary in number (Davison & Wilkie, 1981; Rixon et al, 1984; 
McGeoch et al, 1988b; Perry & McGeoch, 1988). At the very ends of the genome 
there is a 400bp direct repeat called the a sequence, of which one or more copies are 
also found in an inverted orientation at the junction between L and S (Roizman, 
1979; Davison & Wilkie 1981). The genome terminates at each end with an 
unpaired base which has a free 3'-hydroxyl group (Mocarski & Roizman, 1982). 
During DNA replication the L and S segments can adopt different relative 
orientations, so that HSV DNA isolated from virions is composed of equimolar 
amounts of four isomers (Figure la) (Hayward et al, 1975; Wilkie, 1976; Delius & 
Clements, 1976; Roizman, 1979). The average base composition of HSV-1 DNA is 
68.3% G+C (McGeoch etal, 1988b).
The complete sequence of the HSV-1 genome has been determined (McGeoch et al 
1985, 1986, 1988b; Perry & McGeoch 1988). The original analysis (McGeoch 
al, 1988b) identified a total of 72 genes encoding 70 distinct proteins (Figure lb). 
Since then, three additional ORFs have been identified and designated according to 
their position: UL26.5 (Liu & Roizman, 1991a, b), UL49.5 or 49A (Barker & 
Roizman, 1992; Barnett et al, 1992), and Yi34.5 or RL1 (Chou & Roizman, 1990; 
McGeoch et al, 1991; Dolan et al, 1992). In addition, a region of R l encodes the 
latency associated transcripts (LATs), which are the only viral transcripts detectable 
in latently infected cells (Stevens et al, 1987; Wagner et al, 1988; reviewed by 
Fraser et al, 1992). The products of over 50 genes have been identified and
5
Figure 1. Organization of the HSV-1 genome.
a. A representation of HSV-1 DNA as two covalently joined segments, L and S. 
Unique sequences (U l and Us) are shown as solid lines, and major repeat elements 
(T R l and IR l, IRS and TRs) as open boxes. Terminal a sequences and the internal, 
opposite orientation a' sequence are indicated. The relative orientations of the L and S 
segments in the four isomers are indicated by the four lines of arrows. These are 
designated P (an arbitrary prototype), Is (inverted S), I I  (inverted L) and I l s  (both 
inverted). Reproduced from McGeoch, 1987.
* 3 4 .5
RL1A i  IE110 12 3 6 7 10 15
___
LAT 4 5 8 9 11 12 13 14 16 17 18 19
21 24 25 26 26.5 30
34
33 35
—
20 22 23 27 28 29 Ori^ 31 32 36
38 39 40 42 43 44 45 50 52 53 54 55
37 41 46 47 48 49 51 
49.5 
49A
56
LAT 1 3 4 5 6 7 8 9 
» ► IE 175
IE IK) |  V Y134.5 IE175 2
RL1 O n,
t t ^ O r U  11 S
b. The genome in the P orientation, represented on four lines. The locations of open 
reading frames are shown by arrows, with splicing within coding regions indicated. 
In the top four lines, genes UL1—UL56 are shown as 1—56, and, in the bottom line, 
genes US 1—US 12 as 1—12. Locations of origins of DNA replication are indicated. 
Reproduced from McGeoch, 1989, with the addition of UL26.5 (Liu & Roizman, 
1991a, b), UL49.5/49A (Barker & Roizman, 1992; Barnett et al, 1992), yi34.5/RLl 
(Chou & Roizman 1990; McGeoch et al, 1991; Dolan et al, 1992), and LATs 
(Stevens et al, 1987; Wagner etal, 1988).
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characterised, and their functions in the viral life cycle determined to varying extents, 
as described in the following sections.
2.2 The Lytic Cycle
2.2.1 Attachment and penetration
HSV-1 enters cells by a pH-independent fusion of the virion envelope with the cell 
plasma membrane (Morgan eta l, 1968; Para et al, 1980; Wittels & Spear, 1991). 
This is a complex, multi-step process mediated by specific interactions between 
components of the virion envelope and the cell surface (reviewed by Marsden, 1987; 
Spear, 1992).
HSV-1 specifies the synthesis of ten glycoproteins (ULl-gL, UL22-gH, UL27-gB, 
UL44-gC, UL53-gK, US4-gG, US5-gJ, US6-gD, US7-gI and US8-gE), which are 
probably all found in the virion envelope. The architecture of the envelope is not 
well understood, but high resolution electron microscopy of virions shows at least 
two kinds of projections: rod-like spikes about 14nm long, and short "fuzzy" 
material (Stannard et al, 1987). Use of gold-labelled monoclonal antibodies (MAbs) 
showed that the long spikes are composed of gB, and at least some of the shorter 
protrusions are gD, while gC extends even further than gB from the surface of the 
envelope (Stannard et al, 1987). There is evidence for specific associations between 
pairs of glycoproteins, which probably reflect a functional interaction: gl and gE can 
be coprecipitated from extracts of infected cells with antibodies specific for either, or 
with normal IgG (Johnson & Feenstra, 1987; Johnson etal, 1988). The formation 
of a stable complex between gH and gL is required for their correct processing and 
cell surface expression (Hutchinson etal, 1992). A number of other HSV-1 gene 
products (UL10, UL20, UL34, UL43, UL45 and UL49A) are predicted from their 
characteristic hydropathy profiles to be membrane proteins, but they are still poorly 
characterised.
The initial step in attachment is an interaction with the heparan sulphate which is 
covalently linked to cell surface proteoglycans (WuDunn & Spear, 1989; Shieh et al, 
1992). [Heparan sulphate is one of the most common sulphated glycosaminoglycans 
found on the cell surface (Kjelldn & Lindahl, 1991).] Cells that fail to produce 
heparan sulphate, or that have been stripped of it, are highly resistant to HSV 
infection (WuDunn & Spear, 1989; Shieh etal, 1992). Both heparin (Nahmias &
6
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Kibrick, 1964) and heparin-binding proteins (WuDunn & Spear, 1989; Kaner et al,
1990) can block the binding of virus to the cell surface.
There is evidence that gC, which has an affinity for heparin (WuDunn & Spear,
1989), plays a role in the initial attachment, since virions lacking gC adsorb more 
slowly to cells than wt virions (Langeland et al, 1990; Herold et al, 1991). 
Although it facilitates attachment, gC is not essential for this process, and gC~ 
mutants can still infect cells (Heine et al, 1974; Langeland et al, 1990; Herold et al,
1991). Neomycin and polylysine inhibit infectivity, at least in part by blocking 
binding of the virus to a cellular receptor (Langeland et al, 1987, 1988). These 
compounds block the attachment of both wt and gC~ virus, and therefore affect a 
receptor-ligand interaction which is independent of gC (Campadelli-Fiume, 1990; 
Langeland etal, 1990).
Glycoproteins B, D and H are essential for virus growth in cell culture. [The 
recent finding that gL is essential for correct expression of gH (Hutchinson et al,
1992) would imply that it too is an essential glycoprotein.] Virus mutants with 
lesions in the genes for gB (Sarmiento et al, 1979; Little et al, 1981; Cai et al,
1988), gD (Ligas & Johnson, 1988), or gH (Desai et al, 1988; Forrester et al, 
1992), have severely reduced infectivity, but can still attach to cells, indicating that 
these glycoproteins are required for some other step. There is evidence that gD may 
stabilise attachment by interacting with a specific cell surface receptor, since gD-  
virions are unable to block superinfection by wt virus (Johnson & Ligas, 1988), and 
soluble gD blocks infection (Johnson DC et al, 1990). Arrest of virus penetration by 
gH-specific MAbs suggests that gH initiates membrane fusion (Fuller & Lee, 1992). 
Numerous experiments with syn (syncytial) mutants indicate that gB, gD, gH, gL, 
UL20, UL24 and possibly gK are involved in membrane fusion (reviewed by Spear, 
1992). The cell surface molecules with which they interact remain to be identified.
It was recently reported that the basic fibroblast growth factor (bFGF) receptor was a 
specific portal of entry for HSV (Kaner et al, 1990; Baird et al, 1990), but this has 
now been disproved (Shieh & Spear, 1991; Mirda et al, 1992; Muggeridge et al, 
1992). The observed effects were probably due to the interaction of bFGF with cell- 
surface heparan sulphate (Burgess & Maciag, 1989; Shieh & Spear, 1991; 
Muggeridge etal, 1992).
Having entered the cell, the capsid is transported, possibly via the microtubules 
(Kristensson et al, 1986), to the nuclear pores, and the viral DNA is released into the 
nucleus. A function essential for this process has been mapped to a region within 
UL36, which encodes the tegument protein VP1 (Batterson et al, 1983).
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2.2.2 Effects on host cell macromolecular synthesis
Several components of the virion, apart from the viral genome, influence the course 
of infection. One effect of infection is the inhibition of cellular protein, RNA and 
DNA synthesis, which can be seen within an hour of infection. As infection 
proceeds, the synthesis of host cell macromolecules steadily declines and the 
synthesis of virus-specific material increases (reviewed by Fenwick, 1984). The 
first phase of the "host shutoff' is mediated by a component of the virion, and does 
not require viral gene expression (Fenwick & Walker, 1978). A later phase of host 
shutoff, which reduces the remaining levels of host protein synthesis, is dependent 
on the expression of viral genes (Fenwick & Clark, 1982).
The immediate effect of virion host shutoff is the disaggregation of cellular 
polyribosomes (Sydiskis & Roizman, 1966, 1967; Nishioka & Silverstein, 1978) 
and the degradation of cellular mRNA (Fenwick & Walker, 1978; Schek and 
Bachenheimer, 1985). Several vhs mutants have been isolated, which fail to induce 
early shutoff, but are not defective in the secondary shutoff function (Fenwick & 
Clark, 1982; Read & Frenkel, 1983). In cells infected with one such mutant, vhsl, 
the half-lives of all mRNA species examined — both viral and cellular — are longer 
than in cells infected with wt virus (Oroskar & Read, 1989). This indicates that the 
vhs function reduces the stability of all mRNAs, without discriminating between 
cellular and viral messages, and may thus contribute to the downregulation of early 
viral gene expression as infection proceeds (Oroskar & Read, 1989).
The vhs function is mediated by the product of gene UL41 (Kwong et al, 1988; 
Fenwick & Everett, 1990; Smibert & Smiley, 1990), a 58kDa protein, found in 
virions (Smibert et al, 1992), and more precisely in the tegument (McLauchlan et al, 
1992a). It is not, however, an essential structural component (Fenwick & Everett,
1990).
The vhs function of most HSV-2 strains is more potent than that of HSV-1 (Schek 
and Bachenheimer, 1985), but for strain 17+ of HSV-1 and strain HG52 of HSV-2, 
the converse is true. The lack of shutoff by HG52 is due to a frameshift mutation 
within the UL41 coding sequence, which results in a truncated protein (Everett & 
Fenwick, 1990).
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2.2.3 Regulation of gene expression
HSV-1 genes are expressed in a temporally-controlled way, and have been 
designated a, p and y (Honess & Roizman, 1974), or immediate early (IE), early (E) 
and late (L) (Clements et al, 1977). Experiments using metabolic inhibitors showed 
that IE genes are transcribed in the absence of viral protein synthesis, whereas 
transcription of early genes requires de novo protein synthesis, and that of late genes 
requires viral DNA synthesis (Honess & Roizman, 1974, 1975; Clements et al, 
1977; reviewed by Wagner, 1985, 1991). This is, however, a generalisation, and 
not all genes fall neatly into these groupings. The late genes are subdivided into two 
classes: leaky-late (Py, yO and true-late (y2). Both require DNA replication for 
maximal expression, but leaky-late genes are expressed at detectable levels before the 
onset of DNA replication, whereas true-late genes are not (Wagner, 1985). In 
general, IE genes encode transcriptional regulators, E genes encode proteins 
involved in DNA replication — all the replication proteins and nucleotide metabolism 
enzymes fall into this category, while L gene products are virion structural and 
assembly proteins. There are, however, exceptions to this generalisation. For 
example, US11 is expressed as a true-late gene (Johnson et al, 1986), but the 
product is not found in virions (Marsden et al, 1976); R l, the large subunit of 
ribonucleotide reductase (Preston VG et al, 1984) is regulated as an IE protein 
(Clements et al, 1980; Wymer etal, 1989).
2.2.3.1 a-TIF
The first effector in the cascade of transcriptional activation is a virion protein 
(Batterson & Roizman, 1983). This rrarc.y-inducing factor is encoded by gene UL48 
and was identified as Vmw65 (a-TIF, VP 16) (Campbell et al, 1984; Dalrymple et 
al, 1985; Pellet et al, 1985), a 65kDa phosphoprotein which is a major component 
of the tegument (Marsden et al, 1978; Roizman & Furlong, 1974; Szildgyi & 
Cunningham, 1991; McLauchlan & Rixon, 1992). The effect of a-TIF is to induce 
transcription of the IE genes by cellular RNA polymerase II (Post et al, 1981; 
Batterson & Roizman, 1983; Campbell etal, 1984).
All the IE gene promoters contain one or more copies of a far-upstream element with 
the sequence TAATGARAT (R=purine) which is necessary for a-TIF transactivation 
(Mackem & Roizman, 1982; Murchie & McGeoch, 1982; Cordingley eta l, 1983; 
Campbell et al, 1984). The a-TIF, which in isolation does not bind to DNA
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(Marsden et al, 1987), associates with cellular factors to form a complex that binds 
specifically to the TAATGARAT motif (Preston CM et al, 1988; O'Hare & Goding,
1988). One of the factors in this complex is the cellular protein OTF-1 (OCT-1, 
NFIII, TRF), which normally binds to an octamer motif similar to TAATGARAT 
(O'Hare et al, 1988; Gerster & Roeder, 1988). It appears that a-TIF alters the 
specificity of OTF-1, so that it binds to the viral cw-acting element (O'Hare et al, 
1988; Gerster & Roeder, 1988; Aphrys et al, 1989). Mutational studies have 
shown that the acidic C-terminal domain of |a-TIF is responsible for the 
transactivation (Sadowski etal, 1988; Triezenberg etal, 1988; Greaves & O'Hare,
1989), while N-terminal residues are required for complexing with cellular proteins 
(Ace et al, 1988; Triezenberg et al, 1988; Greaves & O'Hare, 1990).
The IE genes contain other upstream c/s-acting elements, apart from the 
TAATGARAT motif, which enhance their transcription even in the absence of a-TIF 
(Lang et al, 1984; Preston CM et al, 1984; Kristie & Roizman, 1984). Experiments 
with UL48 mutants confirm that a-TIF is not absolutely required for the initiation of 
infection, although it greatly increases its efficiency, especially at low m.o.i. (Ace et 
al, 1989).
2.2.3.2 The IE genes and their products
Several nomenclatures exist for the IE genes and their products. The most 
commonly used are listed in Table 1.
Table 1. The IE genes of HSV-1 and their products
Glaseow nomenclature Chicago nomenclature
Gene* Genet Product Gene Product
IE-1 IE110§ VmwllO a0 ICPO
IE-2 UL54 Vmw63 a l l ICP27
IE-3 IE175§ Vmwl75 a4 ICP4
IE-4 US1 Vmw68 a22 ICP22
IE-5 US12 Vmwl2 a47 ICP47
UL39 R1 ICP6
* Original designation (Clements et al, 1979).
t  Later designation in complete HSV-1 sequence (McGeoch et al, 1988b).
§ IE110 and IE175 are located in the terminal and internal repeats (Figure lb).
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All the IE polypeptides except Vmwl2 are phosphorylated proteins which are found 
in the nucleus (Pereira et al, 1977; Hay & Hay, 1980; Marsden et al, 1982). The 
functions of Vmwl2 and Vmw68 are poorly understood; VmwllO, Vmwl75 and 
Vmw63 control the expression of E and L genes (reviewed by Everett, 1987; 
Wagner, 1991).
Vmwl75 is considered to be the major regulatory protein of HSV-1. It is required 
for the activation of E and L promoters (Preston, 1979; Everett, 1984a, 1984b; 
DeLuca, 1985; Gelman & Silverstein, 1985; O'Hare & Hayward, 1985a; DeLuca 
& Schaffer, 1985; Quinlan & Knipe, 1985) and is essential for viral growth 
(Preston, 1979). It also represses its own synthesis and that of other IE gene 
products (O'Hare & Hayward, 1985b; DeLuca & Schaffer, 1985).
The accumulated evidence from many studies indicates that Vmwl75 acts by binding 
to DNA at specific sites and interacting with cellular transcription factors. It binds to 
the sequence ATCGTC, but also to other sequences, and a degenerate 13-base 
consensus has been proposed to more accurately describe the recognition site, of 
which there are over 500 copies throughout the HSV-1 genome (DiDonato et al,
1991). Binding of Vmwl75 at its own transcriptional start site is the likely 
mechanism of self-repression (Roberts et al, 1988; DeLuca & Schaffer, 1988), 
whereas binding within a promoter region leads to transcriptional activation (Tedder 
eta l, 1989).
The DNA-binding domain is located within a highly conserved region, 
encompassing about 230 amino acid residues, near the N-terminus of the protein. 
Mutations within this domain drastically affect transactivation, repression and DNA 
binding (Paterson & Everett, 1988a, 1988b; Shepard et al, 1989; Paterson etal,
1990). A polypeptide corresponding to this region retains the sequence-specific 
DNA-binding properties of the whole protein (Wu & Wilcox, 1991; Everett et al, 
1990, 1991a). The regions responsible for interactions with other proteins have not 
been clearly defined.
Vm wllO is a potent and promiscuous transactivator of gene expression (reviewed 
by Everett et al, 1991b). In transfection assays it activates transcription from IE, E 
and L promoters of HSV-1 (O'Hare & Hayward, 1985a, 1985b; Gelman & 
Silverstein, 1985; Quinlan & Knipe, 1985; Mavromara-Nazos, 1986; Everett,
1986), and from a variety of heterologous promoters, including the SV40 early 
promoter (O'Hare et al, 1986; Everett, 1988a) and the HIV LTR (Mosca et al,
1987).
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In some transfection systems, joint activation by Vmwl 10 and Vmwl75 is up to 20- 
fold greater than by either protein alone (Everett, 1984b), but the magnitude of this 
synergistic effect depends very much on the experimental conditions (Everett, 
1988b). Another indication that the two proteins may interact is the observation that 
ts mutations in Vmwl75 can affect the transport of Vmwl 10 into the nucleus (Knipe 
& Smith, 1986).
Vmwl 10 is not essential in tissue culture, but it confers a growth advantage on the 
virus (Stow & Stow, 1986; Sacks & Schaffer, 1987). An outstanding property of 
VmwllO is its ability to reactivate latent virus. In an in vitro latency system, 
Vmwl 10 alone can replace whole virus as the reactivating agent (Harris et al, 1989). 
However, its role in reactivation is not so clearly demonstrable in vivo, since virus 
lacking VmwllO is able to spontaneously reactivate from latently infected mouse 
ganglia, albeit more slowly than wt virus (Clements & Stow, 1989).
Vmw63 is essential for virus growth; lack of it results in overexpression of IE 
genes and very reduced expression of L genes (Sacks et al, 1985; McCarthy et al, 
1989; reviewed by Sandri-Goldin, 1991). In transfection experiments, Vmw63 has 
little effect on its own, but it can repress the transactivation of IE and E genes by 
Vmwl 10 and Vmwl75, and augment their transactivation of L genes (Everett, 1986; 
Sekulovich et al, 1988; Su & Knipe, 1989). It appears to be involved in the switch 
from early to late gene expression during HSV-1 infection. There is growing 
evidence that it acts post-transcriptionally (Smith et al, 1992; Sandri-Goldin & 
Mendoza, 1992), probably by selectively stimulating mRNA 3' processing of late 
gene polyA sites (McLauchlan et al, 1992b).
It is interesting that, unlike the IE genes, the E and L genes do not contain any virus- 
specific promoter sequences. The sequences required for transactivation by IE 
proteins are the same as those required for cis activation in the absence of viral 
products, and these sequences correspond to the binding sites of cellular 
transcription factors (Everett, 1984a, b; Eisenberg et al, 1985; McKnight & Tijan, 
1986; Johnson & Everett, 1986; Homa etal, 1988). Moreover, cellular genes, eg 
transfected copies of a rabbit p-globin gene,can be efficiently transactivated by HSV- 
1 IE proteins (Everett, 1984a, b, 1985). The mechanisms which determine 
activation of viral genes and concomitant repression of cellular genes during infection 
are still conjectural.
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2.2.4 Synthesis of viral DNA
2.2.4.1 Sites of DNA synthesis
Viral DNA synthesis starts three to five hours after infection and increases to a peak 
between nine and eleven hours after infection (Rixon et al, 1983). Initially, 
synthesis is localised to discrete sites within the nucleus, but these grow and coalesce 
as infection proceeds, until the entire nucleus of the infected cell is filled with 
replicating viral DNA (Rixon et al, 1983). The inital sites of viral DNA replication 
appear to be virus-specific structures induced by infection, and have been called 
"replication compartments" (Quinlan et al, 1984; reviewed by Knipe, 1989). They 
contain viral replication proteins (Quinlan et al, 1984; de Bruyn Kops, 1988; 
Goodrich et al, 1990; Bush et al, 1991), and also various host cell replication 
proteins, which relocate from sites of cellular DNA synthesis (Wilcock & Lane,
1991). Cellular replication protein A (RPA), proliferating cell nuclear antigen 
(PCNA), polymerase a , DNA ligase I, p53 and retinoblastoma protein are found in 
the viral replication compartments (Wilcock & Lane, 1991), but which, if any, of 
these are required to complete the HSV replication apparatus remains to be 
determined.
2.2.4.2 Replicative intermediates
Within 30 minutes of infection, the linear DNA genome loses its free ends, most 
probably by circularising (Jean & Ben-Porat, 1976; Jacob etal, 1979; Poffenberger 
& Roizman, 1985). With the onset of DNA synthesis, molecules of more than unit 
length appear (Jacob & Roizman, 1977; Hirsch et al, 1977). At later stages of 
infection, large, tangled masses of viral DNA can be seen (Jacob & Roizman, 1977; 
Ben-Porat & Rixon, 1979). Analysis by restriction enzyme digestion shows that this 
DNA consists of multiple head-to-tail concatemers (Jacob etal, 1979; Jongeneel & 
Bachenheimer, 1981). It is thought that the concatemeric DNA is generated by a 
rolling-circle mechanism of replication, like that of bacteriophage X (reviewed by 
Kornberg & Baker, 1992). Alternatively, it could arise by homologous 
recombination, which may be linked to replication, as in bacteriophage T4 (Formosa 
& Alberts, 1986; Mosig, 1987).
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2.2.4.3 Nucleotide metabolism enzymes
HSV-1 encodes many of the proteins required to replicate its DNA genome. These 
include proteins which are directly involved in DNA synthesis, and enzymes 
involved in nucleotide metabolism. The seven viral proteins which act directly at the 
replication fork are essential for the viral lytic cycle. (These, and the c/s-acting 
origins of replication, are described in Section 4.) In contrast, the enzymes involved 
in nucleotide metabolism are largely dispensable for viral replication in exponentially 
growing cultured cells, but may be essential for growth in animals and particularly in 
non-dividing cells such as neurones. This makes them potential targets for antiviral 
therapy (reviewed by Weller, 1991).
Thym idine kinase (TK) was one of the first virus-induced enzymes to be 
identified (Kit & Dubbs, 1963) and has been intensively studied since then. The 
HSV TK, unlike its cellular counterpart, phosphorylates not only thymidine (dT), 
but also deoxyuridine (dU), deoxycytidine (dC), thymidilate (dTMP), and a variety 
of nucleoside analogues, including acyclovir (Jamieson et al, 1974; Fyfe et al, 1978; 
Field et al, 1980). The specific antiviral action of acyclovir is due largely to its 
selective phosphorylation by the viral TK (Section 5.1).
Functional TK is not required for virus growth in dividing cells, but is necessary for 
growth in serum-starved cells (Jamieson et al, 1974). A requirement for the enzyme 
in vivo has not been so clearly demonstrated. Several studies have shown that tk~ 
virus has a reduced ability to establish latent infections in mice (Field & Wildy, 1978; 
reviewed by Price, 1985), whereas, in the guinea pig or rabbit, tkr  virus can 
establish reactivatable latent infections (Stanberry et al, 1985; Meignier et al, 1988). 
There is other evidence that TK may have a role in reactivation, but not in the 
establishment of latency (Coen et al, 1989a, 1989b; Efstathiou et al, 1989).
R ibonucleotide reductase (RR) maintains a pool of DNA precursors by the 
conversion of ribonucleotides to the corresponding deoxyribonucleotides (reviewed 
by Thelander & Reichard, 1979). The viral enzyme (Cohen, 1972) is composed of 
two non-identical subunits of 136kDa and 38kDa (Dutia, 1983; Bacchetti et al, 
1984; Frame etal, 1985), encoded by genes UL39 and UlAO, respectively (Preston 
VG et al, 1984; McLauchlan & Clements, 1983). Mutants with lesions in UL39 or 
UL40 are able to grow in cells under normal culture conditions, but not in resting 
cells, nor in cells at 39.5°C (Goldstein & Weller, 1988a, c; Preston VG et al, 1988). 
Studies in mice show that RR-deficient viruses are much less pathogenic than wt 
virus, and are unable to establish latent infections (Cameron et al, 1988; Jacobson et
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al, 1989; Brandt et al, 1991). Although care must be taken in extrapolating from the 
mouse model to human infections, since there is evidence that the growth of RR- 
deficient virus is more severely impaired in mouse than in human cells (Jacobson et 
al, 1989), recent experiments have demonstrated a requirement for the enzyme in 
primary human corneal fibroblast cultures (Brandt et al 1991). These observations 
have stimulated considerable interest in the potential of herpesvirus RR as an antiviral 
target, particularly since the viral enzyme can be specifically inhibited by subunit 
disruption (Section 6.2).
Deoxyuridine triphosphatase (dUTPase) catalyses the hydrolysis of dUTP to 
dUMP and pyrophosphate (Wohlrab & Francke, 1980). It reduces the intracellular 
concentration of dUTP and thus prevents the incorporation of uridine into DNA. 
The dUMP it generates can be converted to dTMP by thymidilate synthase. Mutants 
in UL50, the gene encoding dUTPase (Preston & Fisher, 1984), grow normally in 
exponentially growing and in serum-starved cells (Fisher & Preston, 1986). In a 
mouse in vivo model, dUTPase-deficient mutants are moderately attenuated for 
neurovirulence, neuroinvasiveness and reactivation from latency (Pyles et al, 1992), 
indicating a role for dUTPase in pathogenesis.
Uracil-DNA glycosylase is a DNA repair enzyme that removes uracil residues 
from DNA. These arise by the misincorporation of dUTP during replication, or by 
the deamination of cytosine, and lead to GC to AT transition mutations. The virus- 
specific enzyme, first reported by Caradonna & Cheng (1981), is encoded by gene 
UL2 (Caradonna et al, 1987; Mullaney etal, 1989). Disruption of the UL2 gene 
does not affect viral growth in cultured cells (Mullaney et al, 1989). Its requirement 
in vivo has not been tested, but the high degree of conservation between the 
homologous genes in VZV and EB V may indicate a role for uracil-DNA glycosylase 
in pathogenesis.
A lkaline nuclease, encoded by gene UL12 (Francke & Garrett, 1982; Moss,
1986), is a virus-specific deoxyribonuclease with an unusually high pH optimum 
(Morrison & Keir, 1968; Hoffman & Cheng, 1978; Francke et al, 1978). The 
precise role of this enzyme in the viral life cycle is unknown. Although initial studies 
suggested it might be required for DNA synthesis (Moss et al, 1979; Francke & 
Garrett, 1982; Moss, 1986), subsequent experiments showed that it was not, since a 
UL12 deletion mutant was able to synthesise wt levels of DNA and late viral proteins 
(Weller et al, 1990). This mutant produced very low numbers of infectious virions, 
indicating that the alkaline nuclease may be required for processing or packaging of 
virion DNA (Weller et al, 1990). It has been shown to form a specific complex with
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the major DNA binding protein, ICP8 (Vaughan e ta l, 1984; Thomas et al, 1988,
1992) (Section 4.5), but the significance of this interaction is not known.
2.2.5 Virion structure and assembly
The three structural components of the virion — capsid, tegument and envelope — 
are each composed of numerous proteins. More than half of the 73 genes of HSV-1 
code for proteins which are known or suspected to be present in the virion, or to 
participate in its assembly. (For reviews see Dargan, 1986; Roizman & Sears,
1990).
2.2.5.1 Capsid and core
The capsid is an icosahedral shell, composed of 162 capsomeres, (Wildy et al, 1960; 
Schrag et al, 1989), each of which are hexamers or pentamers of the major capsid 
protein, VP5 (Steven et al, 1986). Three different types of capsids, distinguishable 
by their appearance in electron micrographs and by their protein composition, are 
found in the nuclei of virus-infected cells. Type A (empty) capsids lack any internal 
structure; they are composed of five polypeptides: VP5 (UL19, 155kDa), VP19c 
(UL38, 53kDa), VP23 (UL18, 36kDa), VP24 (UL26, 24kDa) and VP26 (UL35, 
12kDa) (Marsden era/, 1978; Morse etal, 1978; Rixon etal, 1990; Davison etal, 
1992; McNabb & Courtney, 1992). Type B (intermediate) capsids contain an 
internal scaffold of two additional polypeptides, VP21 (UL26, 45kDa) and VP22a 
(UL26.5, 38kDa) (Preston etal, 1983; Braun etal, 1984; Liu & Roizman, 1991b). 
Type C (full) capsids contain a core of genomic DNA, and their protein composition 
is essentially like that of A capsids.
It was thought for many years that the DNA in the core was spooled around a protein 
plug, since in many electron micrographs it appeared to be a toroid (Furlong et al, 
1972). However, Booy et al (1991) have shown, using cryoelectron microscopy 
and image reconstruction, that the DNA forms a uniformly dense ball. It appears to 
be in a liquid-crystalline state, like the encapsidated DNA of the bacteriophages T4 
and X (Lepault et al, 1987). The condensed, toroidal shapes seen previously may 
have resulted from the fixation procedures used for preparing specimens (Puvion- 
Dutilleul etal, 1987).
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2.2.5.2 Capsid morphogenesis
The currently favoured model is that the capsid shell assembles with the scaffolding 
protein and protease, in a process of co-condensation, to form a B capsid. The 
scaffolding protein is then degraded by proteolysis and is absent from the mature 
capsid. Analogous mechanisms for head assembly are used by the large DNA 
phages (Wood & King, 1980). The relationship between the scaffolding protein and 
the protease is an interesting one, and parallels are found in other herpesviruses 
(Welch et al, 1991). UL26 and UL26.5, which encode the protease and VP22a, 
respectively, are nested 3' co-terminal genes which utilise the same reading frame 
(Figure lb). Thus the VP22a protein represents the C-terminal portion of the 
protease. VP22a is cleaved by the protease at a specific site near the C-terminus (Liu 
& Roizman, 1991b, 1992; Preston et al, 1992). The protease cleaves itself at the 
same position, since it shares the same sequence (Liu & Roizman, 1991b), and also 
at another site in the unique N-terminal portion, generating two fragments: the C- 
terminal fragment is VP21, and the N-terminal fragment is another capsid protein, 
VP24. The tel201 mutant, which has a lesion in the N-terminal part of UL26 
affecting the proteolytic activity (Preston et al, 1983, 1992), has been particularly 
useful for elucidating the pathway of capsid morphogenesis. At the non-permissive 
temperature, capsids of the ts 1201 virus are arrested at the stage of large-cored B 
capsids. Following downshift to the permissive temperature, proteolytic processing 
of VP22a and protease occurs, and this is accompanied by the appearance of small- 
cored B capsids, C and A capsids (Rixon et al, 1988).
It has been suggested that the outer shell might condense around a pre-formed 
scaffold, on the evidence that VP22a purified from virions can self-assemble into 
60nm-diameter structures (Newcomb & Brown, 1991). However, no such 
structures have been detected in infected cells, and therefore large cored B capsids 
appear to be the earliest identifiable stage in the pathway of capsid assembly.
2.2.5.3 DNA packaging
Mature C capsids are formed by the removal of VP22a and VP21 from B capsids and 
the packaging of DNA. These two processes appear to be linked, as shown by 
experiments with the te l201 mutant, described above, and similar observations with 
other ts mutants deficient in DNA packaging (Sherman & Bachenheimer, 1988). 
Empty A capsids arise from failed attempts to package DNA. The newly replicated,
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concatemeric DNA is cleaved into unit-length genomes as part of the packaging 
process (Ladin et al, 1980; Deiss & Frenkel, 1986). The signals required for 
cleavage and encapsidation are located in particular regions of the a sequence (Stow 
etal, 1983; Varmuza & Smiley, 1985; Deiss et al, 1986; Deiss & Frenkel, 1986) 
(Section 2.1).
Two viral proteins of >250kDa and 140kDa have been identified which bind 
specifically to sites within the a sequence, and which might play a role in the 
encapsidation process (Chou & Roizman, 1989). A number of gene products may 
be involved in the packaging process, since ts mutations in genes UL6, UL25, 
UL28, UL32 and UL33 affect the formation of full capsids (Addison et al, 1984; 
Sherman & Bachenheimer, 1987; Addison et al, 1990; Al-Kobaisi et al, 1991). 
The transcriptional activator, a-T IF  (UL48) may also have a function in 
encapsidation, since a UL48 deletion mutant is defective in this function 
(Weinheimer et al, 1992).
2.2.5 A  Tegument and envelope
The tegument is the most poorly characterised part of the virion. It is usually 
described as an "amorphous" layer between the capsid and the envelope. Its 
complete protein composition has not yet been defined; virion proteins which are not 
components of the capsid or envelope are assigned to the tegument. The discovery 
of light (L) particles, which consist of tegument and envelope without a core 
(Szildgyi & Cunningham, 1991), has facilitated the identification and study of 
tegument proteins (McLauchlan et al, 1992a; McLauchlan & Rixon, 1992). The 
protein composition of the tegument of L particles and virions is very similar, but not 
identical (Szildgyi & Cunningham, 1991); in particular, Vmwl75 is present in L 
particles but not in virions (McLauchlan & Rixon, 1992). None of the tegument 
proteins are absolutely required for infectivity since transfection of cells with viral 
DNA results in productive infection. However, vhs (UL41) and a-TIF (UL48), 
play important roles during the early stages of infection (Sections 2.2.2, 2.2.3). A 
major tegument protein of unknown function is Vmw82/81 (UL47) (McLean etal, 
1990). The structure of the tegument component of L particles is largely unaffected 
by the removal of the envelope, which shows that it possesses a degree of inherent 
structure.(McLauchlan & Rixon, 1992).
The envelope is a cell-derived membrane, modified by the presence of numerous 
viral proteins and glycoproteins, described in Section 2.2.1. None of the membrane
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constituents appeals to be essential for the process of virion assembly or 
envelopment, but some may be essential for viral egress (Section 22.5.5).
2.2.5.5 Tegumentation, envelopment and egress
Capsids acquire a tegument and envelope en route from the nucleus to the outside of 
the cell, but there is still controversy over the details of these events. It is clear that 
capsids leave the nucleus by budding through the inner nuclear membrane into the 
space between the inner and outer nuclear membranes (Darlington & Moss, 1968; 
Nii et al, 1968). The site of tegumentation of HSV-1 capsids is not known. In 
HHV-6 it appears to take place within an invagination of the cytoplasm into the 
nucleus, termed a tegusome, where capsids can be seen surrounded by varying 
amounts of tegument material (Roffman et al, 1990).
There is good evidence that the Golgi complex and Golgi-derived vesicles are 
involved in virion maturation and transport to the outside of the cell. Disruption of 
Golgi function by monensin inhibits the processing of envelope glycoproteins, their 
transport to the cell surface, and the egress of virions (Johnson & Spear, 1982). The 
virions, which accumulate in the cytoplasm, contain immature forms of the envelope 
glycoproteins (Johnson & Spear, 1982). Maturation of glycoproteins and egress of 
virus is similarly hindered in cells with defects in the Golgi glycosyltransferases 
(Campadelli-Fiume, 1982; Serafini-Cessi, 1983). The UL20 membrane protein 
may be involved in the egress of virus. In some cell types, a virus deleted in this 
gene produces mature infectious virions but fails to transport them to the cell surface 
(Baines etal, 1991).
In fully permissive cells, mature virions are released from 18-20 hours after the 
initial infection.
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3. DNA replication: mechanisms and
enzymology
The faithful duplication of genetic material is achieved by the co-ordinated action of a 
large number of enzymes and proteins. Studies of E. coli, coliphages, eukaryotic 
viruses and mammalian cells show that the general mechanism of DNA replication 
appears to be shared across the whole spectrum of living organisms from bacteria to 
mammals. It can be broken down into a number of distinct steps (Table 2), although 
in vivo these steps are closely linked and the proteins which mediate them act in 
concert.
Table 2. The roles of enzymes and proteins at the replication fork
Pmg.ess
Initiation at origin 
Strand separation 
Release of topological stress 
Helix destabilisation 
RNA priming
Template-guided addition of nucleotides
Proof-reading
Removal of primers
Joining of Okazaki fragments
Protein/enzvme involved 
Origin-binding protein 
DNA helicase 
Topoisomerase
Single-stranded DNA binding protein 
Primase
Polymerase and processivity factors 
3 -5 ' exonuclease 
5 —3* exonuclease, RNase H 
DNA ligase
3.1 Initiation of replication
The characteristics of an origin of replication are (i) a recognition site for an origin- 
binding protein and (ii) a region of AT-rich DNA which is prone to melting 
(Kornberg & Baker, 1992). The E. coli origin, ori C, consists of a minimal 
sequence of 245 bp containing four copies of a 9bp recognition sequence and three
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AT-rich stretches of 13 nucleotides (Hirota etal, 1981). ATP-activated binding of 
the dna A protein to ori C promotes melting of the adjacent AT-rich region and 
allows the helicase to enter (Fuller et al, 1984; Sekimuzu et al, 1987; Bramhill & 
Kornberg, 1988).
The minimal essential sequence of the SV40 origin is only 64bp and consists of (i) 
four repeats of a 5bp sequence to which the large T-antigen binds (Jones & Tijan,
1984), (ii) a 15bp palindrome and (iii) 17 AT base pairs (Dean etal, 1987). ATP is 
required for the duplex to melt (Borowiec & Hurwitz, 1988).
3.2 Strand separation
Helicases use the energy of NTP hydrolysis to break the bonds between the strands 
of duplex DNA and thus open up the replication fork. A helicase is therefore a 
DNA-dependent ATPase.
Of the ten helicases isolated from E. coli, three play a role in replication: dnaB, PriA 
and Rep (reviewed by Matson & Kaiser-Rogers, 1990). The dnaB protein, a 
hexamer of 50 kDa subunits, interacts with single-stranded DNA as a dnaB-dnaC 
complex, and is activated by the ATP-dependent release of dnaC from the complex 
(Wahle et al, 1989). It is responsible for fork movement, and translocates 
processively 5 -3 ' along the DNA, tethered to the template of the lagging strand 
(LeBowitz & McMacken, 1986). PriA (protein n', replication factor Y) translocates 
3 - 5 ’ and probably threads the lagging strand "backwards" through the replisome. 
(Figure 4) (Lee & Marians, 1987; Kornberg & Baker, 1992). The gene 4 protein 
(gp4) of phage T7 and the gene 41 protein (gp41) of phage T4 are helicases with 
similar properties to dnaB; all three interact with a primase, and activate primer 
synthesis (Liu & Alberts,1981; Venkatesan e ta l,  1982; Matson et al, 1983; 
LeBowitz & McMacken, 1986).
The multifunctional SV40 large T-antigen is both a helicase and an origin-binding 
protein (reviewed by Fanning & Knippers, 1992). It is active as two hexamers of 
the 92kDa protein (Mastrangelo et al, 1989) and melts DNA bi-directionally from the 
origin, translocating with 3 -5 ' polarity along the leading strand template (Goetz et 
al, 1988; Wiekowski et al, 1988). T-antigen associates directly with the catalytic 
subunit of pol ot/primase (Dornreiter et al, 1990). Since T-antigen is the only viral 
protein required for replication, the establishment of an in vitro SV40 replication 
system (Li & Kelly, 1984) has allowed host proteins essential for viral DNA 
replication to be identified (reviewed by Challberg & Kelly, 1989).
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3.3 Release of topological stress
Extensive helicase action requires a topoisomerase to relieve the torsional stress 
introduced by unwinding: for every 10.5 bases melted by a helicase, the two strands 
must be untwisted by one turn, otherwise the DNA in front of the replication fork 
becomes supercoiled, and the helicase stalls (Kornberg & Baker 1992). A 
topoisomerase introduces a transient break in the phosphodiester backbone through 
the formation of a covalent protein-DNA intermediate, and allows the DNA strands 
to pass through each other.
There are two types of topoisomerase found in both prokaryotic and eukaryotic cells: 
type I enzymes introduce a break in one strand of the duplex in the absence of ATP, 
while type n  enzymes generate a break in both strands and require the energy of ATP 
hydrolysis (reviewed by Wang, 1985). Either type of enzyme can relax supercoiled 
DNA, but only topoisomerase II can unlink catenated DNA molecules.
E. coli DNA gyrase, a type II topoisomerase, is required at several stages of 
replication:
i) To maintain a negatively supercoiled template for assembly of the initiation 
complex and opening of the duplex at the origin (Funnell et al, 1987).
ii) To provide the swivel for the progress of the replication fork (Baker et al, 1986).
iii) To decatenate and supercoil the daughter molecules during the terminal stages of 
genomic replication (Marians, 1987).
Mammalian topoisomerase II is both functionally and structurally related to E. coli 
gyrase, whereas eukaryotic and bacterial type I topoisomerases are unrelated. In the 
SV40 in vitro replication system, either type of topoisomerase can provide the swivel 
for fork movement, but topoisomerase II is essential for decatenation of daughter 
molecules at the end of replication (Yang etal, 1987). Experiments in yeast suggest 
the same division of labour (DiNardo et al, 1984; Brill et al, 1987).
3.4. Helix destabilisation
The movement of a replication fork requires the concerted action of a helicase, a 
topoisomerase and a single-stranded DNA binding protein (SSB). SSBs bind tightly 
and co-operatively to single-stranded DNA, with no sequence specificity, coating an 
extensive region of the DNA. They convert duplex DNA to single strands at a 
temperature far below the Tm for the DNA, without requiring the energy of ATP
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hydrolysis. They also facilitate the converse process of helix renaturation, by 
melting out regions of secondary structure (Kornberg & Baker, 1992).
E. coli SSB is an extremely stable tetramer of 18.9kDa subunits which increases the 
fidelity and processivity of E. coli pol II and pol III holoenzymes (reviewed by 
Chase & Williams, 1986; Meyer & Laine, 1990). The rate of replication of phage 
T4 depends on the amount of available gp 32, the phage-encoded SSB (Chase & 
Williams 1986).
Replication protein A (RPA) (formerly called RF-A) is the human SSB, made up of 
three tightly associated polypeptides of 70kDa* 32-34kDa and llkD a (Fairman & 
Stillman, 1988). The 70kDa subunit binds to single-stranded DNA (Kenny et al,
1990). The 34kDa subunit is phosphorylated in a cell cycle-regulated manner, but its 
specific function is unknown (Din et al, 1990). RPA is required for the initiation and 
elongation stages of SV40 replication in vitro (Wold et al, 1989; Fairman & 
Stillman, 1988).
3.5 Priming
No DNA polymerase is able to start a DNA chain, and therefore a priming 
mechanism is necessary (Kornberg & Baker, 1992). RNA priming is the 
predominant mechanism, but alternatives exist in some organisms.
The E. coli primase (dnaG product) associates with the dnaB helicase and at least 
five other proteins to form a 'primosome' that translocates along the DNA, fuelled by 
ATP hydrolysis (Weiner et al, 1976; Arai & Kornberg, 1981). The activity of 
primase alone is distributive, and is therefore stimulated by association with the pre- 
primosome, which is processive (Lee & Marians, 1989).
Phage T7 helicase-primase is made up of two distinct polypeptides which are both 
encoded by gene 4 (Dunn & Studier, 1983). The larger form of the gene 4 protein 
has- primase activity and acts distributively, while the smaller form is a highly 
processive helicase (Nakai & Richardson, 1988). The phage T4 primosome is 
composed of two proteins, a DNA helicase (gp 41) and an RNA primase (gp 61) 
(Nossal, 1980; Liu & Alberts, 1981). They are both fully active only when 
complexed (Cha & Alberts, 1989; Richardson & Nossal, 1989).
Eukaryotic primase activity is tightly associated with pol a . The primase activity 
resides in the two smallest subunits (48- and 58kDa) of the heterotetrameric enzyme
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(Plevani etal, 1985) (Section 3.6). The characteristic length of eukaryotic primers is 
8-12 nucleotides (Singh eta l, 1986; Campbell, 1986). The fidelity of primer 
synthesis by pol oc/primase is low, with an error rate of 1/300 to 1/500 (Zhang & 
Grosse, 1990).
The exclusive 5 -3 ' polarity of synthesis by DNA polymerases means that the 
leading (continuous) strand needs to be primed once only, at the origin, whereas the 
lagging (discontinuous) strand must be primed repeatedly. Extension by DNA 
polymerase of primers on the lagging strand yields Okazaki fragments (Okazaki et al, 
1968; Sugino et al, 1972), which are 100-200 bases in eukaryotes and 1000-2000 
bases in prokaryotes (Kornberg & Baker, 1992).
Alternative strategies to RNA priming exist in certain viruses: in phage <|>X174 a 3- 
OH terminus is generated by endonucleolytic cleavage of the genome (Ikeda et al, 
1976); adenoviruses and certain B. subtilis phages employ a terminal protein in 
which a 3'-OH group of a Ser, Thr or Arg provides the primer terminus (Amberg & 
Arwert, 1976; Rekoshefa/, 1977; Challberg et al, 1980).
3.6 Template-dependent polymerisation of DNA
Polymerisation of DNA has 2 basic features:
i) Each deoxynucleotide added is selected by base-pair matching to the template 
strand.
ii) A phosphodiester bond is formed between the 5'-phosphate group of the 
deoxynucleotide and the 3'-hydroxyl group of the primer terminus. The reaction 
consists of a nucleophilic attack by the 3'-OHgroupof the primer terminus on the a- 
phosphate of the dNTP, resulting in linkage of the nucleotide to the primer by a 3 -  
5'-phosphodiester bond and the concomitant release of inorganic pyrophosphate. 
Chain growth is exclusively 5 - 3 ’, and opposite in polarity to the template. 
Polymerase activity invariably requires a divalent metal ion, preferably Mg2+ 
(Kornberg & Baker, 1992).
DNA polymerase activity may be assayed on various DNA templates: (i) "activated" 
dsDNA from a source such as calf thymus or salmon sperm (dsDNA is made into an 
active template by treatment with endo- and exonucleases to generate short single­
stranded regions and 3’-OH termini); (ii) a synthetic homopolymer such as 
poly(dA), multiply primed with oligo(dT); (iii) a defined genomic sequence such as 
single-stranded circular phage DNA, singly primed with a synthetic oligonucleotide.
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Figure 2. The tertiary structure of the Klenow fragment of E. coli Pol I. a-helices 
are represented by tubes (lettered) and p-sheet by arrows (numbered). The break 
between helices H and I shows the position of an approximately 50-residue disordered 
region. The division between the large and small domains is the loop between helices 
F and G. Reproduced from Ollis et al, 1985.
DNA replication: mechanisms and enzymology
The activity of a polymerase on these different types of template provides a useful 
characterisation.
DNA Pol I of E. coli was the first polymerase to be recognised (Kornberg et al, 
1956; Lehman et al, 1958). It contains three enzyme activities in one polypeptide 
chain: the polymerase, a 3 -5 ' exonuclease and a 5 -3 ' exonuclease (reviewed by 
Joyce et al, 1986). The enzyme is readily cleaved by proteases into a small N- 
terminal domain containing the 5 -3 ' exonuclease activity, and a large C-terminal 
fragment — the Klenow fragment — which contains the polymerase and 3'—5’ 
exonuclease activities (Klenow & Henningsen, 1970; Setlow et al, 1972). The 
crystal structure of the Klenow fragment (Ollis et al, 1985) shows two domains, 
corresponding to the two enzyme activities (Figure 2):
i) A large domain folded into a deep cleft, which is the binding site for the template- 
primer (reviewed by Steitz & Joyce, 1987), and a proximal dNTP binding site 
(Polesky etal, 1990).
ii) A small domain which contains the 3'—5' exonuclease activity, the binding site for 
NMP (Ollis et al, 1985), and two binding sites for divalent metal cations (Derbyshire 
etal, 1988).
The in vivo function of Pol I is probably repair rather than replication (Steitz & 
Joyce, 1987), since it has low processivity and contains 5 -3 ' exonuclease activity 
which excises base-paired nucleotides ahead of the growing chain (Klett et al, 1968).
The replicative polymerase of E. coli is DNA Pol HI (Wickner et al, 1973). The 
holoenzyme is a large complex (>lMDa) of at least ten subunits (a, e, 0, x, y, 5, 5', 
X, \|t and (3) (reviewed by McHenry, 1988). The smallest active subassembly is a 
heterotrimer of a , e and 0 (Kornberg & Gefter, 1971). It possesses the polymerase 
and proofreading activities of the holoenzyme, which reside in the a  and e subunits 
respectively, but lacks the processivity of the holoenzyme. Processivity is conferred 
by the remaining subunits (Section 3.7), which interact with the core to form an 
asymmetric hetero-oligomer (Section 3.8).
There are five known eukaryotic polymerases,a, (3, y, 8 and e, which have been 
isolated from a variety of sources; the genes which encode them have been identified 
in budding yeast and in mammalian cells (reviewed by Wang, 1991).
Pol a, the first eukaryotic polymerase to be identified, is a heterotetramer composed 
of a 165kDa DNA polymerase subunit, two subunits of 58kDa and 48kDa which 
make up the primase, and a 70kDa subunit of unknown function (reviewed by 
Lehman & Kaguni, 1989; Wang, 1991). It is the only eukaryotic polymerase with a
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tightly associated primase activity and should therefore be designated pol oc/primase. 
It is essential for replication and for many years was considered to be the only 
replicative polymerase. Unlike the other replicative polymerases, it appears to have 
no proofreading activity (Section 3.9). The moderate processivity of pol a  (Wang,
1991) is modulated by several accessory proteins (Section 3.7).
Pol p, a protein of 39kDa, is the smallest of the polymerases. It has a high affinity 
for nicked duplex DNA and is considered to be a repair enzyme, but may also have a 
role in filling in the gaps between Okazaki fragments after primer excision (Section 
3.10) (reviewed by Wang, 1991; Kornberg & Baker, 1992).
The catalytic subunit of pol y  is a protein of 140 kDa and is found only in 
mitochondria, although it is encoded by a nuclear gene (reviewed by Wang, 1991; 
Kornberg & Baker, 1992).
Pol 8 is composed of a 125kDa catalytic subunit and an associated 48kDa subunit of 
unknown function (Lee et al, 1984; Boulet etal, 1989; Yang et al, 1992). It has an 
intrinsic 3 -5 ' exonuclease activity (Bauer et al, 1988), and is highly processive in 
conjunction with proliferating cell nuclear antigen (PCNA) (Prelich et al, 1987b). It 
is one of the principal replicative polymerases, originally identified as an essential 
factor for the complete replication in vitro of SV40 DNA (Prelich et al, 1987a, b; 
Weinberg & Kelly, 1989).
The catalytic subunit of pol e is a protein of 255kDa and is the largest of the 
polymerases. Like pol 8, it has a tighly linked 3 -5 ' exonuclease activity (Syvaoja & 
Linn, 1989), and the two enzymes have some immunological and structural 
similarities (Wong et al, 1989), but are encoded by distinct genes (Morrison et al, 
1990). Pol e was initially characterised as a PCNA-independent processive 
polymerase, and thus distinguished from pol 8 (Nishida et al, 1988; So & Downey, 
1988). More recently, it has been recognised that PCNA has a stimulatory effect on 
pol e (Yoder & Burgers, 1991; Lee et al, 1991). In budding yeast, pol e has been 
identified as a third essential replicative polymerase (Morrison etal, 1990).
3.7 Processivity
A iion-processive or distributive polymerase dissociates from the DNA template- 
primer after the addition of one nucleotide, while a processive enzyme remains 
associated with the template and translocates along it for repeated additions. The 
processivity of a polymerase is defined as the number of nucleotides incorporated
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into the template-primer before polymerase and template-primer dissociate. It can be 
determined on a defined template such as oligo(dT)/poly(dA), or singly-primed, 
phage ssDNA. All the replicative polymerases have a degree of intrinsic 
processivity, which is greatly increased by accessory factors (Kornberg & Baker, 
1992).
The processivity of E. coli Pol El increases with the complexity of the subassembly 
(Table 3; from McHenry, 1991; Kornberg & Baker, 1992).
Table 3. The processivity of subassemblies of E.coli Polymerase III
Designation Subunit composition Processivitv Stimulatorv factors
Pol El core a, e, 0 10 None
Pol E l’ a, 8, 0, x 60 Spermidine
Pol IE* a, e, 0, x, y, 8, 6', %, y 200 SSB
Pol IE holoenzyme a, e, 0, x, y, 5, 5’, %, y ,  p >105 SSB
In the presence of the x subunit the Pol IE core forms a dimeric complex designated 
Pol IE’, which is several times more processive than the core (Fay et al, 1982). Pol 
El*, which lacks only the P subunit of the holoenzyme, is still more processive, and 
its activity can be further stimulated by SSB (Fay et al, 1982; Meyer & Laine,
1990). The addition of the P subunit to Pol III* restores completely Pol IE 
holoenzyme activity and increases processivity by over 1000-fold (Mok & Marians,
1987).
The 40.6kDa p subunit exists as a dimer in solution (Johanson & McHenry, 1980) 
and is not demonstrably a DNA-binding protein (Stukenberg et al, 1991). The 
highly processive holoenzyme can be reconstituted in two distinct stages (O’Donnell, 
1987; Maki & Kornberg, 1988). In the first stage, the y  complex (y55'xv) 
hydrolyzes ATP and transfers the p subunit onto the primed template, forming a 
preinitiation complex. In the second stage, the core polymerase interacts with the P 
subunit to form the processive polymerase. The y  complex is needed only in 
catalytic amounts and can be subsequently removed, leaving P tightly bound to the 
DNA (Stukenberg et al, 1991). The P subunit slides freely along duplex DNA and 
binds directly to the a  subunit of the core, tethering it to the template (Stukenberg et 
al, 1991).
27
Figure 3„ The tertiary structure of the p-clamp of E. coli DNA polymerase 
III holoenzyme. A ribbon representation of the polypeptide chain o f a 
P subunit dimer is shown, looking down the 2-fold axis of the ring. The a -
helices are shown as spirals and the P-sheets as flat ribbons. The two 
monomers are coloured yellow and red. A standard model of B-form DNA is 
shown in the geometric centre of the ring. Reproduced from Kong, 1992.
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The structure of the p dimer has recently been determined by X-ray crystallography 
to be a closed ring that can encircle duplex DNA (Kong et al, 1992). Each monomer 
consists of three structural domains of identical topology and very similar three- 
dimensional structure. The head-to-tail dimerisation of two monomers results in a 
highly symmetrical, rigid toroid with 12 a  helices lining its inner surface and six P 
sheets forming a star-shaped outer scaffold (Figure 3). At the dimer interface, the 
hydrogen bonded p sheet continues across the molecular boundary. The interface is 
further stabilized by the formation of a small hydrophobic core and six ion pairs in 
which all the positively charged residues are contributed by one monomer and all the 
negatively charged residues by the other. ATP hydrolysis by the y  complex may 
provide the energy to break these interactions in order to open the ring and close it 
again around the DNA (Kong et al, 1992).
Several features indicate that the protein is designed to wrap around duplex DNA 
without sequence-specific interactions. The hole in the middle of the ring (diameter 
~35A), is large enough to accommodate A or B form DNA (diameter ~25A). The a  
helices lining the ring are perpendicular to the major and minor grooves of the DNA 
helix. The electrostatic charge of the protein is distributed in such a way that the 
surface of the hole has strongly positive electrostatic potential, which would stabilize 
it around the DNA, while the outer edge and faces of the ring are negatively charged 
(Kong etal, 1992).
While the crystal structure reveals much about the interaction of P with DNA, it 
reveals little about its interactions with the a  subunit and the other components of the 
Pol III* subassembly. One face of the ring is less strongly charged than the other 
and bears six prominent loops, which may reflect asymmetric protein-protein 
interactions (Kong etal, 1992).
There is evidence that cycling of the holoenzyme from one template to another is 
achieved by the dissociation of Pol HI* from the P clamp, followed by reassociation 
with a fresh P at the new primer terminus — a process which is not yet understood 
but which probably involves interactions between the auxiliary factors. The 
association between Pol in  core and p is stabilized by the presence of ATP (Lasken 
& Kornberg, 1987) and by the x subunit (Maki & Kornberg, 1988). The rate of 
holoenzyme cycling to a new template depends on the concentration of the P-DNA 
preinitiation complex (O'Donnell, 1987). At low concentrations of p, primer 
utilization by polymerase on the lagging strand is less efficient than at higher 
concentrations (Zechner et al, 1992). It is estimated that P exists in a 10 to 20-fold
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excess over Pol IE* in the cell (Kornberg & Baker, 1992), which would support this 
model.
It is intriguing that there is very little (<16%) sequence identity between the domains 
of the (3 subunit (Ohmori et al, 1984; Kong et al, 1992). One consequence of this 
sequence plasticity may be a lack of significant amino acid homology between P and 
other processivity factors, even if they were of similar structure. An alignment of the 
sequences of the three domains of P shows that the hydrophobic core of each domain 
forms a weakly conserved region, in as much as only uncharged residues are found 
at buried positions. A plausible alignment between P and PCNA and phage T4 gp 
45 can be made by matching the buried residues in p with uncharged residues in the 
other sequences (Kong etal, 1992).
The phage T4 holoenzyme consists of a simpler assembly of proteins which have 
analogous functions to those of the host Pol EL The catalytic gp 43 core polymerase 
associates with three accessory factors: the products of genes 44, 45 and 62 
(reviewed by Cha & Alberts, 1988; Young etal, 1992). The gp 44/62 complex is a 
DNA-dependent ATPase and gp 45 is a processivity factor which stimulates it 
(Pipemo & Alberts, 1978; Mace & Alberts, 1984a). These accessory proteins 
assemble with the polymerase on a primer-template junction (Munn & Alberts,
1991). ATP hydrolysis is required for the accessory proteins to form a "sliding 
clamp" that tethers the polymerase to the template (Pipemo & Alberts, 1978; Mace & 
Alberts, 1984b). The gene 32 protein stabilizes the binding of the accessory proteins 
to a hairpin template DNA, both by smoothing out secondary structures in the single 
stranded portion of the template and by direct interactions with the gp 44/62 complex 
(Mace & Alberts, 1984a) and with polymerase (Huberman et al, 1971; Formosa et 
al, 1983; Burke et al, 1980). T4 is a particularly attractive model system, since the 
polymerase catalytic subunit has significant sequence similarity to human pol a  and 
to HSV-1 Pol (Section 4.5).
The processivity of phage T7 polymerase (gp 5) is achieved simply by association 
with the a host protein,thioredoxin, in a 1:1 complex (Huber etal, 1987). Formation 
of the complex requires neither ATP nor DNA template-primer (reviewed by 
Marians, 1992). Thioredoxin stabilises the binding of gp 5 to a primer-template by 
20- to 80-fold and increases its processivity by 1000-fold (Tabor et al, 1987; Huber 
etal, 1987).
Processive synthesis by the eukaryotic pol 5 requires the cooperative action of 
proliferating cell nuclear antigen (PCNA/cyclin), replication factor C (RFC) and
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replication protein A (RPA), and hydrolysis of ATP (reviewed by Wang, 1991; 
Kornberg & Baker, 1992).
PCNA is the functional equivalent of the E. coli Pol III p subunit and of the phage 
T4 gp 45 (Tan et al, 1986; Tsurimoto & Stillman, 1990). It is a cell cycle-regulated 
protein of 36kDa (Mathews et al, 1984), which was found to be essential for SV40 
replication in vitro, and this led to the initial recognition of pol 5 as a replicative 
polymerase (Prelich et al, 1987a&b). PCNA is a highly conserved protein 
(Matsumoto et al, 1987; Bauer & Burgers, 1990), and has some homology with T4 
gp 45 (Tsurimoto & Stillman, 1990), but none with E. coli P, although a tentative 
alignment of non-polar residues based on the structure of p has been made (Kong et 
al, 1992) (Section 3.6).
RPA is the human SSB (Section 3.4). In addition to its role in unwinding DNA, 
RPA can stimulate the activity of polymerases a  and 8 (Kenny et al, 1989, 1990). 
RPA alone can increase the processivity of pol a  (Tsurimoto & Stillman, 1989b; 
1991b), but it has no effect on pol 8 in the absence of PCNA and RFC (Tsurimoto & 
Stillman, 1989b).
RFC is a complex of three polypeptides of 140kDa, 41 kDa and 37kDa, and is 
essential for leading strand synthesis during SV40 replication in vitro (Tsurimoto & 
Stillman, 1989a). It is a DNA-dependent ATPase and binds to DNA at a primer- 
template junction (Yoder & Burgers, 1991; Tsurimoto & Stillman, 1991a). The 
41kDa subunit binds ATP, while the 140kDa subunit binds primer-template DNA 
(Tsurimoto & Stillman, 1991a). The ATPase activity is stimulated by PCNA and by 
RPA (Tsurimoto & Stillman, 1990). RFC and PCNA form an ATP-dependent 
primer recognition complex at the primer-template junction in the presence of RPA 
(Tsurimoto & Stillman, 1991a&b). Interaction of pol 8 with the complex initiates 
processive DNA synthesis. This replicative system has strong functional similarities 
to the T4 holoenzyme, in which the gp 44/62 complex fulfils a role analogous to that 
of RFC (Tsurimoto & Stillman, 1990).
A heterodimeric factor which specifically stimulates pol oe/primase on single-stranded 
DNA templates but has no effect on any other polymerases has been reported 
(Goulian et al, 1990). Alpha accessory factor (AAF) increases the affinity of pol 
a/primase for the DNA template, increasing its processivity from -15 to -115 
nucleotides, and allowing it to traverse double-stranded DNA regions (Goulian & 
Heard, 1990).
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3.8 Coordination of leading and lagging strand 
replication
The replicative polymerases of E. coli, phage T4 and eukaryotic cells all share a 
number of structural and funtional features that allow them to fulfil the asymmetric 
requirements at a replication fork, where the lagging strand polymerase needs to 
dissociate from the template on completion of each Okazaki fragment and reassociate 
with the next primer, while the leading strand polymerase needs to be highly 
processive. The idea that coordinated replication of the leading and lagging strands 
is achieved by the physical association of the leading and lagging strand polymerases 
— the asymmetric dimer hypothesis (Sinha et al, 1980) — has won widespread 
acceptance and is supported by studies of the subassemblies of E. coli Pol HI, T4 
polymerase, SV40 replication in vitro and other systems ( reviewed by Thommes & 
Hubscher, 1990; Kornberg & Baker, 1992; Marians, 1992).
The core of E. coli Pol IQ can be isolated as a dimer (McHenry, 1982), which 
suggests that the functional holoenzyme is also dimeric (Johanson & McHenry, 1984; 
Maki et al, 1988). The x and y  subunits are similar but distinct, and may be 
responsible for structural and functional asymmetry in a dimeric holoenzyme (Maki 
et al, 1988; O'Donnell & Studwell, 1990; Wu et al, 1992). It has been 
demonstrated using holoenzyme reconstituted from individually purified subunits 
that the lagging strand polymerase remains associated with the replication fork, 
presumably via protein-protein interactions with the leading strand assembly (Wu et 
al, 1992). Figure 4 shows the dimeric polymerase and other replication proteins 
associated in a "replisome" at the replication fork, with the lagging strand DNA being 
translocated through the replisome in the opposite direction to the movement of the 
replication fork. The replisome should be compared to a sewing machine through 
which the DNA is threaded, rather than a train travelling along the template 
(Kornberg & Baker, 1992).
Phage T4 holoenzyme is effective in the synthesis of both strands. The holoenzyme, 
made up of gp 43 (pol) and gp 44/62 and 45 (accessory proteins), requires only the 
gp 41 (DNA helicase) for leading strand synthesis. Addition of gp 61 (primase) 
allows lagging strand synthesis, and the two assemblies become coupled in the 
presence of gp 32 (SSB) (Cha & Alberts, 1988, 1989).
A dimeric, asymmetric replisome could be achieved in eukaryotic cells by various 
combinations of multi-subunit replicative polymerases. The simplest model, 
supported by studies of SV40 replication in vitro, is that the highly processive pol 5 
synthesises the leading strand, and the less processive, primase-containing pol a
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Figure 4. A hypothetical model of the E. coli replication fork, showing the 
association of leading and lagging strand polymerases. Primase is associated with the 
lagging strand polymerase. The dnaB and PriA helicases are translocated in opposite 
directions along the DNA template, as indicated by the dashed open arrows. The SSB 
associated with the single stranded DNA is not shown. Reproduced from Kornberg 
& Baker, 1992.
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synthesises the lagging strand (Lee et al, 1989; Weinberg & Kelly, 1989). A more 
complex model proposes that pol e is the leading strand polymerase, while 
polymerases a  and 5 are responsible for lagging strand replication; each Okazaki 
fragment is initiated by pol oc and elongated by 5 (Morrison et al, 1990). The roles 
of 5 and e in this tri-polymerase system may be reversed (Burgers, 1991). The latter 
model, in which pol e completes Okazaki fragment synthesis, is supported by the 
finding that calf pol e functionally interacts with a 5 -3 ' exonuclease (Siegal et al, 
1992) which may be involved in the removal of primers.
3.9 Proof-reading
The ability to proof-read and excise mismatched nucleotides at the primer terminus is 
an essential function of the replication machinery, and is performed by a 3 -5 ' 
exonuclease (reviewed by Kunkel, 1988; Komberg & Baker, 1992). The 3 -5 ' 
exonuclease of E. coli Pol I resides in a distinct domain of the catalytic subunit (Ollis 
et al, 1985), while the 3 -5 ' exonuclease activity of E. coli Pol HI is in the e subunit 
(Scheuermann & Echols, 1984), which associates with the a catalytic subunit to 
form the core polymerase. Phage T4 gp43 has both polymerase and 3 -5 ' 
exonuclease activities (Bessman et al, 1974).
The eukaryotic polymerases y, 5 and e each have an associated 3 -5 ' exonuclease 
activity (reviewed by Wang, 1991). The pol 5 exonuclease resides in the catalytic 
subunit (Simon et al, 1991; Boulet et al, 1989; Yang et al, 1992), and sequence 
comparison suggests that the same is true for pol s (Morrison et al, 1990). It has not 
been clearly resolved whether or not pol a possesses a proofreading 3 -5 ' 
exonuclease activity. A proofreading activity was uncovered in the catalytic subunit 
of D. melanogaster pol a by separating it from the 70kDa subunit (Cotterill et al,
1987). The catalytic subunit of yeast pol a was shown to have exonuclease activity 
in one study (Brooke et al, 1991) but not in another (Kunkel et al, 1989).
The distance between the polymerase and exonuclease sites of E. coli Pol I (25-30A) 
is such that the primer terminus must shuttle between the two active sites to allow 
excision of a mispaired base (Ollis et al, 1985; Joyce, 1989). It may be that this 
relocation is accomplished by the dissociation and reassociation of polymerase and 
template-primer (Joyce, 1989). Experiments with the catalytic subunit of T4 
polymerase, however, show that proofreading is intrinsically processive, ie the 
enzyme can excise one or two mismatched bases and then continue synthesis on the 
same template, without dissociation (Reddy etal, 1992).
32
DNA replication: mechanisms and enzymology
3.10 Removal of primers, ligation of Okazaki 
fragments
The final steps of DNA replication are the removal of RNA primers, filling of the 
gaps, and ligation of the Okazaki fragments. The first of these is mediated by 
ribonuclease H and 5-3* exonuclease, the second by DNA polymerase and the third 
by DNA ligase. RNase H is a ubiquitous enzyme which can specifically hydrolyze 
RNA from RNA/DNA hybrids (reviewed by Crouch & Dirksen, 1982). E. coli 
RNase H cannot remove the ribonucleotide esterified to DNA, and so this requires an 
additional 5 -3 ' exonuclease, such as E. coli Pol I (Westergaard et al, 1973). 
Similarly, in the in vitro SV40 replication system, covalently closed circular DNA 
can only be synthesised if an RNase H, a double strand-specific 5 -3 ' exonuclease 
and a DNA ligase are present (Ishimi et al, 1988). Unlike a 3 -5 ' exonuclease, 
which acts specifically on unpaired bases, a 5'—3' exonuclease excises base-paired 
nucleotides, and can excise short oligonucleotides of up to 10 bases (Crouch & 
Dirksen, 1982).
Pol a  alone is sufficient to fill the gaps left after primer excision in the S V40 in vitro 
system (Ishimi et al, 1988). This does not however exclude a role for polymerases 
P, 8 or e in vivo (Kunkel, 1992).
In the last formal step of DNA replication, a DNA ligase mediates the formation of a 
phosphodiester bond between the 3'-hydroxyl and 5'-phosphate termini of adjacent 
base-paired nucleotides (Komberg & Baker, 1992).
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A fairly recent milestone in this field was the identification of the complete set of viral 
genes that are required for HSV-1 DNA replication. Mark Challberg showed that 
restriction fragments of HSV-1 DNA cloned into plasmid vectors can support the 
replication of HSV-1 origin-containing plasmids when co-transfected into cells 
(Challberg, 1986). This led to the identification of seven genes (UL5, UL8, UL9, 
UL29, UL30, UL42 and UL52) which were necessary and sufficient for origin- 
dependent DNA replication (Wu et al, 1988; McGeoch et al, 1988a). Analyses of 
various mutant viruses had shown that all lesions which rendered the virus unable to 
synthesise DNA mapped to one of these seven genes (Purifoy & Powell, 1981; 
Chartrand e t al, 1980; C on leys al, 1981; Weller et al, 1983; Littler et al, 1983; 
Weller et al, 1987; Carmichael et al, 1988; Goldstein & Weller, 1988b; Zhu & 
Weller, 1988; Marchetti et al, 1988), corroborating the results of the transient 
replication assay.
Genes UL30 and UL29 respectively encode the viral polymerase and the major 
DNA-binding protein, which had been previously identified by biochemical and 
genetic analyses (Sections 4.4 and 4.5). The functions of the remaining gene 
products have since been identified as a helicase-primase (UL5, UL8, UL52), a 
polymerase accessory protein (UL42), and an origin-binding protein (UL9) 
(reviewed by Challberg & Kelly, 1989; Challberg, 1991). The seven replication 
proteins are described in detail below, with particular attention given to the 
polymerase and UL42 proteins.
Two functions essential for replication which appear not to be encoded by HSV-1 are 
a topoisomerase (Section 3.3) and a DNA ligase (Section 3.10). These may be 
supplied by the host cell in both the mammalian (Challberg, 1986) and insect (Stow,
1992) in vivo replication systems. The topoisomerase activity induced upon 
infection of cells by HSV-1 (Leary & Francke, 1984) or HSV-2 (Bapat et al, 1987) 
is indistinguishable from cellular topoisomerases (Bapat et al, 1987). Inhibitors of 
topoisomerase block both HSV-1 replication and reactivation from latency (Spivac et 
al, 1987). Several host cell replication proteins, including DNA ligase I, are seen to
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re-locate to sites of viral DNA synthesis in infected cells (Wilcock & Lane, 1991; 
Section 2.2.4.1). However, an in vitro system that supports origin-dependent HSV- 
1 DNA replication has not yet been established, and cellular factors essential for viral 
DNA replication remain to be determined.
4.1 Origins of replication
The HSV-1 genome contains three ds-acting replication origins: oriL, located near 
the centre of U l, and two copies of oris, one in IRs and one in TRs. These origin 
sequences were originally identified by their presence as tandem repeats in defective 
HSV DNA species, which arise when virus is repeatedly passaged at high 
multiplicity (Frenkel et al, 1975; Kaemer et al, 1979; Vlazny & Frenkel, 1981; 
Spaete & Frenkel, 1982). Plasmids containing the origin sequences were amplified 
in cells infected with HSV (Stow, 1982), allowing the precise localisation of oris 
(Stow & McMonagle, 1983). A similar analysis of oril  was hampered by its 
inherent instability in bacterial plasmid vectors, and was achieved by the sequencing 
of non-cloned viral DNA fragments (Weller et al, 1985; Quinn & McGeoch, 1985).
The sequences of oris and orii are closely related. Both contain an extensive 
palindrome, the centre of which consists exclusively of AT base pairs. The oris 
palindrome has 21 residues in each arm and is imperfect; the oriL sequence is a 
perfect inverted repeat of 72 residues. The biological significance of multiple origins 
is unclear. Mutant viruses lacking ori^ or one copy of oris have been isolated and 
have no obvious growth defect either in cultured cells or in animals (Longnecker & 
Roizman, 1986; Polvino-Bodnar et al, 1987). Both origins are located between 
divergently transcribed genes: oris between IE-3 and IE-4 (IRs) or IE-5 (TRS), 
and orz’L between UL30 and UL29 (Figure lb). The significance, if any, of their 
proximity to genes encoding an important transcriptional activator and the major 
replication proteins is not understood.
Due to the instability of ori^, most analyses of origin function have been done on 
oris. Mutational analyses have shown that both the central AT-rich sequence (Stow,
1985) and the palindromic arms (Lockshon & Galloway, 1988; Weir & Stow, 
1990) are essential for function, while flanking transcriptional regulatory elements 
enhance the efficiency of replication (Wong & Schaffer, 1991). The palindromic 
arms of both origins contain binding sites for the origin-binding protein (Elias et al, 
1986; Elias & Lehman, 1988), product of the UL9 gene (Olivo et al, 1988; Weir et 
al, 1989) (Section 4.2).
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4.2 UL9 (Origin-binding protein)
Prior to the identification of UL9 as one of the seven genes required for HSV-1 
origin-dependent replication (Wu et al, 1988; McGeoch et al, 1988a), a protein of 
apparent Mr 83 000, which bound to the viral origin of replication, had been isolated 
from HSV-1-infected cells (Elias et al, 1986; Elias & Lehman, 1988). This origin- 
binding protein was then shown to be the product of the UL9 gene (Olivo et al, 
1988; Weir et al, 1989).
The UL9 protein binds to two high affinity sites, designated site I and site n , which 
are present in opposite orientations on either side of the central AT domain of the 
origin sequence (Elias & Lehman, 1988; Olivo if  al, 1988; Weir et al, 1989). The 
protein specifically recognises an 11 bp sequence, CGTTCGCACT (Elias et al, 1990; 
Koff & Tegtmeyer, 1988). In oris (but not in orii) the sequence of site n  differs 
from that of site I in two positions, which results in a 10-fold lower binding affinity 
for UL9 (Elias & Lehman, 1988; Elias et al, 1990). There is also a third site of 
much lower affinity, which differs from site I by a single base pair. All three UL9 
binding sites are necessary for optimum DNA replication in transient assays 
(Lockshon & Galloway, 1988; Hernandez et al, 1991; Weir & Stow, 1990). The 
binding of UL9 to sites I and II is cooperative (Elias et al, 1990, 1992), and results 
in looping and distortion of the DNA (Koff et al, 1991; Fierer & Challberg, 1992). 
Purified UL9 exists predominantly as a dimer in solution (Fierer & Challberg,
1992), which may reflect a capacity to form a higher-order nucleoprotein complex 
when bound to sites I and II at the origin. The N-terminal region of the protein is 
required for dimerisation (Elias et al, 1992).
Like other origin-binding proteins, UL9 also has helicase and DNA-dependent 
ATPase activities (Bruckner et al, 1991; Fierer & Challberg, 1992). Assays using 
short oligonucleotides annealed to single-stranded DNA show that the helicase 
translocates 3 -5 ' along the DNA, and that unwinding is dependent upon hydrolysis 
of ATP, dATP, CTP or dCTP (Fierer & Challberg, 1992).
Sequence comparisons and site-directed mutagenesis show that the helicase activity 
resides in the N-terminal two-thirds of the protein. The N-terminal 400 amino acid 
residues of UL9 contain six conserved motifs which characterise a superfamily 
(SF2) of helicases (Gorbalenya et al, 1989). Two of the motifs define a nucleotide 
binding domain (Walker et al, 1982), while the functions of the other regions are 
unknown. The nucleotide binding domain and at least three of the other regions are 
necessary for UL9 function, as tested by the ability of mutant UL9 protein expressed 
from a transfected plasmid to complement DNA replication by a UL9-deficient virus
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(Martinez et al, 1992). The functions of the UL9 protein have also been studied in a 
replication assay in which insect cells are transfected with an HSV-1 origin- 
containing plasmid and superinfected with recombinant; baculoviruses expressing the 7 
DNA replication proteins (Stow, 1992 ). The nucleotide binding
site (and by implication helicase activity) is important for origin-dependent DNA 
replication (Stow et al, 1993). However, there is no direct evidence that binding of 
UL9 to the origin brings about local strand separation (Fierer & Challberg, 1992).
The DNA-binding domain of UL9 has been localised to the C-terminal one-third of 
the protein (Weir et al, 1989; Deb & Deb, 1991). Analysis of UL9 proteins altered 
in this region shows that DNA-binding is essential for replication (Arbuckle & Stow, 
1993; Stow et al, 1993). The DNA-binding domain alone has a dominant 
inhibitory effect on replication, showing that DNA binding alone is insufficient for 
UL9 function and that the helicase activity is also required (Stow, 1992; Stow et 
al, 1993).
No direct protein-protein interactions between UL9 and any of the other replication 
proteins have yet been described.
4.3 UL5, UL8, UL52 (Helicase-primase)
A novel DNA helicase, initially identified as a DNA-dependent ATPase activity, was 
found to be induced in HSV-1 infected cells (Crute et al, 1988). A complex of three 
polypeptides of 120kDa, 97kDa and 70kDa was found to be responsible for this 
activity (Crute et al, 1989). Rabbit antisera were used to identify the components of 
the complex as the products of the UL52, UL5 and UL8 genes, respectively (Crute 
et al, 1989). The Mr of the complex was determined to be 263 000, indicating that it 
is a heterotrimer of the UL5, UL8 and UL52 proteins (Crute & Lehman, 1991).
The helicase can utilise ATP or GTP as a cofactor. When assayed on a model 
substrate, it preferentially unwinds DNA duplexes that have a 3'-OH single-stranded 
tail, suggesting that it translocates in a 5 —3* direction, ie bound to the lagging strand 
template at the replication fork (Crute etal, 1989). In the presence of ICP8 (Section 
4.5) and ATP, it can fully unwind a nicked 2.3kbp circular plasmid DNA, at a rate of 
2 nucleotides/s (Crute & Lehman, 1991); in the absence of ICP8, only limited 
unwinding occurs. The complex contains two separate nucleoside triphosphatase 
sites; one catalyses the hydrolysis of both ATP and GTP, the other hydrolyses only 
ATP. These two sites are activated by independent DNA effector sites that support 
the helicase activity of the enzyme (Crute etal, 1991).
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In addition to helicase activity, the enzyme was found to have a tightly associated 
DNA primase, which synthesises oligoribonucleotide primers 10-12 nucleotides in 
length on an M 13 template, or 6-8 nucleotides in length on a poly(dT) template 
(Crute & Lehman, 1991). A similar coupling of helicase and primase activities is 
found in bacteriophages T4 and T7 (Section 3.5).
A complex with identical physical and enzymatic properties assembles in insect cells 
triply-infected with baculoviruses expressing the UL5, UL8 and UL52 genes 
(Dodson et al, 1989). The contribution of the individual subunits to the activity of 
the complex is only partially understood. Co-expression of the UL5 and UL52 
proteins results in a stable sub-assembly with all the enzymatic activities — DNA- 
dependent ATPase, DNA-dependent GTPase, DNA helicase and DNA primase — of 
the trimeric complex (Calder & Stow, 1990; Dodson & Lehman, 1991). The UL5 
gene is highly conserved among the herpesviruses, and contains a consensus ATP- 
binding site (McGeoch et al 1988a). It also contains six sequence motifs found in all 
the members of the SF1 superfamily of DNA and RNA helicases (Hodgman, 1988; 
Gorbalenya et al, 1988a, 1988b). [SF1 and SF2 are distinct but distantly related 
superfamilies of helicases (Gorbalenya et al, 1989)]. It has been demonstrated by 
mutational analysis that all six conserved motifs are essential for helicase function, 
but not for binding of UL5 to the other subunits (Zhu & Weller, 1992). Therefore, 
helicase activity can be assigned with some confidence to the UL5 subunit, and, by 
default, primase activity to the UL52 subunit The isolated UL5 protein is inactive, a 
behaviour which resembles that of the phage T4 gene 41 helicase, which is fully 
active only when complexed with the gene 61 primase (Section 3.5). The difficulty 
of obtaining the isolated UL52 protein in a soluble form has hampered its study.
Only the intact trimeric complex is transported into the nucleus of an infected cell. In 
the absence of any one of the subunits, the other two remain in the cytoplasm (Calder 
et al, 1992). Therefore, a function of UL8 may be to facilitate entry of the 
enzymatically active UL5-UL52 complex into the nucleus, but this is unlikely to be 
its only role. Another possible role for the UL8 subunit has been demonstrated in a 
"lagging strand synthesis assay", in which DNA polymerase elongates primers 
synthesised by the helicase-primase complex on an M 13 ssDNA template (Sherman 
et al, 1992). In the absence of UL8, the efficiency of primer utilisation by either 
HSV or E. coli polymerase was greatly decreased. On this basis, it was proposed 
that UL8 stabilises the association of nascent primers with the DNA template 
(Sherman etal, 1992).
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4.4 UL30 and UL42 (DNA polymerase)
The HSV-1 DNA polymerase is currently considered to be a heterodimer of the 
UL30 and UL42 polypeptides. The part played by the UL42 protein in the 
holoenzyme complex is still not fully understood (Section 4.4.3).
4.4.1 UL30 (DNA polymerase catalytic subunit)
The induction of a DNA polymerase by HSV was first recognised by Keir and Gold 
(1963). The viral enzyme could be distinguished from its cellular counterpart 
immunologically (Bolden et al, 1975; Keir et al, 1966a), by its greater sensitivity 
to phosphonoacetic acid (PAA) (Mao et al, 1975; Hay & Subak-Sharpe, 1976) and 
by a higher optimum salt concentration (Weissbach et al, 1973; Keir et al, 1966b).
Purification of the virus-induced activity showed the catalytic subunit of the 
polymerase (Pol) to be a polypeptide of ~140kDa (Powell & Purifoy, 1977). The 
associated 3 -5 ' exonuclease activity (Knopf, 1979; O'Donnell et al, 1987) has been 
shown to reside in the same polypeptide (Marcy etal, 1990). The genetic locus of 
Pol was identified by mapping ts and PAA-resistant mutants (Honess & Watson, 1977; 
Chartrand et al, 1979,1980). Sequencing of the pol gene — later designated UL30 
(McGeoch et al, 1988b) — showed Pol to be a protein of 1235 amino acid residues, 
with a predicted Mr of 136 272 (Quinn & McGeoch, 1985).
The HSV-1 Pol belongs to a conserved family of replicative polymerases (reviewed 
by Wang et al, 1989; Wang, 1991). A central region of about 400 amino acid 
residues contains six motifs conserved between the herpesviruses, vaccinia virus, 
budding yeast polymerases a , 6 and e, and human polymerases a  and 5 (reviewed 
by Wang, 1991). Five of these motifs are also conserved in adenovirus and phage 
T4 polymerases, and three are found in the polymerases of B. subtilis phage <J>29 and 
E.coli phage PRD1.
The conserved regions are designated I to VI, in order of decreasing similarity 
(Wong et al, 1988). Their relative position in the polypeptide is unaltered throughout 
the family of a-like polymerases (Figure 5). An additional short but highly 
conserved motif between regions I and V has been designated region VII (Hwang et 
al, 1992). The catalytic subunits of yeast polymerases 8 and e (Boulet et al, 1989; 
Morrison et al, 1990), human pol 8 (Yang et al, 1992) and the herpesvirus 
polymerases (Baer et al, 1984; Quinn & McGeoch, 1985; Davison & Scott, 1986; 
Kouzarides et al, 1987; Telford et al, 1992) form a subfamily with more extensive 
homology. This is reflected in their greater enzymatic similarity: they all have an
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S. cerevlslae DNA pol a  NH 2
S. cerevlslae DNA pol c NH 2
COOHHuman DNA pol a
COOH
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COOHS. cerevlslae DNA pol 6
COOHHerpes Simplex DNA pot
COOHCytomegalovirus DNA pol
COOHHHhEpsteln-BarrDNA pol
COOHVaccinia Virus DNA pol
COOHAdenovirus 2 DNA pol
COOHT4 DNA pol
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100 amino adds
Figure 5. The conserved regions of a-like DNA polymerases, designated I-V I in 
order of decreasing homology. The boxes represent the consensus sequences of each 
region. Similar regions of each DNA polymerase polypeptide are joined by vertical 
lines, showing the conservation of their linear spatial arrangement. Reproduced from 
Wang, 1991.
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associated 3 -5 ' exonuclease activity, proposed, on the basis of sequence 
comparisons with T4 polymerase and E.coli Pol I, to reside within region IV and 
adjoining sequences (Reha-Krantz, 1988; Bemad etal, 1989).
HSV-1 Pol is a major target of anti-viral compounds (Section 5). Many drug- 
resistant or hypersensitive mutants of HSV-1 have been isolated that contain 
mutations-in the pol gene. Sequence analyses show that most of these contain point 
mutations within regions I, II, III, V and VII, and a region designated A, which is 
shared only among herpesvirus polymerases and polymerases 8  and e (Gibbs et al, 
1988; Hwang et al, 1992; reviewed by Coen, 1992). It is therefore reasonable to 
suppose that these highly conserved regions are directly involved in substrate and 
drug interactions.
Unlike the host polymerases 8  and e, HSV Pol has an associated 5'-3' exonuclease 
with ribonuclease H activity (Crute & Lehman, 1989; Hernandez & Lehman, 1990; 
Marcy et al, 1990), proposed to reside in the N-terminal region of the polypeptide 
(Bemad et al, 1989; Haffey et al, 1990). The HSV-1 Pol therefore has the same 
three enzyme activities as E.coli Pol I. It has been suggested that HSV-1 Pol may 
have a three-domain structure resembling that of E.coli Pol I, although the sequences 
show no gross homology (Haffey et al, 1990). Opposed to this model is the finding 
that point mutations in the proposed 3 -5 ' exonuclease site severely impair 
polymerase activity (Gibbs etal, 1991).
Deletion studies have shown that the extreme C- and N-termini of the Pol 
polypeptide are not required for catalytic activity (Haffey et al, 1990), but that C- 
terminal sequences are involved in the interaction of Pol with its accessory protein, 
the UL42 gene product (Section 4.4.3). The conserved regions and functional 
domains of HSV-1 Pol are shown in Figure 6 .
4.4.2 UL42 (DNA polymerase accessory protein)
HSV-1 infection of cells induces the synthesis of a number of proteins that bind to 
DNA, as demonstrated by their ability to bind to dsDNA-cellulose. One of the major 
protein species thus identified is a 65kDa protein (BP4, Bayliss et al, 1975), which 
was designated 65KDBp (Marsden et al, 1987). It is heavily phosphorylated 
(Marsden et al, 1987), and displays strong, non-cooperative and sequence- 
independent binding to DNA in the absence of any other protein (Gallo et al, 1988; 
Gottlieb et al, 1990).
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UL42 was identified as the gene encoding 6 5 K d b p  b y  using a 65KoBP-specific MAb 
to immunoprecipitate the products of in vitro translation from mRNA selected with 
oligonucleotide sequences from three candidate ORFs (Marsden et al, 1987; Parris et 
al, 1988). The assignment was confirmed by showing that antisera produced against 
two peptides from the C-terminal region of UL42 reacted with 6 5 K d b p  (Parris et al,
1988). This map location corresponds to that of the HSV-2 DNA-binding protein 
ICSP34,35 (Powell & Courtney, 1975; Vaughan et al, 1985). Analysis of a series 
of HSV-l/HSV-2 intertypic recombinants, using type-specific MAbs reactive with 
65Kdbp or ICSP34,35, showed that the two proteins were equivalent (Gallo et al,
1988).
The first suggestion that this DNA-binding protein might form part of a functional 
complex with polymerase came from the observation that ICSP34,35 consistently 
co-purified with DNA polymerase from HSV-2 infected cells (Vaughan et al, 1985). 
An interaction between HSV-1 DNA Pol and 6 5 K d b p  was subsequently recognised 
(Gallo et al, 1988). The two proteins copurified through successive chromatography 
steps and were separated only by glycerol gradient centrifugation. Other DNA- 
binding proteins, including the viral ICP8  and alkaline nuclease, and cellular 
topoisomerase, also co-eluted with the polymerase from DEAE-Sephacel and Blue 
Sepharose, but were separable by chromatography on Mono-Q. The most tenacious 
and specific association was between Pol and 65KDBP, demonstrated by the retention 
of Pol on an immunoaffinity column containing MAb 6898, which is specific for 
65Kdbp (Gallo et al, 1988).
The evidence that UL42 is essential for viral replication comes not only from the 
results of transient replication assays (Wu ^  al, 1988; Stow, 1992) but also from the 
finding that lesions in the UL42 gene result in viruses that are defective for DNA 
replication (Marchetti etal, 1988; Johnson etal, 1991).
4.4.3 The functional interaction between Pol and UL42
The study of the Pol-UL42 interaction has been stimulated by the idea that it may 
prove to be a novel target for anti-viral drugs. The extreme difficulty of obtaining a 
pure preparation of Pol, uncontaminated with UL42, was overcome by cloning the 
UL30 and UL42 genes and and obtaining small amounts of protein by in vitro 
transcription and translation (Digard & Coen, 1990), or overproducing the proteins 
in the heterologous baculovirus expression system (Crute & Lehman, 1989; Marcy 
et al, 1990; Gottlieb et al, 1990; Stow, 1992) This has allowed the study of their 
interaction.
41
HSV-1 DNA replication
A comparison of the hydrodynamic properties of isolated Pol and UL42, with those 
of the Pol-UL42 complex purified from infected cells, indicated that the complex is 
most probably a heterodimer, of Mr 181 000-190 000 (Crute & Lehman, 1989; 
Gottlieb et al, 1990). A complex with identical physical and enzymatic properties is 
assembled in insect cells co-infected with baculoviruses expressing the two proteins, 
showing that the formation of a functional complex does not require any other viral 
proteins (Gottlieb etal, 1990).
Several groups have studied the role of the UL42 subunit in the heterodimer. Gallo 
et al (1989) purified polymerase from HSV-1-infected cells and separated the two 
subunits by centrifugation through a glycerol gradient, a step which resulted in an 
apparent loss of much of the polymerase activity. When the UL42 protein was 
added back to the Pol, polymerase activity (assayed on an activated DNA template in 
high salt conditions) was stimulated 4-10-fold. A similar stimulation was seen on 
mixing Pol and UL42 that had been produced by in vitro transcription and translation 
of cloned UL30 and UL42 (Gallo et al,1989).
Gottlieb et al (1990) did not find that UL42 stimulated Pol activity on an activated 
DNA template, but demonstrated instead that it increased the processivity of Pol on a 
defined template. When assayed on singly-primed M13 ssDNA, the Pol-UL42 
complex utilised fewer primers and synthesised much longer products than did Pol 
alone (Gottlieb et al, 1990). Hernandez & Lehman (1990) reported that the UL42 
protein increased both the processivity and the activity of Pol, but only if the ssDNA 
template was coated with ICP8  (Section 4.5). A stimulation by E. coli SSB of Pol- 
UL42 activity and processivity on (j)X ssDNA has also been reported (O'Donnell et 
al, 1987).
In a template challenge experiment, the presence of UL42 reduced the rate of 
dissociation of the polymerase from the DNA (Gottlieb et al, 1990). Gel shift and 
filter binding assays showed that the affinity of Pol for a synthetic hairpin 
oligonucleotide increased five to ten-fold in the presence of UL42 (Gottlieb & 
Challberg, unpublished). These data indicate that the role of UL42 in the 
holoenzyme may be to "clamp" the polymerase to the DNA template, in a manner 
analogous to other processivity factors, such as the E.coli P-clamp, or PCNA 
(Section 3.7).
Some of the discrepancies described above arise from the use of different assay 
conditions in different laboratories. The effect of UL42 on Pol is critically dependent 
on the nature and concentration of the salt present in the assay: The apparent Km for 
Pol-UL42 for the DNA template remains unchanged over a range of salt
42
HSV-1 DNA replication
concentrations, whereas the Km for Pol alone increases with salt concentration (Hart 
& Boehme, 1992). Concomitantly, at low salt concentrations, the Vmaxfor Pol alone 
is greater than that for Pol-UL42. This complex kinetic relationship is manifest as 
an inhibition by UL42 of polymerase activity in low salt conditions, an activation in 
high salt (as used by Gallo et al, 1989), and little effect at intermediate concentrations 
of salt (as used by Gottlieb et al, 1990 and Marcy et al, 1990) (Hart & Boehme,
1992). The discrepancies in the observed effects of ICP8  on processivity remain to 
be resolved.
There is as yet no published quantitation of the processivity of HSV-1 Pol (in terms 
of the number of nucleotides incorporated per binding event) in the presence and 
absence of UL42. The HSV-1 polymerase is usually described as being 
exceptionally slow (0.25 nucleotides/s), but highly processive, on the basis of 
experiments carried out with Pol-UL42 before the functional contribution of UL42 
to the holoenzyme was recognised (O’Donnell etal, 1987). [The addition of E. coli 
SSB increased the rate 20-fold (O'Donnell et al, 1987), which is still an order of 
magnitude below the observed in vivo rate of PRV replication fork movement of 50 
nucleotides/s (Ben-Porat et al, 1977).] The predominant products synthesised by 
Pol on an M13 ssDNA template in the presence of UL42 are about 10 times longer 
than those synthesised in its absence (Gottlieb et al, 1990).
4.4.4 Regions involved in the Pol-UL42 interaction
The UL42-binding domain of Pol has been investigated by testing the ability of 
mutated Pol proteins to interact with UL42. Co-immunoprecipitation of the proteins 
translated in vitro in rabbit reticulocyte lysates showed that the C-terminal 227 amino 
acid residues of Pol are necessary and sufficient for specific interaction with UL42 
(Digard & Coen, 1990). Three subsequent studies have extended this finding to 
show that amino acid residues close to or at the the very C-terminus of this region are 
essential for the interaction, but different conclusions were reached regarding exactly 
which residues are important (Diggard et al, 1993a; Tenney et al, 1993; Stow,
1993).
A detailed analysis of deletion and insertion mutants showed that only -35 amino 
acid residues at the extreme C-terminus of Pol (residues 1201-1235) are necessary 
for interaction with UL42 as detected by co-immunoprecipitation (Digard et al, 
1993a). Moreover, the processivity of a Pol frameshift mutant in which the C- 
terminal 27 residues were replaced with an unrelated sequence could not be
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stimulated by UL42, and mutants lacking the C-terminal 19 or 27 residues were 
unable to complement a pol null mutant in a transfection assay (Digard et al, 1993a). 
However, the correlation is not absolute: a mutant with a four-amino acid in-frame 
insertion at residue 1216 was unaffected in its ability to complement a pol null 
mutant, but was severely impaired in its ability to interact with UL42 as detected by 
co-immunoprecipitation (Digard etal, 1993a).
An analysis of several truncated Pol proteins expressed in yeast cells yielded 
substantially different results, indicating that the region essential for interaction with 
UL42 is not at the extreme C-terminus of Pol, but between residues 1176 and 1195 
(Tenney et al, 1993). C-terminal truncations of 19 and of 40 residues did not affect 
the ability of Pol to be stimulated by UL42, but removal of 59 residues abolished 
UL42 stimulation. The Pol lacking 19 residues interacted with UL42 in a co- 
immunoprecipitation assay, but the mutants lacking 40 and 59 residues were not co- 
immunoprecipitated with UL42 (Tenney etal, 1993).
A third study (Stow, 1993) showed that Pol lacking the extreme C-terminal 27 amino 
acid residues was unable to support origin-dependent DNA replication in insect cells 
in the presence of the other six replication proteins. Full-length but not truncated Pol 
could be co-immunoprecipitated with UL42 from extracts of co-infected cells. The 
baseline catalytic activity of the truncated Pol was unimpaired, but, unlike the full- 
length control, it could not be stimulated by UL42 (Stow, 1993).
Both Digard et al and Tenney et al observed a lack of binding to UL42 of one or two 
Pol mutants which exhibited a functional interaction. This apparent contradiction 
may be due to such mutants forming complexes of reduced affinity, which are 
sufficient for a functional interaction, but do not survive the relatively high 
stringency of the co-immunoprecipitation assay. The major contradiction in these 
three studies, however, is that Digard et al and Stow find that the presence of the 
extreme C-terminus of Pol is essential for function, whereas Tenney et al find that it 
is not. This controversy will need to be resolved.
An important implication of the finding that a functional interaction between Pol and 
UL42 is essential for viral origin-dependent DNA replication and for virus growth 
(Stow, 1993; Digard et al, 1993) is that the Pol-UL42 interface is indeed a potential 
target for antiviral drugs.
It is interesting that the site of interaction of polymerase 5 with PCNA is proposed to 
be located in the C-terminus of the protein (Yang etal, 1992), in a region where the
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sequence of polymerase 5 diverges completely from that of its herpesvirus 
counterparts.
The region of the UL42 protein involved in the interaction has not been identified, 
and is the subject of intense investigation by several groups. Digard et al have 
analysed an extensive set of mutant UL42 proteins (obtained by in vitro transcription 
and translation of cloned UL42), testing (i) their ability to associate with Pol, (ii) to 
increase Pol processivity and (iii) to bind to DNA. They found that the N-terminal 
340 amino acid residues of UL42 were sufficient for all three activities, whereas 
deletions of more than 35 residues anywhere within this region abolished all three 
activities (Digard et al, 1993b). In contrast, single in-frame insertions of 4-5 
residues at any position had no effect, with the exception of an insertion at residue 
160, which destroyed Pol-binding and the capacity to increase processivity, but did 
not affect DNA-binding. This mutant was unable to complement a UL42 null virus 
in vivo (Digard et al, 1993b). Thus the main conclusions of this analysis are (i) that 
the DNA-binding and Pol-binding properties of UL42 are separable; (ii) that 
stimulation of processivity requires a direct interaction with Pol; (iii) that this 
interaction is essential in vivo. However, a more precise delineation of the functional 
domains of UL42 remains elusive. It seems that the N-terminal two-thirds of the 
protein constitute a single domain which cannot be subdivided without loss of 
structure and concomitant loss of both Pol- and DNA-binding properties.
The amino acid sequence of UL42 (McGeoch et al, 1988a) contains no recognised 
functional motifs and few interpretable features. In contrast to Pol, which is highly 
conserved among the herpesviruses, UL42 is the least conserved of the seven 
essential replication proteins. It has significant homology with its counterparts in 
PRV (29%) (Alberto Epstein, personal communication), in EHV-1 (27.8%; gene 
18) (Telford et al, 1992), and in VZV (23.5%; gene 16) (Davison & Scott, 1986). 
The processivity factors of HCMV (ICP36) and HHV- 6  (p41), share 41% sequence 
identity with each other, but have no significant sequence homology with UL42 
(Chee etal, 1990; Chang & Balachandran, 1991a, 1991b; Ertl & Powell, 1992). 
There is a positional homologue in EBV (BMRF1), with barely significant homology 
(21%) (Baer etal, 1984).
An alignment of the PRV, EHV-1 and VZV homologues with UL42 shows that, in 
the N-terminal two-thirds of the protein, there are several regions where conservative 
substitutions predominate (Figure 7). At the C-terminus there is no homology, and 
the proteins differ both in length and in sequence. This division of UL42 into a 
relatively conserved N-terminal domain and a unique C-terminal domain is reflected
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in the predicted structural features: the N-terminal region of -325 amino acid 
residues is more hydrophobic, less flexible, has a higher probability of P-sheet 
structure and a lower surface probability — all of which would indicate a more 
compact structure — than the C-terminal region (Figure 8 ). The region of UL42 
found to be necessary for function (Digard et al, personal communication) coincides 
precisely with the conserved N-terminal domain.
4.4.5 A comparison of UL42 with other processivity factors
At the current level of knowledge, there appear to be interesting similarities but also 
important differences between the UL42 protein and other processivity factors, such 
as PCNA, the E. coli p-clamp, T4 gp 45 and thioredoxin.
There is a molar excess (at least 20-fold) of UL42 relative to Pol in infected cells 
(Gottlieb et al, 1990), which has led to suggestions that the free UL42 may have an 
additional role in infection. However, the P subunit of E. coli Pol m  is also found 
in a 10-20-fold excess relative to the catalytic core (Komberg & Baker, 1992). 
Studies of E. coli Pol III indicate that the mechanism by which polymerase cycles 
from one replication fork to another requires a relative abundance of the processivity 
factor (Section 3.7).
One feature shared by UL42 and all the above-mentioned processivity factors is a 
direct interaction with the catalytic subunit of the respective polymerase (Section 
3.7). Another property that they may have in common is a plasticity of sequence. 
There is virtually no sequence homology between the three domains of the P-clamp, 
despite their strikingly similar three-dimensional architecture (Section 3.7). The high 
divergence between the herpesvirus UL42 homologues may indicate a similarly low 
restriction on amino acid substitutions. Not surprisingly, there is no detectable 
amino acid homology between UL42 and PCNA or the prokaryotic processivity 
factors. It is conceivable, however, that UL42 should be compared to the small 
subunit of polymerase 5, rather than to PCNA (Gottlieb et al, 1990). The sequence 
and function of the 48kDa subunit are as yet unknown, but it is seen to co-purify 
with the catalytic subunit through numerous chromatographic steps (Tan et al, 1986), 
in a manner reminiscent of UL42.
The DNA-binding property of the UL42 protein sets it apart from the other 
processivity factors. The E. coli p-clamp (Stukenberg et al, 1991), the T4 gp 45 
(Mace & Alberts, 1984a), PCNA (Tan et al, 1986; Prelich et al, 1987a), and 
thioredoxin (Huber et al, 1986), do not bind to DNA in the absence of other factors.
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The binding of PCNA, of the (3-clamp, and of gp 45 to DNA is mediated by RFC, 
by the y-complex, and by the gp 44/62 protein complex, respectively, in an ATP- 
dependent process (Section 3.7). In contrast, the formation of a processive, 
template-bound Pol-UL42 complex does not require ATP hydrolysis (O'Donnell et 
al, 1987), and resembles the T7 gp 5-thioredoxin complex in this respect.
The P-clamp is a dimer, both in solution and bound to DNA (Section 3.7), but there 
is no evidence for dimerisation of UL42 (Gottlieb et al, 1990).
4.5 UL29 (Major DNA-binding protein; ICP8)
The UL29 gene product, commonly designated infected-cell polypeptide 8  (ICP8 ) 
(Honess & Roizman, 1973), is the major viral DNA-binding protein (Bayliss et al, 
1975; Purifoy & Powell, 1976). It is an abundant protein of about 130kDa which 
binds more tightly to single-stranded than to double-stranded DNA (Ruyechan & 
Weir, 1984). Its binding is cooperative and sequence-independent (Ruyechan, 1983; 
Ruyechan & Weir, 1984). These properties are characteristic of the prokaryotic 
helix-destabilising proteins like the E. coli SSB and T4 gp 32 (Section 3.4), and 
suggest that ICP8  plays an analogous role in replication. Conditional lethal mutants 
mapping in the gene for ICP8  (Conley et al, 1981), or its HSV-2 equivalent, 
ICSP11,12 (Littler et al, 1983), were found to display a DNA-negative phenotype, 
confirming that the protein is essential for DNA replication.
There is clearly a functional interaction between ICP8  and the UL5/UL8/UL52 
helicase-primase (Section 4.3). There are also several lines of evidence that ICP8  
interacts with DNA polymerase. It stimulates polymerase activity on activated DNA 
(Ruyechan & Weir, 1984; Gottlieb et al, 1990), and on singly-primed M13 ssDNA 
(Hernandez & Lehman, 1990). Hernandez and Lehman (1990) found that ICP8  
potentiates the enhancement by UL42 of Pol processivity, but Gottlieb et al (1990) 
did not see this effect (Section 4.4). The stimulation of HSV-1 polymerase by E.coli 
SSB (O'Donnell et al, 1987) may reflect the functional similarity of E. coli SSB and 
ICP8 . A direct interaction between the major DNA binding protein and polymerase 
is indicated by the specific retention of the latter on an immunoaffinity column 
containing a MAb specific for HSV-2 ICSP 11,12 (Vaughan et al, 1984). Several ts 
mutants with defects in ICP8  have an altered sensitivity to the DNA polymerase 
inhibitors PAA and aphidicolin (Chiou et al, 1985). Immunofluorescent studies have 
shown that, at early times (2-3h) after infection, ICP8  localises to the cell nucleus 
where it assumes a punctate distribution at "pre-replicative sites" (Quinlan et al,
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1984). As viral DNA replication proceeds, these develop into large globular 
"replication compartments" where viral DNA replication occurs (Rixon et al, 1983; 
de Bruyn Kops & Knipe, 1988) (Section 2.2.4.1). ICP8  shows identical 
localisation in the absence of any other viral proteins (Quinlan et al, 1984), but the 
localisation of Pol and of cellular replication proteins to the pre-replicative sites 
requires a functional ICP8  (Bush et al, 1991). This indicates that it may play a key 
role in organising cellular and viral components into structures related to HSV 
replication (de Bruyn Kops & Knipe, 1988; Wilcock & Lane, 1991).
Studies of the major DNA-binding protein of both HSV serotypes have shown that it 
also interacts with the viral alkaline nuclease (Section 2.2.4.3). The two proteins 
interact specifically on immunoaffinity columns (Vaughan et al, 1984) and are co- 
immunoprecipitated by MAbs specific for either protein (Thomas et al, 1988,1992). 
The significance of this interaction is not known.
Some functional domains of ICP8  have been identified. The C-terminus contains a 
nuclear localisation signal (Gao & Knipe, 1989). A "zinc finger" motif is found in 
the central region of the sequence, and recently it was shown that zinc is tightly 
associated with the protein (Gupte et al, 1991). A 300bp region proximal to the zinc 
finger is absolutely required for DNA binding (Leinbach & Heath, 1988; Gao & 
Knipe, 1989; Wang & Hall, 1990). There is a weak but detectable homology 
between the N-terminal regions of ICP8  and PCNA (Matsumoto et al, 1987). 
Mutants deleted in this region fail to replicate DNA, showing that it has an essential 
function (Gao & Knipe, 1989). Whether this region is involved in interactions with 
Pol or with cellular proteins remains to be seen.
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5. Anti-herpetic drugs
There are a number of compounds which are used to control herpesvirus infections. 
The most successful antiviral drugs to date are nucleoside analogues, which 
specifically block viral DNA replication. The structures of several anti-herpetic 
drugs are shown in Figure 9a. The ultimate target of all these drugs is the viral DNA 
polymerase. The ability of nucleoside analogues to selectively inhibit viral 
polymerases is apparently due to the inherently lower precision of base selection by 
the viral enzymes compared to their cellular counterparts (Hall et al, 1985). The 
selectivity of a drug determines its therapeutic index, ie the effective antiviral dose 
relative to the dose which has an adverse effect on the host. The molecular basis of 
anti-herpetic drug action has been succinctly reviewed by Coen (1992).
5.1 Acyclovir
ACV; acycloguanosine; 9-[(2-hydroxy-ethoxy)methyl]guanine
ACV has the highest therapeutic index (300-3000) of any anti-herpetic drug 
(Crumpacker etal, 1979; Dorsky & Crumpacker, 1987), and the molecular basis of 
its action is well understood. ACV consists of a guanine base linked to a molecule 
representing an incomplete sugar ring (Figure 9a). It is a potent inhibitor of HSV, 
VZV and EBV DNA synthesis (Elion et al, 1977; Schaeffer et al, 1978; Colby et al,
1980). The selectivity of this drug is determined by its interactions with two viral 
enzymes, thymidine kinase (TK) and DNA polymerase.
As described in Section 2.2.4.3, the viral TK, being less specific than its cellular 
counterpart, is able to phosphorylate a range of nucleosides and nucleoside 
analogues, including ACV (Elion et al, 1977; Fyfe et al, 1978). The ACV 5'- 
monophosphate is then converted to the di- and triphosphate forms by cellular 
kinases. ACV triphosphate (ACVTP) selectively inhibits HSV polymerase (Furman 
et al, 1979; Derse et al, 1981) in a three-step process: (i) ACVTP competes with 
dGTP for binding to the polmerase; (ii) it is incorporated into the DNA chain; (iii)
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the polymerase translocates to the next position and binds the next required 
nucleotide, but cannot catalyse the formation of a phosphodiester bond in the absence 
of a 3'-OH on the ACVTP, which results in the formation of a tight dead-end 
complex and apparent inactivation of the enzyme (Reardon & Spector, 1989 and 
references therein).
That the viral TK and Pol are the molecular targets with which ACV selectively 
interacts is confirmed by the analysis of mutant viruses resistant to the drug — which 
arise in patients treated with ACV and in laboratory culture. The mutations 
conferring ACV resistance map exclusively to the pol and/or tk genes (Coen & 
Schaffer, 1980; Schnipper & Crumpacker, 1980; Field etal, 1980; Furman etal,
1981). Many mutants are TK~, but others encode TK and polymerase enzymes 
which have altered substrate specificities (Furman etal, 1981; Larder eta l, 1983; 
Coen etal, 1984; Darby eta l, 1984).
5.2 Ganciclovir
DHPG; 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
Ganciclovir is a nucleoside analogue similar in structure to acyclovir (Figure 9a). It 
is one of the few drugs effective against HCMV, and is also active against HSV, 
VZV and EBV (Cheng et al, 1983). HCMV does not encode a TK (Chee et al, 
1990), and is therefore relatively refractory to the action of ACV. It does, however, 
possess another pyrimidine kinase activity capable of phosphorylating ganciclovir 
(Biron et al, 1985). This enzyme has been identified, by the study of ganciclovir- 
resistant HCMV isolates, as the product of gene UL97 (Littler et al, 1992; Sullivan 
etal, 1992).
Cellular enzymes convert the ganciclovir 5'-monophosphate to the triphosphate, 
which selectively inhibits the viral polymerase (Mar et al, 1985). Incorporation of 
ganciclovir into DNA causes the polymerase to pause or to dissociate from the 
template, but does not inactivate it in the manner of acyclovir (Frank et al, 1984; 
Reid etal, 1988).
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5.3 Other nucleoside analogues
5.3.1 Vidarabine
araA, 9-(P-D-arabinofuranosyl) adenine
This is an analogue of adenosine, in which an adenine base is attached to the sugar 
arabinose (Figure 9a). It is 5’-phosphorylated to an active triphosphate only by 
cellular enzymes, and is therefore far less selective than ACV. It does, however, 
have sufficiently selective activity against HSV, VZV, CMV and EBV to be used as a 
drug. Its antiviral activity is probaly entirely due to its interaction with viral 
polymerases and incorporation into DNA at a lower concentration than that which 
affects cellular replication (reviewed by North & Cohen, 1984). The isolation of 
araA-resistant mutants of HSV with lesions in the pol gene confirms that the 
inhibition of the viral polymerase is selective (Coen et al, 1982, 1985).
5.3.2 Halogenated pyrimidine nucleoside analogues
Numerous halogenated analogues of pyrimidine nucleosides have been evaluated for 
their antiviral effects (reviewed in De Clercq, 1985), and some of the earliest antiviral 
drugs, such as idoxuridine and trifluridine, are in this category. These compounds 
are phosphorylated by both cellular and viral TKs, and their major selective target is 
the viral polymerase (reviewed by Prusoff etal, 1984; De Clercq, 1985).
An extensively studied compound of this type is (E)-5-(2-bromovinyldeoxyuridine) 
(BVdU) (Figure 9a), which is active against HSV-1 and VZV, but not so active 
against HSV-2. BVdU is phosphorylated to the 5'-monophosphate by the viral TK, 
and then to the diphosphate by the thymidilate kinase activity of HSV-1 and VZV 
(but not HSV-2) TK (Fyfe et al, 1982). The 5'-triphosphates of BVdU and other 
similar compounds are competitive inhibitors of thymidine triphosphate utilisation by 
viral DNA polymerases (Allaudeen et al, 1981; Ruth & Cheng, 1981). They are 
used as alternative substrates and incorporated quite efficiently into viral DNA 
(Allaudeen et al, 1982; Kowalzick et al, 1982). This results in deleterious effects 
such as DNA fragmentation (Chen et al, 1976; Mancini et al, 1983) and 
transcriptional defects (Ruth & Cheng, 1982; S£gi et al, 1982).
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5.3.3 Phosphonomethylalky 1 derivatives
These phosphorylated nucleoside analogues are a newer class of antiviral drug. The 
prototype compound, (S)-HPMPA (Figure 9a), is active against a broad spectrum of 
DNA viruses (De Clercq et al, 1986). The clinical importance of these compounds 
lies in the fact that, being already phosphorylated, they are effective against TK~ 
mutant viruses which are resistant to other drugs (De Clercq et al, 1986). These 
compounds are further phosphorylated by cellular kinases and almost certainly act by 
selectively inhibiting viral DNA polymerase, as indicated by the isolation of a pol 
mutant of HSV-1 resistant to a phosphonmethylalkyl compound (Foster et al, 1991).
5.4 Foscamet
Phosphonoformic acid, PFA
Like phosphonoacetic acid, foscamet is an analogue of pyrophosphate (Figure 9a), 
which is a product of the polymerisation of DNA. It is a potent inhibitor of 
herpesvirus replication (Helgstrand et al, 1978). It acts by non-competitive 
inhibition, interacting directly with Pol at the pyrophosphate binding site (Erikkson et 
al, 1980; Ostrander & Cheng, 1980). The existence of foscamet-resistant pol 
mutants shows that it acts selectively on the viral enzyme (Erikkson & Oberg, 1979).
5.5 Triterpenoid compounds
These compounds exhibit broad-range antiviral activity, both in tissue culture and in 
man (reviewed by Dargan & Subak-Sharpe, 1992). The synthetic tri terpenoids 
carbenoxolone (CBX) and cicloxolone (CCX) are based on the structure of 
glycyrrhizin (GL), which is the active constituent of licorice (Revers, 1946) (Figure 
9b). GL is routinely used in Japan for the treatment of viral hepatitis. Clinical trials 
have shown that topical treatment with CCX or CBX accelerates the healing of HSV 
lesions (Poswillo & Roberts, 1981; Csonka & Tyrrell, 1984).
The antiviral activity of GL, CBX and CCX is largely a result of their disruption of 
host cell membrane functions, particularly the postranslational modification and 
transport of glycoproteins by the Golgi, which in turn affects the replication and 
assembly of a wide range of viruses — in vitro studies have shown that viruses from 
at least 1 2  different virus families are sensitive to one or more of these compounds.
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A major potential advantage of the triterpenoid compounds is that — since they do 
not selectively target a particular virus protein but act by altering the cellular 
environment — the likelihood of drug-resistant mutants arising is minimal.
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6. Disruption of protein interactions
Any biological process which relies on the specific interaction between two 
macromolecules could, in principle, be inhibited by interfering with that interaction. 
Recognition sites on proteins are exquisitely specific, and there are various examples 
of peptides, derived from the recognition site on one of the ligands, which retain 
sufficient structure to compete with the whole protein for a binding site. This may 
indicate that a particular sequence is directly involved in an interaction; it also 
identifies a compound which is capable of specifically disrupting that interaction.
Essential interactions between viral protein subunits are potential targets for antiviral 
agents. Described below are some examples of interactions involving virus proteins 
that can be specifically inhibited. This topic has been more comprehensively 
reviewed by Marsden (1992). The challenging task of developing therapeutically 
useful drugs from lead peptides is briefly considered.
6.1 FI protein of Paramyxoviridae
Membrane fusion by Paramyxoviridae is an example of a virus-host cell interaction 
that can be disrupted by a peptide fragment of the virus component. 
Paramyxoviridae — the family to which measles and mumps viruses belong — have 
two surface glycoproteins: an attachment protein and a fusion (F) protein. The F 
protein is made fusogenic by proteolytic cleavage of an inactive precursor (Fo) to 
give two disulphide-linked polypeptides, Fi and F2 . The newly-generated N- 
terminus of Fi is very hydrophobic and can insert into the cell membrane (reviewed 
by Kingsbury, 1990a). Short peptides with amino acid sequences similar to the N- 
terminal region of Fi specifically inhibit virus-induced cell fusion and virus infection 
(Nicolaides et al, 1968; M ille rs  al, 1968; Richardson etal, 1980; Richardson & 
Choppin, 1983). The cell membrane components of this interaction are as yet 
undetermined.
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6.1a The a-TIF-Oct-1 transcription complex
The HSV-1 virion protein a-TIF (Vmw65, VP 16) plays a central role in the 
assembly of a virus-specific transcription complex responsible for the expression of 
IE genes (Section 2.2.3.1). The complex is composed of a-TIF and at least two 
cellular proteins: the cellular transcription factor Oct-l(OTF-l, NFIII, TRF), and 
the complex forming factor CCF (HCF, VCAF-1, C l) (Gerster & Roeder, 1988; 
O'Hare & Goding, 1988; Preston et al, 1988; Kristie et al, 1989; Katan et al, 
1990; Xiao & Capone, 1990).
Formation of the complex can be inhibited by peptides corresponding to a region of 
a -T F  involved in the interaction (Haigh et al, 1990; Hayes & O'Hare, 1993). The 
region of a-T IF  encompassing amino acid residues 360-388 was found, by 
muUtional analysis, to be critical for complex assembly (Greaves & O'Hare, 1990). 
The susceptibility of this region of a-TIF to proteolysis, and its selective protection 
frorr proteolysis upon complex assembly, indicated that it was (i) exposed on the 
surface of the protein, and (ii) likely to be involved in protein-protein interactions 
withn the complex (Hayes & O'Hare, 1993). A peptide corresponding to amino 
acids 360-373 was found to inhibit complex assembly without affecting the DNA- 
bindng property of Oct-1 alone (Haigh et al, 1990). The peptide, proposed to act 
by competing with a-TIF for binding to the cellular components <of the complex, 
inhildted complex formation when added to a nuclear extfact prioif to the addition 
of a-TIF, but was not able to disrupt a pre-formed complex (Haigh et al, 1990). 
Singe amino acid substitutions within this region which reduced the complex- 
formng ability of the whole protein (Greaves & O'Hare, 1990) correspondingly 
reduted the inhibitory properties of the peptide (Hayes & O'Hare, 1993). By using 
overhpping peptides, the inhibitory sequence has been narrowed down to eiglht 
amiro acids, REHAYSRA, corresponding to residues 360-367 (Hayes & O'Hane,
1993). Interestingly, this sequence does not encompass all the residues shown tto 
be esential for complex formation (Greaves & O'Hare, 1990). It remains to be 
testei whether the presence of this peptide in a cell prevents the expression of EE 
gene} upon HSV-1 infection.
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6.2 Herpesvirus ribonucleotide reductase (RR)
HSV RR provides the best-studied example of an interaction between two viral 
protein subunits that can be dissociated by a peptide. It is likely that the enzyme 
plays an important role in pathogenesis, and is therefore a valid antiviral target 
(Section 2.2.4.3).
RR consists of two dissociable, homodimeric proteins: a large subunit (Rl) and a 
small subunit (R2) (Thelander & Reichard, 1979; Averett et al, 1984; Ingermarsson 
& Lankinen, 1987). A nonapeptide (YAGAVVNDL), corresponding to the very C- 
terminus of the small subunit, specifically inhibits the viral enzyme and does not 
affect its cellular counterpart (Dutia etal, 1986; Cohen et al, 1986). The peptide acts 
by competing for the R2 binding site on the Rl protein, and thus inhibits the normal 
association of the two subunits (Figure 10) (Dutia et al, 1986; Cohen et al, 1986; 
McClements et al, 1988; Paradis ef a/, 1988; Darling e ta l, 1990).
The mammalian and E. coli enzymes can be similarly inhibited by the corresponding 
C-terminal peptidesfYang etal, 1990; Cosentino et al, 1991). Moreover, peptides 
from the HSV, mammalian and E. coli C-terminal R2 sequences — which are totally 
diverse —  can each inhibit the homologous, but not the heterologous enzymes 
(Cosentino etal, 1991).
Although effective at inhibiting HSV RR enzyme activity in vitro, the YAGAVVNDL 
peptide does not inhibit virus growth in tissue culture, probably because it is too 
large to cross the cell membrane (Dutia et al, 1986). Nevertheless, it provides a 
starting point for the development of therapeutically useful compounds. The most 
active derivatives yet reported have 500-fold greater potency (IC50 for inhibition of 
RR activity = lOOnM) and are significantly smaller (Mr = 682) than the lead peptide 
(Biomega Inc, 1990). Their antiviral activity, if any, has not been reported.
The likely spectrum of activity of such compounds has been investigated. The RRs 
induced by PRV and EHV-1 are inhibited by the YAGAVVNDL peptide (Cohen et 
al, 1987; Telford et al, 1990), indicating that a drug based on the peptide would also 
be active against these alphaherpesviruses. It is doubtful whether the more distantly 
related HCMV encodes a RR. Several workers have been unable to detect an 
HCMV-induced RR activity (Lankinen, Darling, personal communication). The 
predicted protein sequence of HCMV gene UL45 shares significant homology with 
the C-terminal one-third of other herpesvirus Rl subunits (Chee et al, 1990). 
However, it lacks all of the motifs — including a C-terminal pair of redox shuttle 
cysteines, essential for enzyme activity — which are conserved in the R l subunits of
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Figure 10. A schematic representation of the mechanism by which HSV 
ribonucleotide reductase is inhibited by the peptide YAGAVVNDL. The figure is a 
simplification of the enzyme in which both the large and small subunits are 
homodimers. Reproduced with modifications from Dutia et al, 1986.
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mouse, E. coli, T4, Vaccinia, VZV, HSV and EBV (Eriksson & Sjorberg, 1989). 
The R2 subunits also contain highly conserved residues, which are postulated to 
make up the iron centre of the enzyme (Stubbe, 1989), but no HCMV gene encodes 
these motifs. These (unpublished) data indicate that HCMV does not encode a 
functional RR, and therefore virus growth would not be susceptible to inhibition by 
the blocking of this enzyme.
6.3 Semliki forest virus (SFV) spike glycoprotein
SFV is one of the two well-studied members of the alphavirus genus. Virions of 
these small, enveloped RNA viruses consist of a nucleocapsid surrounded by a host­
cell derived envelope, which contains spikes of the viral glycoproteins E l and E2. 
The virion is assembled at the inner surface of the plasma membrane, by a process in 
which the nucleocapsid protein associates specifically with the cytoplasmic domain 
of the E2 glycoprotein. Mature virions then bud from the plasma membrane 
(reviewed by Schlesinger & Schlesinger, 1986,1990).
By using a network of anti-E2 anti-idiotype and anti-anti-idiotype antibodies, the 
region which interacts with the nucleocapsid was localised to the very C-terminus of 
the glycoprotein (Vaux etal, 1988; Kail etal, 1991). An octapeptide corresponding 
to E2 C-terminal sequence (CCAPRAHA) interacted specifically with nucleocapsids, 
and blocked binding of a MAb specific for the nucleocapsid recognition site (Kail et 
al, 1991). The effect of the octapeptide on virus growth was tested by co- 
microinjecting cells with peptide and infectious SFV RNA. In the presence of the 
peptide, budding and spread of virus was inhibited and virus yield was reduced by at 
least an order of magnitude (Kail et al, 1991). It remains to be seen whether this is a 
route to developing an antiviral therapy.
6.4 Influenza virus haemagglutinin
Inhibition of influenza virus, apparently similar to the inhibition of SFV described 
above, has also been reported (Collier et al, 1991). Influenza A, an orthomyxovirus, 
contains two membrane glycoproteins, haemagglutinin (HA) and neuraminidase (N). 
HA consists of two disulphide-linked chains, HAi and HA2. The protein is 
anchored in the cell membrane close to the C-terminus of HA2, with a short (11 
amino acid residue) region on the internal side of the membrane. Virion assembly is 
poorly characterised, but appears to involve interactions between viral matrix
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proteins, the nucleocapsid, and the cytoplasmic domains of the viral glycoproteins at 
the plasma membrane (reviewed by Kingsbury, 1990b).
A 10 amino acid peptide (NGSLQCRICI), corresponding to the cytoplasmic domain 
of HA2 , was shown to inhibit the release of infectious virions when added to the 
culture medium during infection (Collier etal, 1991). The peptide acted specifically 
on influenza virus and had no effect on two other enveloped RNA viruses, Sindbis 
and vesicular stomatitis virus. It was postulated to cross the plasma membrane and 
act by competing with the hemagglutinin for sites recognised by nucleocapsids or 
matrix proteins.
6.5 Development of useful drugs from lead peptides
Inhibitory peptides are not therapeutically useful because they are rapidly metabolised 
and are generally too large to cross cell membranes. This means that any lead 
peptide requires extensive modification through a process of molecular mimicry 
whereby overall size is reduced, labile and flexible peptide bonds are replaced by 
bonds which are more resistant to degradation and have a more restricted 
conformation, and side-chains are substituted by more potent groups. The success 
rate is low, the time scale is long, and an element of luck is involved (reviewed by 
Johnson AL etal, 1990).
One reason for persevering with the development of compounds which act by 
subunit dissociation is that, potentially, the incidence of drug-resistant mutations 
could be orders of magnitude lower than that seen with drugs such as nucleoside 
analogues. Drug resistance would require simultaneous, complementary mutations 
in both of the protein subunits such that a functional complex could be formed in the 
presence of the drug. It will be very interesting to see if this proves to be true in 
practice.
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1. Chemicals and reagents
Unless specifically stated below, all chemicals and reagents were obtained from 
BDH Chemicals Ltd, Poole, Dorset, or from Sigma (London) Ltd and were of 
analytical grade or better.
Ammonium persulphate,
N,N,N',N-tetramethylethylenediamine
(TEMED)
Bio-Rad protein assay reagents and 
standards
Ecoscint A
Acetic acid, acetonitrile (HPLC-grade S), 
f-amyl alcohol, diethyl ether, 
dimethylformamide, formic acid, 
piperidine, trifluoroacetic acid
Ethanedithiol, ethylmethylsulphide, 
m-cresol, tetrabutylammonium fluoride, 
thioanisole, trimethylsilylbromide
Fmoc amino acid active esters, 
1-hydroxybenzotriazole (HOBt), 
Fmoc-Ultrosyn C resin
Ultrosyn A resin with Fmoc Pro attached
Bio-Rad Laboratories, Richmond, 
California, USA.
Bio-Rad Laboratories, Richmond, 
California, USA.
National Diagnostics, Manville, New 
Jersey, USA.
Rathbum Chemicals Ltd., Walkerbum, 
Scotland, UK.
Aldrich Chemical Co Ltd, Gillingham, 
Dorset, UK.
Novabiochem (UK) Ltd, Nottingham, 
UK.
Peptide & Protein Research, Exeter, 
Devon, UK.
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32P-lahel1ed nucleotide Activity Concentration Code
[a 3 2P]dATP ~3000Ci/mmol lOmCi/ml PB 10204
[a 3 2P]dCTP ~3000Ci/mmol lOmCi/ml PB 10205
[Y52P]ATP ~5000Ci/mmol lOmCi/ml PB 10218
Materials
X DNA
M13 m pl8  ssDNA
M13 sequencing primer no. 1211:
5 -GT AAAACG ACGGCC AGT
Duplex oligonucleotide:
5 ' -GATCCGCGAAGCGTTCGCACTTCGTCCCA
GCGCTTCGCAAGCGTGAAGCAGGGTCTAG-5'
Radiochemicals
Deoxynucleoside triphosphates, ATP 
(lOOmM solutions, pH 7.5)
2. Miscellaneous materials
Whatman DE81 ion exchange paper
Kodak X-Omat XS1 film 
Dynamax HPLC columns
3. Enzymes
Restriction enzymes 
T4 polynucleotide kinase 
Klenow polymerase
BRL, Paisley, Scotland,UK.
1) New England Biolabs, Bishops 
Stortford, UK.
2) Cambridge Bioscience, Cambridge, 
UK.
New England Biolabs, Bishops 
Stortford, UK.
Synthesised and purified in house by 
Nigel Stow.
Amersham International PLC, Bucks, 
UK.
Pharmacia LKB, Uppsala, 
Sweden
Whatman International Ltd, Maidstone, 
UK.
Kodak Ltd, UK.
Anachem, Luton, Bedfordshire, UK.
Boehringer Mannheim, Lewes,
E. Sussex, UK.
New England Biolabs,
Bishops Stortford, UK.
Purified in house by Moira Watson 
from E. coli cells expressing a plasmid 
construct (Joyce & Grindley, 1983).
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HSV-1 Pol 
HSV-1 UL42 protein
4. Buffers and solutions
Annealing buffer 
Alkaline electrophoresis buffer 
Alkaline loading buffer
Binding buffer
Buffer B
Klenow buffer 
Loading buffer 
Pol reaction buffer
Gift from J Gottlieb and M Challberg, 
purified from insect cells infected with 
recombinant baculovirus (Gottlieb et al, 
1990).
1) Gift from J Gottlieb and M 
Challberg, purified from insect cells 
infected with recombinant baculovirus 
(Gottlieb etal, 1990).
2) Purified in house by Mary Murphy 
from insect cells infected with 
recombinant baculovirus (Stow, 1992).
20mM Tris-HCl pH7.5, 25mM NaCl
30mM NaOH, 2mM EDTA
lOOmM NaOH, ImM EDTA,
2.5% Ficoll, bromophenol blue
20mM HEPES pH7.6, 0.5mM DTT, 
0.5mM EDTA, 10% glycerol, 
50p.g/ml BSA
lOmM Tris-HCl pH 8 , 5mM MgCl2, 
100 mM NaCl,
ImM 2-mercaptoethanol
50mM Tris-HCl pH7.5, 
lOmM MgCl2, ImM DTT
25% glycerol, lOmM DTT,
0.01% bromophenol blue in TBE
20mM HEPES pH7.6, ImM MgCl2, 
4% glycerol, O.lmM EDTA,
ImM DTT, 75mM NaCl
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Pol storage buffer
PK (T4 polynucleotide kinase) buffer 
Stop solution 
TBE 
TE
20mM HEPES pH7.6, 0.5mM DTT, 
0.5mM EDTA, 10% glycerol, 50p,g/ml 
BSA
40mM Tris-HCl pH 7.5, 
lOmM MgCl2, 5mM DTT
2 0 p,g/ml of sonicated calf thymus 
DNA, 0.67% SDS, 300mM NaCl
90mM Tris, 89mM boric acid,
ImM EDTA
lOmM Tris-HCl pH 7.4, ImM EDTA
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1. Oligopeptides
1.1 Synthesis of overlapping peptides
Ninety six pentadecapeptides spanning the entire 488 amino acids of the UL42 
protein were synthesised by continuous-flow Fmoc chemistry (reviewed by Atherton 
& Sheppard, 1989) using a Novabiochem peptide synthesiser. DHBT amino acid 
esters were used for coupling Arg, Thr and Ser; PFP esters in conjuction with HOBt 
were used for coupling all the other amino acids. The progress of the synthesis was 
monitored by measuring the UV absorption of the fluorenylmethyl chromophore 
during each cycle of acylation and deprotection, and remedial action taken whenever 
necessary.
Each peptide was 15 amino acids long and overlapped the adjacent one by 10 amino 
acids, with some exceptions, discussed in the results. The three in-series columns of 
the synthesiser were used for simultaneous coupling of each five-amino-acid epitope 
to three consecutive peptides. With the exception of the carboxy-terminal peptide, 
they were synthesised on Ultrosyn C Kieselguhr polyamide resin, to which the first 
residue is attached on the machine under standard conditions for peptide bond 
formation. Ultrosyn C is specifically designed to make peptide carboxy-amides. 
The scale of synthesis was 0.12mmol, ie 0.04mmol of functionalised resin (400mg) 
was used in each column. Pre-packed vials containing 0.5mmol of Fmoc amino acid 
esters were used, giving a 4x excess of amino acid during coupling reactions.
Synthesis of the C-terminal peptide
The C-terminal peptide was synthesised as a peptide acid on Ultrosyn A resin to 
which a proline had been coupled via an acid-labile linkage. Synthesis of a peptide 
with a C-terminal proline posed a potential problem, since C-terminal Pro dipeptide 
esters tend to undergo spontaneous cleavage from the resin support due to base- 
catalysed intramolecular aminolysis during deprotection of the second residue with 
20% piperidine in dimethylformamide (DMF). An alternative deprotection reagent,
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0.02M tetrabutyl ammonium fluoride in DMF, was therefore used for the second 
deprotection (Ueki & Amemiya, 1987).
Extra peptides
Other peptides, as described in the text, were also synthesised. Unless stated 
otherwise, all were purified to greater than 95% homogeneity and had an Mr 
(determined by FAB MS analysis — 1.3, below) in agreement with that expected.
1.2 Cleavage and deprotection
The peptide resin was transferred from the column into a sintered glass funnel and 
washed with the following solvents: DMF, r-amyl alcohol, acetic acid, r-amyl alcohol 
and diethyl ether. It was then transferred into a 100ml round-bottomed flask and 
dried in an evacuated dessicator. As a precaution against an unsuccessful cleavage or 
any mishap, in most cases only half of the peptide resin was cleaved initially while 
the rest was stored at -20°C. 95% trifluoroacetic acid(TFA) (lml/lOmg resin) was 
used to cleave the peptide from the resin and remove the sidechain protecting groups.
For peptides which did not contain Arg(Mtr), Cys(Trt), Met or Trp, a 95% aqueous 
solution of TFA was used, while for peptides containing any combination of the 
above amino acids, appropriate scavengers were added (Table 4). The cleavage 
reaction was carried out in a stoppered flask at room temperature for the time shown 
in Table 4. The resin was removed by filtration under reduced pressure through a 
sintered glass funnel and washed with 5ml of TFA. The peptide solution was 
reduced on a rotary evaporator to a volume of l-2m l (except in the case of peptides 
containing Cys-Trt, which, to avoid reattachment of the Trt group, were only 
reduced to 8 -10ml). The peptide was then precipitated out of solution by the addition 
of 20ml of diethyl ether. The precipitate was centrifuged, the ether removed and the 
precipitate thoroughly washed twice with ether. The peptide was then dissolved in 
25ml of Milli-Q water and, after removal of any residual ether by rotary evaporation, 
it was shell-frozen and lyophilised.
Cleavage of peptides containing Arg and Trp
Peptides containing Arg(Mtr) and an unprotected Trp residue can be cleaved 
successfully in 95% TFA/ 5% phenol/ 1% EDT, but occasionally problems occur 
due to the irreversible modification of Trp residues, either by dithioketal formation or 
by transfer of the Mtr group from arginine to the indole ring of tryptophan (Atherton 
& Sheppard, 1989). An alternative two-step method recommended by Peter White 
of Novabiochem was therefore used for all peptides containing both Arg and Trp.
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Table 4. CONDITIONS FOR CLEAVAGE OF PEPTIDES
Arg Cys Met Trp TFA (%) Scavengers (%) Time (hrs)
-  -  -  -  95 Water (5) 1-1.5
+ -  -  -  95 Phenol (5) >6
+ 95 EDT (5) 1-1.5
-  -  + -  95 EMS (5) 1-1.5
-  -  -  + 1-1.5
-  + -  + 94 Phenol (5) EDT (1) 1-1.5
+ + -  -  >6
+ + + -  93 Phenol (3) >6
+ -  + -  EDT (1) EMS (3)
+ -  + + TMSB (12.5)
+ + -  + 71 EDT (4.5) 0.5
+ + + + m-cresol (1)
Thioanisole (11)
Scavenger abreviations
EDT ethanedi thiol
EMS ethylmethylsulphide
TMSB trimethylsilylbromide
Methods
The peptide was first cleaved from the resin by allowing 5% TFA in dichloromethane 
(DGM) to drip through the resin in a sintered glass funnel for an hour. The TFA and 
DCM were removed on a rotary evaporator. The cleavage mixture of TMSB, EDT, 
ra-cresol and thioanisole in TFA (Table 4) was made up under under nitrogen, 
cooled to 0°C and added to the protected peptide. This was allowed to stand at 0°C 
under a blanket of nitrogen for 20-30 minutes. The mixture was then evaporated 
using a stream of nitrogen and the peptide precipitated in ether as above.
1.3 Analysis of peptides
Mass spectrometry
The molecular weight of each peptide was determined by mass spectrometry (MS). 
Several were analysed by M-Scan Ltd, Ascot, England, using the Fast Atom 
Bombardment (FAB) ionisation technique (Barber etal, 1981). The majority were 
analysed by plasma desorption ionisation on a time-of-flight mass spectrometer by 
John Kitchin at Glaxo Group Research. These MS techniques of peptide analysis 
have been reviewed by Biemann (1992).
Reverse phase high pressure liquid chromatography (HPLC)
The purity of each peptide was determined by reverse phase HPLC monitored at 
225nm, on a Beckman System Gold HPLC using a Dynamax 300A C8 analytical 
column (4.6mm internal diameter x 250mm length, catalogue number 83-303-C) and 
a gradient of 0-95% acetonitrile (plus 0.05%TFA) in water (plus 0.1%TFA) run 
over 20 minutes at a flow rate of 0.5ml/min.
Capillary zone electrophoresis (CZE)
Where indicated, purified peptides were analysed by CZE by Barry Coomber at 
Glaxo Group Research. The physical basis of separation in CZE is different from 
that in reverse phase HPLC, and is therefore an appropriate way of checking their 
purity.
1.4 Purification of Peptides
Where indicated, peptides were purified by reverse phase chromatography on a 
Beckman System Gold HPLC using a Dynamax 300A C8 preparative column 
(21.4mm internal diameter x 250mm length, catalogue number 83-323-C) and a 
gradient of 0-95% acetonitrile (plus 0.05%TFA) in water (plus 0.1%TFA) run over
64
Methods
20 minutes at a flow rate of lOml/min. Fractions were analysed by reverse phase 
HPLC as above, the peak fractions pooled, lyophilised and reanalysed by reverse 
phase HPLC.
1.5 Storage of peptides
Lyophilised peptides were stored at-20°C in dry universal bottles. On removal from 
storage, they were warmed to room temperature before opening.
1.6 Dissolution of peptides
Peptides were dissolved in Milli-Q water for analysis, purification and addition to 
assays. Those which were not easily soluble in water were treated as follows: 
Suspensions of acidic peptides in water were bubbled with ammonia vapour 
(typically 1-2 volumes of vapour/volume of water) in order to raise the pH of the 
solution. Basic peptides were dissolved in a small amount of 100% formic acid and 
then water was added to the required volume.
2. DNA polymerase assays
2.1 HSV-1 DNA polymerase
HSV-1 DNA polymerase activity was assayed using a singly primed, single stranded 
circular M13 (7.25kb) DNA template under conditions described previously 
(Gottlieb et al, 1990) with minor modifications. The template was prepared by 
hybridising lpmol of synthetic oligonucleotide primer to 400fmol of M13 mpl8 
ssDNA in 20pl of annealing buffer. The mixture was incubated at 65°C for 2 
minutes and allowed to cool slowly to room temperature for 2 hours.
The assay was performed at 37°C in a 50|il volume of pol reaction buffer containing 
0.5mM ATP, 60|liM of each of three unlabelled deoxyribonucleoside triphosphates 
and 2pM of the fourth [a32P]-labelled nucleotide (either dATP or dCTP at 9xl04 
cpm/pmol), 2.5p,g BSA (protease free) and Pol andUL42 proteins as described in the 
Results. M13 DNA template-primer was used at lOjig/ml (4nM) for measuring the 
activity of Pol alone, and at lpg/ml for all other assays, unless specified otherwise. 
Peptides were included as indicated and the mixture pre-incubated at 37 °C for 10 min
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(3 min in assays of full length M13 DNA synthesis). Reactions were initiated by the 
addition of [a32P] dNTP.
2.1.1 Measurement of processive activity
To measure the synthesis of full-length M13 DNA the reactions were terminated after 
30 minutes by adding 150^1 of stop solution. The reaction products were extracted 
with an equal volume of phenol (pre-equilibrated with TE buffer) foUowed by 
chloroform/isoamyl alcohol (24:1), precipitated in ethanol and re-dissolved in 40pl 
of alkaline loading buffer, then analysed by electrophoresis in alkaline 1% agarose 
gels. The DNA was denatured to single strands under these conditions (Sambrook et 
al, 1989). Gels were run overnight at 40V in alkaline electrophoresis buffer, dried 
and exposed to X-Omat XS1 film at -70°C for autoradiography.
Densitometry
A Hoeffer GS-300 Scanning Densitometer and GS-360 data analysis system was 
used to quantitate the density of bands on the autoradiographs, by scanning through 
the centre of each band and integrating the absorbance.
Radiolabelled marker DNA
Full length linearised M13 DNA was radiolabelled and used as a size marker on aU 
gels. Double stranded M13mp8 DNA, linearised with Sma I and treated with calf 
intestinal phosphatase, was obtained from Aidan Dolan. lOOng of DNA were 
incubated with 0.5 unit T4 polynucleotide kinase for 20 min at 37°C in a 5 j l x 1 volume 
of £K buffer containing 5p,Ci [y32P] ATP (6.6xl06 cpm/pmol). M13mp8 DNA is 
30 base-pairs shorter than mpl8, but this difference is undetectable at the top of a 1% 
agarose gel.
Radiolabelled fragments obtained by Hind III digestion of X DNA were used as 
molecular size markers. 4pg of X DNA were incubated for 90 min at 37°C with 10 
units of Hind ID in a 20pl volume of buffer B. Then 0.5|ig of the digested DNA 
was incubated for 15 min at 30°C in a 7.5p,l volume of Klenow buffer containing 
5mM dGTP, 5mM dCTP, 5mM dTTP, 10|nCi [a32P] dATP (6.6xl06 cpm/pmol) 
and 2 units of Klenow polymerase (methods generally according to Sambrook et al, 
1989).
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2.1.2 Measurement of total activity
To measure the rate of DNA synthesis, samples of 10pl were removed at intervals 
and spotted onto Whatman DE81 ion-exchange filters, which had been previously 
soaked in 0.1M EDTA and air-dried. (This pre-treatment of the filters had the effect 
of stopping immediately the polymerase reaction and prevented high blank counts.) 
The discs were washed for 3 x 1 0  min with 5% (w/v) Na2HPC>4 , then for 2 x 5 min 
with water and finally for 2 x 30 sec with industrial methylated spirits. They were 
dried in a current of warm air and transferred to scintillation vials. Ecoscint was 
added (4ml/vial) and the radioactivity counted in a Beckman LS5000CE scintillation 
counter.
2.2 Polymerase a
Mammalian DNA polymerase a  activity was assayed at 37°C in 200pl of 75mM 
Tris-HCl buffer pH 7.5, containing 6.5mM MgCh, 83|iM dATP, 83pM dCTP, 
83|lM dGTP, 1.67mM 2-mercaptoethanol, llp.g/ml activated calf thymus DNA, 
0.42mg/ml BSA, 3.4pM [3H] d'lT'P (10.2 Ci/mmol), and 30mM NaCl carried over 
into the assay from the enzyme solution. Peptides were included as appropriate and 
assay mixtures were pre-incubated at 37°C for 10 min in the absence of [3H] dTTP 
prior to initiation of reaction with the labelled nucleotide. Samples of 20pl were 
removed at intervals over the first 16 min of reaction and spotted onto a DEAE-filter 
mat, previously soaked in 0.1M EDTA and air-dried. The filter mat was washed as 
described in 2.1.2 above and counted in an LKB beta-plate scintillation counter.
2.3 Klenow polymerase
The activity of the Klenow fragment of E. coli Pol I was assayed at 37°C in a 50|il 
volume of Klenow buffer containing 60|iM dATP, 60p.M dGTP, 60p.M dTTP, 
20|iM [a32P] dCTP (9xl03 cpm/pmol), 20pg BSA, 4nM primed M l3 DNA and 0.1 
unit of enzyme. Peptides were included as indicated and the mixture pre-incubated at 
37°C for 10 min. Reactions were initiated by the addition of [a32P] dCTP. Samples 
were removed at intervals onto Whatman DE81 filters as described above.
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3. Assays for DNA binding
3.1 DNA mobility shift assay
A duplex oligonucleotide was radiolabelled by incubating 200ng of oligonucleotide 
in a 50pl volume of Klenow buffer containing 20pCi [ a 32P] dGTP (6.6xl06 
cpm/pmol) with 2 units of Klenow polymerase at room temperature for 30 min. The 
single stranded ends were then filled by adding 100|llM dATP, dCTP, dGTP and 
dTTP to the reaction mix and incubating for a further 15 min at room temperature.
The DNA was extracted with 1:1 phenol/chloroform followed by chloroform, 
precipitated in ethanol, lyophilised, dissolved in water and stored at -20°C.
The assay was performed at 37°C in a 20(0.1 volume of binding buffer containing 
0.2ng of radiolabelled DNA. Peptides were added as described in the text. After 20 
min incubation, 5pl of loading buffer were added and the samples analysed by 
electrophoresis in 8% polyacrylamide gels (40:1 acrylamide:N,Nr-methylenebisacrylamide) 
containing TBE. Gels were run in TBE at 120V for 3 hrs, dried and exposed to 
X-Omat XS1 film at -70°C for autoradiography.
3.2 DNA precipitation assay
Primed M13 ssDNA and activated salmon sperm DNA were labelled with 32P by 
incubating 2(ig of DNA in a volume of 180(1.1 for 30 min with Klenow polymerase 
under the conditions described in Section 2.3 above. The assay was performed in a 
volume of 50pl containing 50ng of radiolabelled DNA. Peptides were added as 
described and the mixture incubated for 20 min at 37°C. The tubes were spun for 10 
min at 13000# in a bench centrifuge, a 10(0.1 sample of the supernatant was removed 
onto Whatman DE81 filters as described in Section 2.1.2 above and the radioactivity 
measured by scintillation counting.
4. Measurement of protein concentration
The Bio-Rad Protein Assay (Micro-assay) was carried out according to the 
manufacturer's instructions, using bovine y-globulin as a standard.
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1. Oligopeptides
The peptides were numbered 1—96: the nth peptide contained amino acids 5n-6  to 
5«+8 in the published amino acid sequence of UL42 (McGeoch et al, 1988a). 
There were a few exceptions: peptide 1 contained residues 1-13; peptides 6, 22, 38 
and 67 were extended by one residue at the N-terminus to 16 amino acids, in order 
to avoid peptides with an N-terminal glutamine which could cyclize spontaneously 
in aqueous solution to form pyroglutamic acid (Grant, 1992); peptides 3, 19, 35 
and 64 were correspondingly shortened to 14 amino acids (Table 5).
Analysis by mass spectrometry (MS) showed that all 96 peptides were of the 
correct molecular weight (Table 5). Most were analysed by time-of-flight-MS 
which is not always accurate to within one mass unit. This accounts for the 
differences of 2 or 3 mass units between the calculated and the measured Mr 
values (Table 5). Several peptides were reanalysed by FAB-MS, which is an 
inherently more accurate technique, and the predicted and measured Mr values 
corresponded to within one mass unit (peptides 18, 27, 53, 54, 94, 95, 96).
The yields were mostly within 50% of the maximum expected yield (Table 5). The 
yields of peptides containing both Arg and Trp, which were cleaved by the TMSB 
method, were exceptionally low: only 10% of the expected amount. The first step 
of this method used 5% TFA in DCM to cleave the peptide from the resin, which 
was in fact too low a concentration of acid for complete cleavage. Thus a large 
proportion of the peptide remained attached to the resin and was lost.
Of the 96 peptides, 93 were soluble in water, although at least 19 required the 
solution to be acidified or made alkaline, depending on their charge. Peptides 43, 
54 and 61, were very poorly soluble. To check that this was a sequence-dependent 
characteristic and not caused by impurities or a poor synthesis, these three peptides 
were resynthesised individually on single columns. The resynthesised peptides 
were as insoluble as the original ones.
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Table 5. UL42 PEPTIDES
Peptide
no
Sequence Residues 
in UL42
Calculated
M r
M easured
M r
Yield
(mg)
Purity
(%)
1 MTDSPGGVAPASP 1-13 1185 1186 19 96.4
2 SPGGVAPASPVEDAS 4-18 1339 1340 22* 66.2
3 APASPVEDASDASL 9-22 1328 1329 18* 75.2
4 VEDASDASLGQPEEG 14-28 1502 1503 19* 91.1
5 DASLGQPEEGAPCQV 19-33 1499 1500 24 94.6
6 GQPEEGAPCQVVLQGA 23-38 1581 1581 32 62.2
7 APCQVVLQGAELNGI 29-43 1510 1511 20 73.2
8 VLQGAELNGILQAFA 34-48 1542 1544 25* 53.6
9 ELNGILQAFAPLRTS 39-53 1628 1629 30* 86.9
10 LQAFAPLRTSLLDSL 44-58 1643 1645 60* 93.9
11 PLRTSLLDSLLVMGD 49-63 1629 1629 23* 51.0
12 LLDSLLVMGDRGILI 54-68 1627 1628 25* 75.2
13 LVMGDRGILIHNTIF 59-73 1698 1699 67* 87.6
14 RGILIHNTIFGEQVF 64-78 1743 1746 59 64.8
15 HNTIFGEQVFLPLEH 69-83 1780 1780 19* 50.7
16 GEQVFLPLEHSQFSR 74-88 1773 1773 36* 87.8
17 LPLEHSQFSRYRWRG 79-93 1931 1931 57 50.0
18 SQFSRYRWRGPTAAF 84-98 1828 1827 6 74.5
19 YRWRGPTAAFLSLV 89-102 1636 1636 5 81.6
20 PTAAFLSLVDQKRSL 94-108 1644 1645 36* 70.7
21 LSLVDQKRSLLSVFR 99-113 1759 1761 37* 53.6
22 DQKRSLLSVFRANQYP 103-118 1920 1922 43* 39.7
23 LSVFRANQYPDLRRV 109-123 1832 1834 39* 74.2
24 ANQYPDLRRVELAIT 114-128 1757 1759 34* 79.9
25 DLRRVELAITGQAPF 119-133 1684 1683 33* 79.4
26 EL AITGQAPFRTL V Q 124-138 1643 1643 33* 85.3
27 GQ APFRTL V QRIWTT 129-143 1772 1771 22 72.2
28 RTL V QRIWTTTSDGE 134-148 1761 1762 37 78.5
29 RIWTTTSDGEAVELA 139-153 1647 1648 30 76.8
30 TSDGEAVELASETLM 144-158 1551 1553 35 38.8
31 AVELASETLMKRELT 149-163 1689 1691 39 47.8
contd..
Peptide
no
Sequence Residues 
in UL42
Calculated
M r
M easured
M r
Yield
(mg)
Purity
(%)
32 SETLMKRELTSFVVL 154-168 1752 1753 32* 26.6
33 KRELTSFVVLVPQGT 159-173 1672 1672 33* 33.1
34 SFVVLVPQGTPDVQL 164-178 1597 1597 32* 84.0
35 VPQGTPD V QLRLTR 169-182 1579 1579 31* 83.1
36 PD V QLRLTRPQLTKV 174-188 1762 1763 37* 76.9
37 RLTRPQLTKVLNATG 179-193 1666 1666 38* 46.8
38 PQLTKVLNATGADSAT 183-198 1585 1585 31* 58.9
39 LNATGADSATF1TFE 189-203 1494 1494 19* 97.9
40 ADSATPTTFELGVNG 194-208 1479 1479 29* 87.3
41 PTTFELGVNGKFSVF 199-213 1642 1641 31* 68.9
42 LGVNGKFSVFnSTC 204-218 1559 1558 30* 34.8
43 KFSVFrrSTCVTFAA 209-223 1608 1610 30* NSt
44 TTSTCVTFAAREEGV 214-228 1571 1570 31* 45.0
45 VTFAAREEGVSSSTS 219-233 1526 1528 23* 44.7
46 REEGVSSSTSTQVQI 224-238 1606 1608 28* 54.0
47 SSSTSTQVQILSNAL 229-243 1534 1537 40 58.4
48 TQVQILSNALTKAGQ 234-248 1570 1572 40 64.2
49 LSNALTKAGQAAANA 239-253 1399 1400 49 80.0
50 TKAGQAAANAKTVYG 244-258 1449 1450 51 83.1
51 A A AN AKT V Y GENTHR 249-263 1601 1601 30* 86.7
52 KTVY GENTHRTFS V V 254-268 1736 1739 43* 72.0
53 ENTHRTFSVVVDDCS 259-273 1707 1707 70 62.0
54 TFSVVVDDCSMRAVL 264-278 1640 1640 65 NSt
55 VDDCSMRAVLRRLQV 269-283 1759 1762 60 74.0
56 MRAVLRRLQVGGGTL 274-288 1625 1626 68 76.3
57 RRLQVGGGTLKFFLT 279-293 1691 1691 37* 63.5
58 GGGTLKFFLTTPVPS 284-298 1520 1520 29* 88.5
59 KFFLTTP VPSLC VT A 288-303 1622 1622 37* 61.5
60 TPVPSLCVTATGPNA 294-308 1426 1426 27* 57.8
61 LC VT ATGPNAVS A VF 299-313 1448 1448 26* NSt
62 TGPNAVSAVFLLKPQ 304-318 1540 1540 25* 89.1
63 VSAVFLLKPQKICLD 309-323 1672 1672 35* 40.2
64 LLKPQKICLDWLGH 314-327 1622 1622 12 69.0
65 KICLDWLGHS QGSPS 319-333 1626 1626 28 67.1
66 WLGHSQGSPSAGSSA 324-338 1427 1426 44 87.2
contd..
Peptide Sequence Residues Calculated Measured Yield Purity
no in UL42 M r M r (mg) (%)
67 SQGSPSAGSSASRASG 328-343 1392 1392 55 69.0
68 AGSSASRASGSEPTD 334-348 1378 1378 55 84.3
69 SRASGSEPTDSQDSA 339-353 1493 1493 46 79.8
70 SEPTDSQDSASDAVS 344-358 1494 1494 43 69.4
71 SQDSASDAVSHGDPE 349-363 1500 1500 39 90.6
72 SD AV SHGDPEDLDG A 354-368 1483 1483 48 84.4
73 HGDPEDLDGAARAGE 359-373 1508 1508 58 72.2
74 DLDGAARAGEAGALH 364-378 1422 1422 54 90.2
75 ARAGEAGALHACPMP 369-383 1450 1450 51 83.2
76 AGALHACPMPSSTTR 374-388 1498 1498 57 74.1
77 ACPMPSSTTRVTPTT 379-393 1548 1548 56 80.8
78 SSTTRVTPTTKRGRS 384—398 1633 1633 67 61.6
79 VTPTTKRGRSGGEDA 389—403 1530 1530 52 72.1
80 KRGRSGGEDARADTA 394—408 1545 1546 51 86.2
81 GGED AR ADT ALKKPK 399-413 1555 1555 66 81.9
82 RADTALKKPKTGSPT 404—418 1569 1569 70 89.4
83 LKKPKTGSPT APPPA 409^123 1488 1489 59 95.8
84 TGSPTAPPPADPVPL 414-428 1415 1415 51 83.6
85 APPPADPVPLDTEDD 419-433 1547 1547 62 74.1
86 DPVPLDTEDDSDAAD 424-438 1573 1573 58 64.0
87 DTEDDSDAADGTAAR 429-443 1508 1508 54 74.2
88 SDAADGTAARPAAPD 434-448 1384 1384 52 76.0
89 GTAARPAAPDARSGS 439-453 1383 1383 43 88.8
90 PAAPDARSGSRYACY 444-458 1584 1584 59 68.7
91 ARSGSRYACYFRDLP 449—463 1760 1760 70 55.3
92 RYACYFRDLPTGEAS 454-468 1747 1747 59 83.9
93 FRDLPTGEASPGAFS 459-473 1550 1550 56 96.3
94 TGEASPGAFSAFRGG 464-478 1410 1410 51 56.5
95 PGAFSAFRGGPQTPY 469-483 1551 1551 52 89.1
96 AFRGGPQTPYGFGFP 474-488 1598 1598 35 82.8
* Only half (200mg) of the resin was cleaved, 
t  These peptides were not soluble enough to be analysed.
Results
The soluble peptides were analysed by reverse phase HPLC monitored at 225nm 
(Table 5). By this method, their average purity was 72%.
2. Optimisation of assay conditions
The effect of the UL42 protein on Pol is detectable as (i) an increase in the rate of 
incorporation of radiolabelled nucleotides into a template DNA — measured in an 
"activity” assay — and (ii) an increase in the proportion of full-length DNA 
synthesised on a singly-primed, single-stranded circular M13 DNA template —  
measured in a "processivity" assay.
Both of these assays were used to investigate the inhibitory potential of the UL42 
peptides. Initially, only the processivity assay was used; in later experiments, the 
activity assay was introduced. Here, the optimisation of the two assays is 
combined because taken together the experiments illustrate more fully the effect of 
UL42 on Pol. An undefined template, such as activated calf thymus DNA is 
standardly used in polymerase activity assays. However, in the experiments 
described here, a defined template was used in both types of assay, to allow a direct 
comparison of the data. The assay conditions used were closely based on those 
described by Gottlieb et al (1990). The following experiments were carried out to 
ensure that any inhibition would be reflected by a corresponding reduction in the 
amount of product.
2.1 Titration of UL42
Figure 11 (parts a and b) shows the effect of adding increasing amounts of UL42 to 
a fixed amount (140fmol) of Pol. As observed previously (Gottlieb et al, 1990), 
the amount of full-length M13 DNA product increases with UL42 concentration up 
to an amount above which there is no more stimulation, and there is a 
corresponding decrease in the amount of shorter products. [In this experiment the 
amount of full-length product apparently falls below the maximum at the highest 
concentrations of UL42, but this drop was not consistently observed in other 
experiments (Figure 14).]
Figure 12 (parts a and b) shows the effect of a parallel titration in which the rate of 
incorporation of [ a 32P] dCTP into M13 DNA was measured. The rate of 
incorporation (measured from 0-5 min) increases with UL42 concentration up to a
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Figure 11. The effect on the processivity of HSV-1 polymerase of adding 
increasing amounts of UL42 protein to a fixed amount (140fmol) of Pol. The 
concentration of M l3 template-primer DNA was 2p,g/ml.
a. An autoradiograph showing the products of reaction analysed by electrophoresis in 
an alkaline 1% agarose gel. The top band in each track corresponds to full length 
M13 (not shown). The numbers above each track indicate the amount of UL42 
protein (fmol) added to the reaction.
b. A plot of the relative amounts of full length product, obtained by densitometry of 
the bands in the above autoradiograph, against UL42 concentration.
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Figure 12. The effect on the activity of HSV-1 polymerase of adding increasing 
amounts of UL42 protein to a fixed amount of Pol.
a. The rate of incorporation of [a 32P] dCTP into DNA by 140fmol of Pol in the 
absence (A) and in the presence of 2.1fmol (A) ,  6.4fmol (□ ), 19fmol (■ ), 58fmol 
( • ) ,  173fmol (O ) and 520fmol (masked behind 173fmol) of UL42 protein. The 
concentration of M l 3 template-primer DNA was 2jig/ml.
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b. A plot of the rates shown in a against UL42 concentration.
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Figure 13. The correlation between the increase in full length product ( A)  and the 
increase in enzyme rate (O) with UL42 concentration. The values for Pol alone have 
been subtracted and the plots normalised to the maximum at 58fmol UL42.
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Figure 14. The effect on the processivity of HSV-1 polymerase of adding 
increasing amounts of UL42 protein (batch 1) to a fixed amount (70fmol) of Pol. The 
results of two independent experiments are shown, in each of which the amount of 
product represents the average densitometric measurement of the full length M13 
bands in two duplicate samples. The concentration of M l3 template-primer DNA was 
l|ig/ml.
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Figure 15. The effect on the activity of HSV-1 polymerase of adding increasing 
amounts of UL42 protein (batch 2) to a fixed amount of Pol. The rate of 
incorporation of [a 32P] dCTP into singly-primed M l3 DNA (2|ig/ml) by 140fmol 
( A )  and 350fmol ( # )  Pol, in the presence of the indicated concentrations of 
UL42 protein, was measured in two independent experiments.
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Figure 16. Time course of accumulation of full length product.
a. An autoradiograph showing the products of reaction at 5 min intervals from 0 to 40 
min, analysed by electrophoresis in an alkaline 1% agarose gel. The numbers above 
each track show the time of reaction in minutes. The outermost tracks contain full 
length, linearised M l3 DNA end-labelled with 32P.
b. A plot of the relative increase in the amount of full length product with time. The 
plotted values represent the average densitometric readings of duplicate samples.
Results
level above which there is no further stimulation. A superimposition of the plots of 
full-length product and initial rate against UL42 concentration (Figure 13) shows 
; the correlation between the increase in the rate of incorporation of a 32P dCTP 
and the increase in the amount of full-length product, indicating that the 
two assays detect a stimulation of Pol at similar concentrations of UL42.
The two batches of UL42 used in these experiments were titrated several times 
using the activity and processivity assays (Figures 14 and 15), and an amount 
which gave near maximal stimulation was used for further experiments: 70fmol of 
batch 1 (from John Gottlieb) and 130fmol of batch 2 (from Mary Murphy).
2.2 Time course of accumulation of full-length product
The rate of accumulation of full-length product was monitored. It was found to be 
linear up to 40 min, after an initial lag of several minutes, as shown in Figure 16 
(parts a and b). The initial lag during which there was no appearance of full-length 
product is due to the time taken by the Pol-UL42 complex to traverse the template. 
An incubation time of 30 min was chosen for further experiments.
2.3 Synthesis of full-length product by Pol alone
In the absence of UL42 protein, HSV Pol is processive, although, to produce the 
same amount of full-length, product 5- to 10-fold greater amounts of Pol alone than 
of Pol-UL42 are required (Gottlieb et al, 1990). The rate of accumulation of full- 
length product was again linear up to 35 minutes after an initial lag, and increased 
with Pol concentration (data not shown). An incubation time of 30 mins, and 
350fmol of Pol (5 times the amount used with UL42) were used for further 
experiments.
2.4 Substrate concentration and measurement of Km
To ensure that the DNA substrate was in excess, the rates of accumulation of full- 
length product in the presence of different concentrations of primed M13 template 
DNA were measured. A concentration of 0.2p.g/ml DNA was found to be rate- 
limiting, while a concentration of l|ig /m l allowed the maximum rate of
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accumulation of full-length product (data not shown). On this basis a concentration 
of lp,g/ml was used in processivity assays.
The effect of template-primer concentration on enzyme activity was studied in 
more detail by using the activity assay to measure the Km for Pol and that for Pol- 
UL42 for primed M13 DNA. Figure 17a shows progress plots of the rate of 
incorporation of [a 32P] dCTP into primed M13 DNA by Pol (350fmol) at four 
different DNA concentrations. A Lineweaver-Burk double-reciprocal plot of the 
rate against the substrate concentration is shown in Figure 17b. The Km derived 
from the plot is InM (2.5p,g/ml). The data from a similar experiment to determine 
the Km for Pol-UL42 are shown in Figure 18 (parts a and b). The Km derived from 
the Lineweaver-Burk plot is 0.14nM (0.35|ig/ml).
These results show that the Km for Pol for the template-primer is about 7-fold 
lower in the presence of UL42 than in its absence. This is consistent with the 
observed 5- to 10-fold increase in the affinity of Pol for a synthetic "hairpin" 
template in the presence of UL42 (Gottlieb and Challberg, unpublished data). 
Accordingly, M13 template-primer was used at l|ig/ml to assay Pol-UL42 activity 
and at 10|ig/ml to assay Pol alone, which resulted in approximately equal rates of 
incorporation by Pol-UL42 and Pol (Figure 24).
It is also evident from these data that the concentration of the DNA substrate is one 
factor which determines the observed magnitude of stimulation of Pol by UL42.
2.5 Salt concentration
All the above experiments were done in the presence of 75mM NaCl. During the 
course of these experiments it became clear that the ability of UL42 to stimulate 
Pol was critically dependent on salt concentration (Hart & Boehme, 1992; see 
Introduction, 4.4.3). The effect of salt concentration on the relative amounts of 
full-length M l3 synthesised by Pol and Pol-UL42 was therefore examined. The 
results (Figure 19a and b) show that at NaCl concentrations of 76mM and 120mM 
there is a large difference in the amount of full-length product synthesised in the 
presence and absence of UL42. In contrast, at lower salt concentrations of ImM 
and 4 ImM NaCl, there is very little difference in the amount of full-length product: 
Pol alone is almost as processive as Pol-UL42. This is consistent with the finding 
that the Km for Pol for the DNA template increases sharply with salt concentration, 
while that for Pol-UL42 remains relatively unaffected (Hart & Boehme, 1992).
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Figure 17. Measurement of Km for HSV-1 Pol.
a. Progress plots of the rate of incorporation of [a32P] dCTP by Pol into singly- 
primed M13 DNA at ljig/ml (A), 2pg/ml (■), 5pg/ml (□) and 10|ig/ml (•) .
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b. A Lineweaver-Burk double-reciprocal plot of the rate vs the substrate 
concentration. More weight is given to the data at higher substrate concentrations. 
The negative intercept on the abcissa gives the reciprocal of the Km.
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Figure 18. Measurement of Km for Pol/UL42.
a. Progress plots of the rate of incorporation of [a32P] dCTP by Pol/UL42 into 
singly-primed M l3 DNA at 0.2|ig/ml ( A) ,  0.25p.g/ml ( A ) ,  0.3fig/ml (□ )  and 
0.5ng/ml ( • ) .
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b. A Lineweaver-Burk double-reciprocal plot of the rate vs the substrate 
concentration. More weight is given to the data at higher substrate concentrations. 
The negative intercept on the abcissa gives the reciprocal of the Km.
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Figure 19. The effect of NaCI concentration on the processivity of Pol in the 
presence and absence of UL42 protein.
a. An autoradiograph showing the amount of full length product synthesised by Pol 
in the presence (+) and absence (-) of UL42 at six different concentrations of NaCI. 
The numbers above the tracks indicate the mM concentration of NaCI in the reactions. 
The products of the reaction were analysed by electrophoresis in alkaline 1% agarose 
gels.
b. A plot of the relative amounts of full length product in the presence ( • )  and 
absence (O) of UL42, obtained by densitometry of the bands in the autoradiograph 
shown in a, against NaCI concentration.
Results
These data show that 75mM is a suitable concentration of NaCI to test for 
inhibition of UL42-mediated Pol processivity. It should be noted, in addition, that 
the Km values determined in 2.4 above are valid only in the presence of 75mM 
NaCI.
3. Peptide inhibition of the synthesis of full-length 
M13 DNA by the Pol-UL42 complex
3.1 Screening of peptides
Peptides were initially screened at a concentration of 50pM, without purification, 
for their effect on the synthesis of full-length M l3 DNA. Each peptide was tested 
on at least two occasions, first as a single sample and then in duplicate. If the result 
was unclear, the test was repeated until a reliable result was obtained. Reactions 
with Pol-UL42 and Pol were always included as controls. Figure 20 shows the 
results of two such experiments (parts a and b) which identify peptides 47, 48, 57, 
58 and possibly 46 as inhibitory. Using this assay, peptides 6, 7, 8, 14, 15, 18, 19, 
34, 41, 42, 46, 47, 48, 57 and 58 were found to be inhibitory.
Graham Hart, at Glaxo Group Research, carried out an independent screen of the 
peptides, testing them at a concentration of lOOpM for inhibition of Pol-UL42 
activity on an activated DNA template. Only peptides 8, 14, 41, 47 and 48 
inhibited Pol-UL42 by more than 50%; a number of others, including peptides 6, 
7, 15, 19, 42, 46, and 57 showed some degree of inhibition. The two screens 
therefore gave essentially similar results.
3.2 Purification of peptides
Two or more peptides from each overlapping set were purified by reverse phase 
(RP) HPLC for further study (Table 6). Peptides 34, 41 and 42 were found to be 
non-inhibitory upon purification, so are not included in the table and were not 
investigated further. Peptide 95 was purified as a non-inhibitory control (purity = 
>99%). Figure 21 shows an analysis of peptide 15 before and after purification, as 
an example of the degree of purification typically obtainable by preparative RP- 
HPLC. The purity of all peptides was determined by analytical RP-HPLC. The 
purity of peptides 47, 57 and 95 was further checked by capillary zone
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Figure 20. The effect of peptides (50|iM) on the formation of full length M l3 DNA 
by HSV-1 Pol/UL42. Two separate experiments (parts a and b) are shown in both of 
which the formation of full length M13 DNA in the presence of UL42 protein 
(Pol/UL42) and absence of UL42 protein (Pol) is demonstrated. The effect of 
peptides 46, 47, 48 and 49 on the formation of full length M13 DNA by 70fmol of 
Pol/UL42 (Pol/UL42 + peptides) is shown in part a, while the effect of peptides 55, 
56, 57, 58 and 59 is shown in part b. All reactions were performed in duplicate. 
Also shown are molecular weight markers: X DNA digested with Hind III (Kb, part 
a) and full length, linearised M13 DNA (M13, parts a and b) both end-labelled with 
32P. The numbers on the left of the figure give the sizes of the products in kilobases. 
The products of the reaction and marker DNAs were analysed by electrophoresis in 
alkaline 1 % agarose gels.
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Figure 21. An example of the purification of a peptide by RP-HPLC.
a. A chromatogram of peptide 15 before purification, analysed by RP-HPLC 
monitored at 225nm. The main peptide peak represents 52.1% of the total material.
b. A similar analysis of the same peptide after purification. The peptide peak 
represents 99.6% of the total material.
Table 6. INHIBITORY PEPTIDES PURIFIED BY REVERSE PHASE
HPLC
Peptide Sequence
5 DASLGQPEEGAPCQV
6  GQPEEGAPCQWLQGA
7 APCQVVLQGAELNGI
14 RGILIHNTIFGEQVF
15 HNTIFGEQVFLPLEH
18 SQFSRYRWRGPTAAF
19 YRWRGPTAAFLSLV
46 REEGVSSSTSTQVQI
47 SSSTSTQVQILSNAL
48 TQVQILSNALTKAGQ
R esidues Purity 
in UL42 (%)
19-32 >99
23-38 96
29-43 91
64-78 97
69-83 >99
84-98 97
89-102 >99
224-238 97
229-243 95-99
234-248 >99
57
58
RRLQVGGGTLKFFLT
GGGTLKFFLTTPVPS
279-293
284-298
>99
95
Results
electrophoresis, by Barry Coomber at Glaxo Group Research Ltd, which showed 
them to be homogeneous.
Purified preparations of peptides 6  and 7 contained two peaks of material when re­
analysed after standing in solution for a few hours. The relative proportions of the 
two peaks varied and could be influenced by time or pH: the later eluting peak 
increased with time, and also when the pH of the solution was raised by bubbling 
with ammonia vapour. The nature of the two species was not established but they 
possibly represent different states of oxidation of the cysteine residue. 
Independently synthesised batches of peptide 6  displayed identical behaviour.
Peptide 47 and related sequences (truncated peptides and peptides containing one 
or two amino acid substitutions) showed very unusual properties when subjected to 
reverse phase HPLC: only a fraction of the peptide (15-20%) was eluted from the 
column using the standard elution conditions (a 20 min gradient of 0-95% 
acetonitrile in water). The remainder of the peptide could be eluted using repeated 
gradients. About 10 consecutive gradients were required to elute all of the peptide 
from either the analytical or the preparative columns. This behaviour remained 
essentially unaltered in various chromatographic conditions as follows:
1 ) doubling the TFA concentration in the solvents;
2 ) replacing TFA with 30mM ammonium formate;
3) replacing acetonitrile with methanol;
4) replacing acetonitrile with isopropanol;
5) changing from a C8  to a C3 column;
6 ) eluting at elevated temperatures: 50°C, 60°C.
Consequently, purification was achieved by using the standard conditions and 
eluting the peptide with three consecutive gradients, then washing the column with 
a sufficient number of gradients to remove all of the residual peptide. Similar 
behaviour has apparently been observed with strongly a-helical peptides (Peter 
White, personal communication).
3.3 Determination of IC50
IC50 values for the inhibition of full-length M13 DNA synthesis by purifired 
peptides were measured. Figure 22 shows titrations of peptides 6 , 14, 47 and 48 
from which IC50 values of 3.5qM, 7.5pJM, 0.8p,M and 9p,M, respectively, were 
determined. The values for peptides 6 , 14,19,47, 57 and 95 are shown in Table 7.
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Figure 22. Inhibition of full length product by peptides 6  ( • ) ,  14 (■), 47 (A ) and 
48 (A ). The data were obtained by densitometry of autoradiographs of duplicate 
titrations, and the amount of full length M13 DNA produced in the presence of peptide 
was expressed as a percentage of that produced in the uninhibited reaction.
Results
4. Peptide inhibition of the synthesis of full-length 
M13 DNA by Pol
Peptides were tested for inhibition of full-length M13 DNA synthesis by Pol alone. 
The results with purified peptides 5, 47, 56, 57 and 95 at a concentration of 50|iM 
are shown in Figure 23 (part a) and show peptides 47 and 57 to be completely 
inhibitory at this concentration. An IC50 of 1.5p.M for inhibition by peptide 47 was 
obtained by densitometric analysis of the data shown in Figure 23b. This value and 
those for other peptides are listed in Table 7. Two shorter M13 DNA products (5 
Kb and 3Kb) accumulate to a greater extent in the absence of UL42 protein 
(compare Figures 19 and 23) and probably arise from the polymerase 'pausing' at 
specific sites on the template (compare Figures 20 and 23). Densitometric analysis 
showed these species to be inhibited to the same extent as the full-length product 
(data not shown). Synthesis of these shorter molecules by Pol-UL42 was also 
inhibited by the peptides (Figure 20) as was the accumulation of DNA products of 
sizes 0.5Kb to 0.7Kb.
5. Peptide inhibition of the rate of DNA synthesis by 
Pol and Pol-UL42
The action of these peptides was further investigated by determining their effect on 
the rate of incorporation of [oc3 2 P] dCTP into DNA. To achieve linear 
incorporation peptides were pre-incubated for 10 minutes at 37°C with the assay 
mixture lacking dCTP. The inhibition by peptides 6 , 14 and 47 of polymerase 
activity in the presence and absence of UL42 is shown in Figure 24. The progress 
plots at various concentrations of all three peptides show virtually linear kinetics 
over the first 10 minutes of reaction. These rates were plotted against peptide 
concentration (Figure 27) to determine IC50 values (Table 7). The IC50 values for 
peptides 19 and 57 were similarly determined (Figure 27 and Table 7).
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Figure 23. The effect of peptides on the synthesis of full length M13 DNA by 
350fmol of Pol alone. Part a shows the effect of peptides 5, 47, 56, 57 and 95, all at 
a concentration of 50|iM, as well as a control which lacks peptide (Con). Part b 
shows the products formed in the presence of various concentrations of peptide 47. 
All reactions were performed in duplicate. The single track on the right shows full 
length, linearised M13 DNA end-labelled with 32P. The DNAs were analysed by 
electrophoresis in alkaline 1% agarose gels. The numbers on the left of the figure give 
the sizes of the products in kilobases.
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Figure 24. Progress plots of [a32P] dCTP incorporation into M l3 DNA by Pol
(left panels) and Pol/UL42 (right panels) in the presence of peptides 6, 14 and 47 at 
the indicated concentrations (pM).
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Figure 25. Km for E. coli Klenow polymerase.
a. Progress plots of the rate of incorporation of [a 32P] dCTP by Klenow polymerase 
into primed M13 DNA at 0.08|ig/ml (A), 0.17|ig/ml (A), 0.5jig/ml (■), l|ig/ml (□) 
and 2 ^g/m l(#).
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b. A double-reciprocal plot of the rate vs the substrate concentration. (The rates for 
the two lowest substrate concentrations have not been included.)
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Figure 26. Progress plots of [a 32P] dCTP incorporation into M13 DNA by Klenow 
polymerase in the presence of peptides 6 , 14 and 47 at the indicated concentrations 
(pM).
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Figure 27. A comparison of the inhibition of HSV-1 Pol (O ), Pol/UL42 ( 0 ) s 
polymerase a  (■ ) and Klenow polymerase (A )  by peptides 6, 14, 19, 47 and 57. 
The rate of incorporation of [a32P] dCTP into M13 DNA in the presence of peptide is 
expressed as a percentage of the uninhibited rate.
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Results
6. Peptide inhibition of E. coli Pol I and mammalian 
polymerase a
The specificity of these peptides for HSV-1 polymerase was assessed by testing 
their effect on mammalian polymerase a , and also on the Klenow fragment of E. 
coli Pol I, the catalytic domain of which bears no sequence homology to HSV-1 
Pol (Quinn & McGeoch, 1985).
Incorporation of [a 32P] dCTP into DNA by the E. coli enzyme was linear under the 
conditions described. The Km for the Klenow polymerase for the M l3 template 
was found to be 1.6nM (4jig/ml) (Figure 25 a and b), and a concentration of 
1 0 p,g/ml was used for inhibition experiments.
Progress plots for the Klenow polymerase in the presence of peptides 6 , 14 and 47 
are shown in Figure 26. Inhibition by peptides 14 and 47 increases with time, 
particularly at the higher peptide concentrations. To determine IC50  values for 
these peptides, the rates of incorporation between 2.5 and 5 min were used, and the 
derived IC50 values are given in Table 7.
Incorporation of [3 H] dTTP into activated calf thymus DNA by pol a  in the 
absence of peptide and in the presence of various concentrations of peptides 6 , 14, 
19, 47 and 57 was linear with respect to time. The rates of incorporation are 
plotted in Figure 27 and the derived IC50 values are shown in Table 7. The data for 
pol a  inhibition were generated by Graham Hart at Glaxo Group Research.
Figure 27 shows a comparison of the inhibition of HSV-1 Pol, Pol-UL42, pol a  
and Klenow polymerase by peptides 6,14,19,47 and 57. Inhibition is largely non­
specific, although peptides 6 , 14, 47 and 57 display some limited specificity. 
Peptide 6  shows the greatest specificity for the HSV polymerase, being 10-fold less 
active against Klenow polymerase and 2-fold less active against polymerase a  
(Table 7).
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7. Interaction of peptides with DNA
7 .1  B in d in g  o f  in h ib ito ry  peptides to D N A
One mechanism by which the inhibitory peptides could interfere with polymerase 
would be by blocking its binding to DNA. A gel mobility shift assay was used to 
investigate their DNA-binding properties. Peptides were tested at a concentration 
of 50p,M, in similar buffer conditions to those used for the polymerase assays, for 
their ability to complex with a synthetic duplex oligonucleotide. Peptides 14, 18, 
19, 47, 48 and 57 formed complexes which had various mobilities, while peptides 
6, 7, 15 and 95 did not bind (Figure 28). Identical binding was seen in the presence 
of 76mM NaCl and in the absence of salt (data not shown). Further binding 
experiments were done in the absence of salt. Peptide 6, at concentrations of up to 
250|iM, showed no evidence of binding to DNA (data not shown).
7 .2  S creen ing  o f  the U L 4 2  peptides fo r  D N A -b in d in g
The remaining UL42 peptides were tested for their ability to bind to DNA in the 
gel mobility shift assay. Peptides were screened in duplicate at a concentration of 
50p,M, without purification. Twenty peptides, in addition to those already 
identified above, were found to form complexes with the DNA. All the DNA- 
binding peptides are listed in Table 8.
The peptides shown in Table 8 (with the exception of peptides 17, 33, 37, 55 and 
90) were purified by RP-HPLC to >90% homogeneity and re-tested for DNA 
binding. Only peptide 67 was found not to bind in a purified form. All further 
experiments were done with purified peptides.
7 .3  M e a s u re m e n t o f  Kd
The dissociation constant, Kd, for a DNA-binding protein can be estimated from 
the concentration of protein required to bind half of the DNA in a gel mobility shift 
assay (provided that the molar DNA concentration is at least 100-fold lower than 
the protein concentration required to bind half of the DNA) (Carey, 1991). This 
method was used to obtain an approximate IQ value for the DNA-binding peptides. 
One such experiment is shown in Figure 29. Part a shows an autoradiograph of 
four-fold dilutions of peptides 46, 47 and 48 tested in the gel mobility shift assay;
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Figure 28. The mobility of a duplex oligonucleotide in the absence of peptide (Con) 
and in the presence of peptides 6, 7, 14, 15, 18, 19, 47, 48, 57 and 95, all at a 
concentration of 50|iM.

b1 0 ° 2
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Figure 29. The effect of peptides on the mobility of a duplex oligonucleotide.
a. Autoradiograph showing the complexes formed with four-fold dilutions of 
peptides 46,47 and 48. The numbers above the tracks indicate the pM concentration 
of peptide.
b. Plots of the fraction of free DNA vs log of peptide concentration for peptides 46 (A), 
47 (■), 48 (□) and 49 (• ) . The data were obtained by densitometry of the bands in
the autoradiograph shown in a, and a similar titration of peptide 49.
Table 8. DNA-BINDING PEPTIDES
P eptide Sequence C harge K d (pM )
13 LVMGDRGILIHNTIF +1 8.5
14 RGILIHNTIFGEQVF +1 15
17 LPLEHSQFSRYRWRG +3 ND*
18 SQFSRYRWRGPTAAF +3 >50
19 YRWRGPTAAFLSLV +2 1.2
27 GQ APFRTLV QRIWTT +2 5
33 KRELTSFVVLVPQGT +1 ND
35 VPQGTPDVQLRLTR +1 12
36 PDVQLRLTRPQLTKV +2 5
37 RLTRPQLTKVLNATG +3 ND
41 F1TFELGVNGKFS VF 0 0.9
42 LGVNGKFSVFTTSTC +1 0.5
46 REEG VSS STSTQVQI -1 64
47 SSSTSTQVQILSNAL 0 0.9
48 TQVQILSNALTKAGQ +1 0.4
55 VDDCSMRAVLRRLQV +1 ND
56 MRAVLRRLQVGGGTL +3 15
57 RRLQVGGGTLKFFLT +3 0.2
58 GGGTLKFFLTTPVPS +1 0.4
59 KFFLTTPVPSLC VT A +1 1
62 TGPNAVSAVFLLKPQ +1 4.5
63 VSAVFLLKPQKICLD +1 0.8
67 SQGSPSAGSSASRASG +1 ND
90 PAAPDARSGSRYACY +1 ND
91 ARSGSRYACYFRDLP +2 11
92 RYACYFRDLPTGEAS 0 ND
* Kd not determined
Results
part b displays the densitometric data from the same autoradiograph as a Bjerrum 
plot of the fraction of free DNA vs log of peptide concentration.
Peptides 47 and 48 form different types of peptide-DNA complexes (Figure 29a). 
Peptide 48 precipitates most of the DNA into a complex that does not enter the gel. 
A similar phenomenon has been observed with very basic proteins (Carey, 1991). 
Several of the basic UL42 peptides precipitated the DNA in this way. Peptide 47 
forms a soluble complex which migrates as a discrete band at the higher peptide 
concentrations, but which increases in mobility and becomes less defined at lower 
peptide concentrations (see also Figures 30 and 31). Other peptides formed 
complexes which smeared throughout the length of the gel.
The values obtained by this method (Table 8) are probably not very accurate, 
but they give some indication of the relative binding strengths. Only one peptide 
(47) was titrated more than once: the values from three independent titrations were 
0.4pM, 0.7pM and 1.7pM.
7 .4  P e p t id e  4 7
The following experiments were designed to test the possibility that peptide 47 
might represent a major DNA-binding region of UL42, and were carried out with 
purified peptides.
7.4.1 Competition of peptide 47 with UL42 protein
Titration of peptide 47 in the presence of UL42 protein showed that, at a 70-fold 
molar excess, the peptide prevented the protein from binding to DNA, but at an 
excess of 23-fold or lower it did not compete (Figure 30).
7.4.2 Mapping of residues important for binding
To identify the residues important for binding to DNA, truncated peptides were 
synthesised. However, none of the peptides truncated by more than two amino 
acids was soluble and therefore could not be adequately tested. The shortest 
soluble peptides were:
301: STSTQVQILSNAL
302: SSSTSTQVQILSN 
Kd values were 2|llM for peptide 301 and 9|iM for peptide 302, compared with 0.9 
pM for peptide 47 itself. The relative binding affinities of peptides 46, 47, 48 and
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F igure 30. The binding of three-fold dilutions of peptide 47 to a duplex 
oligonucleotide in the presence and absence of UL42 protein (0.13|iM), as indicated 
below the tracks. The numbers above each track indicate the |iM concentration of 
peptide present in the reaction. The position of the UL42-DNA complex is indicated.
301 (|aM): STSTQVQILSNAL 372(^iM): LQASNVSTLQITS
I—  ------- — — -  n  ~ _ :—  ------- --
750 192 48 12 3 .75 .2 0 750 192 48 12 3 .75 .2
371 A(|iM): STSTEVEILSNAL 371 B((iM): STSTEVEILSDAL
Figure 31. The binding of four-fold dilutions of peptide 301 and peptides with 
variant sequences to a duplex oligonucleotide. The sequence and pM concentration of 
peptide present in each reaction is indicated above the tracks.
Table 9. DNA BINDING OF SUBSTITUTED AND 
SCRAMBLED PEPTIDES
Peptide Sequence Kd (pM )
47 SSSTSTQVQILSNAL 0.9
301 STSTQVQILSNAL 2
363A STSTQVEILSNAL 75
363B STSTEVQILSNAL 17
371A STSTEVEILSNAL 62
37 IB STSTEVEILSDAL >750
372 LQASNVSTLQITS 6
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Figure 32. Progress plots of [a 32P] dCTP incorporation into M13 DNA by HSV-1 
Pol in the absence of peptide ( • )  and in the presence of peptides 301 (■), 371A (A), 
37IB (□) and 372 (A ), all at a concentration of IOOjiM.
Results
49 (Figure 29 and Table 8 ) suggest that the whole of the sequence common to 
peptides 47 and 48 (TQVQILSNAL) is necessary for strong DNA binding, while 
neither half of it, present in peptides 46 and 49, is sufficient.
Acidic residues were substituted for the glutamine and asparagine residues in the 
sequence of peptide 301, generating the series of peptides shown in Table 9. The 
DNA binding of all of the substituted peptides was lower than that of the original 
sequence. DNA binding was reduced more by substituting the central glutamine, 
Q7, (peptides 363A and 371 A) than by substituting Q5 (peptide 363B) with a 
negatively charged glutamic acid (Table 9). Binding was only abbrogated 
completely by the introduction of three negatively charged residues, in peptide 
37 IB (Figure 31 and Table 9).
The relative importance of amino acid sequence and composition for binding was 
investigated by synthesising a scrambled sequence with the same amino acid 
composition as 301. The scrambled peptide (372) bound to DNA almost as 
efficiently as the native sequence (Figure 31 and Table 9). The measured JQ was 
3-fold higher, but this is within the margin of error of this technique.
An experiment was carried out to investigate whether the DNA-binding properties 
of the substituted and scrambled peptides correlated with their capacity to inhibit 
HSV-1 Pol. Peptides 301, 371 A, 37IB and 372 were tested at IOOjiM for their 
effect on Pol activity. The results (Figure 32) showed that the peptides which 
bound to DNA to a measurable extent, ie 301, 371A and 372 (Table 9), 
substantially inhibited Pol activity, whereas peptide 37IB, which did not bind to 
DNA, had only a slight, and probably insignificant, effect on Pol.
7.5 DNA precipitation
All the DNA-binding experiments had been carried out using a short synthetic 
duplex oligonucleotide unrelated in sequence to the M l3 or activated DNA 
templates used in the polymerase assays. To demonstrate unequivocally that the 
DNA-binding peptides were capable of precipitating template DNA, peptides were 
incubated with radio-labelled M13 and activated salmon sperm DNAs. The 
radioactivity remaining in solution was measured after centrifugation. Incubation 
with a 50pM concentration of peptides 14, 19, 47 and 57 removed over 95% of the 
DNA from solution (Table 10). Peptide 6 , in contrast, appeared to increase the
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Table 10. PRECIPITATION OF DNA 
BY PEPTIDES
Peptide % DNA remaining in solution
M13 Activated SS
None 100 100
6  109.7 132.7
14 0.2 1.0
19 0.02 0.6
47 2.5 2.7
57 0.1 0.1
95 53.5 30.9
Results
number of counts in the sample, probably by preventing binding of the DNA to the 
walls of the plastic Eppendorf tube.
The finding that peptide 95 also precipitated about half of the DNA was 
unexpected, since it did not appear to bind to DNA in the gel retardation assay, nor 
did it inhibit in the polymerase assay, in fact it was used throughout as a non- 
inhibitory control. Peptide 95 has a charge of +1 and could therefore be expected 
to interact with DNA, as observed with many of the other positively-charged 
peptides.
8. The effect on Pol-UL42 of peptides from the C- 
terminus of Pol
Peptides corresponding to the C-terminus of Pol were tested in the processivity 
assay for their ability to disrupt the Pol-UL42 interaction. Peptide 384 
encompassed residues 1209-1235, and peptide 386, residues 1194-1223 (Figure 
33a).
These peptides were first tested, at 10p,M-100|iM, for their ability to precipitate 
DNA. Peptide 384 (charge = +1) was found to precipitate about 50% of the DNA, 
and peptide 386 (charge = -1) apparently increased the amount of DNA in solution 
by 30% (data not shown). The extent of DNA precipitation by peptide 384 is 
similar to that of peptide 95 (Table 10), and would not therefore be expected to 
interfere with the polymerase assay.
The peptides were then tested for their effect on the synthesis of full-length M13 
DNA by Pol-UL42. No inhibition was observed at concentrations of up to 50|iM 
under the standard assay conditions (data not shown). To increase the sensitivity of 
the assay, the experimental conditions were adjusted from the standard protocol as 
follows: i) the amount of UL42 in the reaction was reduced to 33fmol — which 
results in less than maximal stimulation of processivity; ii) the peptides were 
incubated for 3 min at 37°C with UL42 in the assay mixture lacking both Pol and 
dCTP, then Pol was added and the reaction initiated by the addition of [oc3 2P] 
dCTP. Again, there was no detectable difference in the processivity of Pol-UL42 
in the presence of peptides 384, 386, and 95, at concentrations of up to 200|iM 
(Figure 33b).
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a------------------------ 386-------------------------
SLLKRFIPEVWHPPDDVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA-COOH
---------------------- 384----------------------
Figure 33.
a. The C-terminal 50 amino acid residues of Pol. The horizontal lines show the parts 
of the sequence synthesised as Pol peptides 384 (residues 1209-1235) and 386 
(residues 1194-1223).
b. The effect of Pol peptides 384 and 386 on the synthesis of full length Ml 3 DNA 
by Pol/UL42. Tracks 1,2 and 15 show the products of polymerisation by Pol alone, 
in the presence of 200|iM peptide 95 (which does not affect polymerase activity). 
Tracks 3-14 show the products of polymerisation by Pol/UL42 in the presence of 
IOOjiM and 200|iM peptides 384, 386, and 95 (Con), each tested in duplicate, as 
indicated above the tracks.
bPol Pol/UL42
_ 1 0 0 |iM __________  2 0 0 |iM
Con Con 384 386 Con 384 386
Pol
Con
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
DISCUSSION
The aim of this project was to identify the region(s) of the UL42 protein involved in 
interacting with Pol, the catalytic subunit of HSV-1 polymerase. At the time when 
the project was started, there was no information about the regions of UL42 likely to 
be involved in the interaction. The use of overlapping peptides to address such a 
question was a novel approach, and one which had the potential advantage that 
peptides identified at an early stage of the investigation might serve as leads for anti­
viral drug development. The application of this approach was stimulated by the 
observation that the HSV ribonucleotide reductase is specifically inhibited by the 
nonapeptide YAGAVVNDL, which corresponds to the C-terminus of the small 
subunit of the enzyme. The peptide competes with the small subunit for a binding 
site on the large subunit and thus disrupts their interaction (Introduction 6.2). The 
aim of this project was also, therefore, to answer the more general question of 
whether this phenomenon is peculiar to ribonucleotide reductase, or whether a 
similiar disruption of other interacting subunits can be effected by peptides from the 
interface.
1. Oligopeptides
The only problems encountered during the synthesis, cleavage and analysis of the 96 
UL42 peptides (Table 5) were (i) a low yield of peptides containing arginine plus 
tryptophan — this was due to using the TMSB cleavage method under suboptimal 
conditions (Results 1); (ii) the heterogeneity of peptides 22, 30, 31, 32, 33, 37, 42, 
44 and 63, of which less than 50% represented the desired product (Table 5); (iii) 
the poor solubility of peptides 8 , 13, 20, 34, 41, 42, 43, 45, 47, 52, 54 and 61.
The first two of these problems have since been alleviated by the development of 
new reagents for solid-phase peptide synthesis. The successful synthesis of peptides 
containing arginine plus tryptophan has been aided by the availability of Trp(Boc) — 
the Boc side-chain protecting group prevents modification of the indole ring of 
tryptophan during cleavage —, and by the introduction of Arg(Pmc), which is
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deprotected far more rapidly than Arg(Mtr). Peptides containing arginine plus 
tryptophan, synthesised with these reagents, can be cleaved using a standard cocktail 
of TFA and chemical scavengers. The replacement of PFP and DHBT amino acid 
esters by the novel, more reactive PyBOP® chemistry (developed by Novabiochem) 
yields peptides of higher purity.
Only peptides 43, 54 and 61 were insoluble (except in concentrated acid). Several 
others, eg peptides 13, 34,41,42 and 47 were incompletely soluble in water in their 
crude state, but completely soluble after purification, which suggests that impurities 
accounted for the insoluble material in the crude preparation.
In principle, the purification and analysis of peptides should be carried out by two 
diverse chromatographic techniques, eg reverse phase HPLC and capillary zone 
electrophoresis (CZE), since not all peptides with closely related sequences are 
resolved by RP HPLC (Grant, 1992). We did not have regular access to CZE, 
however, and therefore used reverse phase chromatography for both purification and 
analysis. That this can achieve adequate results in most cases was shown by a CZE 
analysis of several of the purified peptides, which confirmed their purity (Results 
3.2).
The decision to screen the unpurified peptides was made on the assumption that 
impure peptides are more likely to yield false positive than false negative results in an 
enzyme inhibition assay. One advantage of purifying all of the peptides before 
screening would have been the apparent improvement in solubility. Recent 
improvements in the capacity of reverse phase columns would make it possible to 
purify all peptides before screening, and this would be the approach of choice.
2. Optimisation of assay conditions
The experiments described in Section 2 of the Results were carried out to ensure that 
the peptides were tested under conditions that would allow the detection and 
measurement of their inhibitory properties. Suitable concentrations of UL42, of salt 
and of DNA template-primer were established as described, and the rate of 
accumulation of product was observed to be linear for the duration of the assay. The 
experiments described in Section 2 touch on some interesting questions regarding the 
HSV polymerase — such as the rate of polymerisation, or the relative affinity for 
DNA of Pol and Pol-UL42 — but do not provide enough data to make a real 
contribution towards answering them. For instance, the measurements of Km for 
Pol and for Pol-UL42 are probably not very accurate, since they were based on a
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minimum amount of data. They were adequate as a basis for establishing the 
concentrations of DNA template that would be in an approximately four-fold excess 
over Km, but they should not be taken as an accurate measure of the relative affinities 
of Pol and of Pol-UL42 for a DNA template-primer. [It should be pointed out that 
the measured Km values are apparent Kms, composed of the intrinsic affinity of the 
protein(s) for DNA, and the relative probabilities of their dissociating from the DNA 
template or translocating along it for successive rounds of polymerisation.]
3. Identification of inhibitory peptides
The 96 UL42 peptides were screened for their ability to inhibit the synthesis of full- 
length M13 DNA by Pol-UL42 (Results 3.1). None of the peptides was seen to 
reduce the processivity of Pol-UL42 to that of Pol, ie to cause a reduction in the 
amount of full-length M13 product and a corresponding increase in the amount of 
shorter products. The inhibitory peptides which were identified reduced the amount 
of full-length product without causing an evident increase in the amount of shorter 
products, as seen in Figure 20. Nevertheless, the observed inhibition was worthy of 
further investigation.
Purified peptides 6 , 7, 14, 15, 18, 19, 47, 48, 57, and 58 — representing five 
discrete regions of the UL42 protein — were consistently inhibitory, whereas 
peptides 34,41 and 42 were no longer inhibitory upon purification, and thus proved 
to be "false positives". The inhibition by these crude peptides may have been 
associated with their poor solubility. The very insoluble peptides 43, 54 and 61 also 
caused an apparent inhibition when added to the assay as an undissolved precipitate, 
but this cannot be interpreted as an adequate test of their inhibitory potential. It is 
possible, but unlikely, that these peptides contain inhibitory sequences, since all the 
sequences present in the insoluble peptides were tested in the adjacent soluble ones.
The presence of a number of peptides, for example peptides 55 and 56 (Figure 20), 
appeared to increase the amount of full-length product This effect was seen with 
peptides 4, 10, 55, 56, 77, 78, 79 and 91, but was not investigated further.
4. Investigation of polymerase inhibition by UL42 
peptides
The potency of the peptides was assessed by determining IC50 values for their 
inhibition of Pol-UL42 and of Pol, obtained by measuring (i) the amount of full-
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length product and (ii) the rate of incorporation of triphosphates into a primed M l3 
DNA template in the presence of a range of peptide concentrations (Results 3.3,4, 5) 
(Table 7). The most potent was peptide 47, and the least potent was peptide 19. 
More reliance should be attached to the values from the incorporation experiments for 
the following reasons. First, the values for the formation of full-length product are 
based on a single datum point (the average of two samples, taken at 30 min). 
Second, it is not known whether the rate of formation of product in the presence of 
peptide is linear. Third, the method used for densitometry was less accurate than is 
radioactivity counting in a scintillation counter. In general, the extent of inhibition by 
the peptides of formation of full length product or incorporation of triphosphates was 
similar (within a factor of 2.4). However, peptide 6  was five- to six-fold more 
inhibitory of the formation of full length product.
The data obtained with both assays indicated that the peptides inhibited both Pol and 
Pol-UL42, and therefore provided no evidence that any of the peptides acted by 
disruption of the Pol-UL42 interaction. A peptide which acted in this manner might 
have been expected to reduce the level of Pol-UL42 activity to that of Pol alone and 
to have no effect on Pol itself.
The specificity of the peptides was assessed by comparing their inhibition of 
polymerase a  and of Klenow polymerase with their inhibition of HSV-1 polymerase 
(Results 6 ) (Table 7 and Figure 27). Inhibition was found to be largely non-specific, 
although peptides 6 , 14, 47 and 57 displayed some limited specificity. Peptide 6  
showed the greatest specificity for the HSV polymerase, being 10-fold less active 
against Klenow polymerase and 2-fold less active against polymerase a . Whether 
this reflects a specificity for a-like polymerases remains to be tested.
5. Interaction of UL42 peptides with DNA
The investigation of DNA-binding as a mechanism of non-specific polymerase 
inhibition by the peptides provided clear evidence that peptides 14, 19, 47 and 57 
interfered with polymerase activity by interacting with the DNA template (Results 7). 
By incubation of template DNA (lpg/ml) with a 50pM concentration of peptides 14, 
19, 47 and 57, over 95% of the DNA was removed from solution (Table 10). The 
Kd values for oligonucleotide-binding (Table 8 ) for peptides 14 and 47 were close to 
their IC50S for inhibition of HSV polymerase; the K<jS for peptides 19 and 57 were 
substantially lower than their IC50S for enzyme inhibition. These data indicate that
84
Discussion
the DNA-binding activity of peptides 14, 19, 47 and 57 probably accounts for the 
observed polymerase inhibition.
The finding that the rate of DNA synthesis by Pol-UL42 was more inhibited by 
peptides 14, 19, 47 and 57 than was the rate of synthesis by Pol alone (Figure 27) 
was probably a reflection of the lower concentration of DNA used in the Pol-UL42 
assay (l(ig/ml) than that used in the Pol assay (lOpg/ml). In contrast, peptide 6 — 
which does not bind to DNA — showed the same activity against Pol-UL42 and Pol 
alone. The limited specificity of peptides 14,47 and 57 for the different polymerases 
may reflect the different affinities of the enzymes for DNA. The specificity of 
peptide 6 must be due to another mechanism.
The detection of the DNA-binding properties of these peptides prompted further 
investigations to address the following questions: Did these peptides represent the 
only DNA-binding sequences among the 96 UL42 peptides? Did they represent 
DNA-binding regions of the protein?
Screening of all the UL42 peptides for DNA-binding in a gel mobility shift assay 
(Results 7.2) showed that 26 out of the 96 peptides exhibited a detectable level of 
binding to a radiolabelled oligonucleotide (Table 8). It is evident that the majority of 
peptides that bind to DNA are positively-charged: out of the 26 DNA-binding 
peptides, 22 are positively charged. The segregation of the 96 UL42 pepides into 
basic, acidic and uncharged, and the number in each category that bind to DNA is as 
follows:
Almost 50% of all the basic peptides, less than 20% of the uncharged peptides and 
less than 3% of the acidic peptides have DNA-binding properties detectable by this 
method. Therefore the peptides almost certainly bind to DNA predominantly by 
means of electrostatic interactions between basic amino acid side-chains and the 
acidic phosphate groups of the sugar-phosphate backbone of the DNA. The only 
DNA-binding peptides containing no basic groups were peptides 46 and 47.
It is evident that there is a rather poor correlation between the relative DNA-binding 
strengths and the relative potency of polymerase inhibition by the peptides. Several 
possibilities might account for the discrepancy. First, this method of quantitating 
DNA-binding may be inappropriate for peptides. Second, the relative strengths of
Total
45
34
17
DNArMnding
Basic :
Acidic :
Uncharged :
22
1
3
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interaction of peptides with M13 DNA and with the test oligonucleotide may differ. 
Third, polymerase inhibition might involve a mechanism in addition to binding of the 
peptides to DNA. However, the single, double and triple substitution of acidic 
residues for polar residues in the sequence of peptide 47 (Results 7.4.2) showed that 
the presence of three acidic residues abbrogated both DNA-binding and polymerase 
inhibition. This adds weight to the argument that, in the case of peptide 47, the 
observed polymerase inhibition can be accounted for solely by the DNA-binding 
capacity of the peptide.
Some of the DNA-binding peptides — 55, 56 and 91 — were seen to enhance, 
rather than inhibit, polymerase activity in the original screen. Subtle differences in 
the way that peptides interact with DNA may determine whether they enhance, 
inhibit, or have little effect on polymerase activity. An enhancement of protein-DNA 
interactions by basic peptides has been observed: Bannister & Kouzarides (1992) 
report that the sequence-specific DNA-binding of a transcription factor in a gel 
mobility shift assay was enhanced by the addition of poly L-Lys or another basic 
peptide, but not by the addition of a neutral or acidic peptide. However, in contrast 
to the results presented here, they found that the two basic peptides did not 
themselves bind to DNA.
The limited data obtained by DNA precipitation (Results 7.5) suggest that this may 
be a better method than DNA mobility shift for assaying the DNA-binding properties 
of peptides. The precipitation assay may be more sensitive than the gel retardation 
assay, since the interaction of peptide 95 (charge =+1) with DNA is detectable by 
precipitation but not by gel retardation (Results 7.5). The prediction that an 
interaction of all basic peptides with DNA would be detectable by this method was 
not tested. The precipitation assay is also quicker to carry out and could be expected 
to give more accurate quantitation than the gel mobility shift assay. It would provide 
a simple way of screening peptides for DNA-binding before testing them for some 
other activity in a DNA-containing enzyme assay.
It is difficult to comment on the extent to which the DNA-binding peptides might 
represent DNA-binding regions of the UL42 protein. Considering the high 
proportion of DNA-binding peptides, and their distribution throughout the length of 
the protein, it seems improbable that they all represent portions of the UL42-DNA 
interface, although the tight but non-specific DNA-binding of UL42 would predict an 
extensive surface of interaction. The binding of overlapping peptides which differed 
in charge was seen to be determined by their charge, and by implication to be largely 
independent of sequence or other features. This is exemplified by peptides 33-36, 
the charge and binding properties of which are shown overleaf:
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Peptide Charge DNA-binding
33 + 1 yes
34 -1 no
35 4-1 yes
36 4-1 yes
However, it is also likely that many of the positively charged residues, particularly 
arginines, are to be found on the surface of the protein (Chothia, 1976) and may 
therefore contribute to its DNA-binding by electrostatic interactions.
6. Peptide 47
Throughout this study, peptide 47 generated a lot of interest: it was the most potent 
of the inhibitory peptides; peptides 47,48, 49 and 50 represented a region of UL42 
(residues 239-256) predicted to be a strongly amphipathic helix which might be 
involved in a coiled-coil hydrophobic interaction with the C-terminus of Pol (Digard 
et al, 1993a); its anomalous behaviour in reverse phase chromatography suggested 
unusual structural or binding properties; it stood out among the DNA-binding 
peptides because it formed a more discrete complex than any of the others, and it was 
the only peptide containing no charged residues which bound to DNA. These 
considerations suggested that it might represent a major DNA-binding region of 
UL42. The experiments described in Results 7.4 were carried out to test this 
possibility.
Attempts to identify the minimum binding region were frustrated by the insolubility 
of peptides truncated by more than two residues at either the N- or the C-terminus. 
To test the idea that the polar residues in the sequence TQVQILSNAL (residues 234- 
243, represented in both peptides 47 and 48) might be be involved in interactions 
with DNA, the glutamine and asparagine residues were substituted singly and in 
combination. Substitution by alanine residues resulted in insoluble peptides which 
could not be tested. Substitution of glutamine by glutamic acid and of asparagine by 
aspartic acid resulted in a progressive loss of DNA-binding (Table 9). Peptide 371A 
(STSTEVEILSNAL), containing two acidic residues, still bound detectably to DNA, 
whereas peptide 37 IB (STSTEVEILSDAL), containing three acidic residues, 
showed no evidence of binding (Figure 31 and Table 9). However, since the loss of 
binding is almost certainly caused by a general electrostatic repulsion between the 
peptide and the oligonucleotide, it is highly probable that substituting any other
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residues in the peptide sequence by acidic residues would have produced similar 
effects.
In some cases, the DNA-binding properties of a peptide may be determined solely by 
its amino acid composition. A comparison of the binding characteristics of a 44- 
residue peptide corresponding to an RNA-binding domain of the yeast poly(A) 
binding protein, and of peptides with randomised sequences but the same amino acid 
composition, showed that the randomised peptides retained the binding properties of 
the peptide with the natural sequence (Nadler et al 1992a, 1992b). These 
observations prompted an experiment to investigate the relative importance of amino 
acid sequence and Composition in determining the DNA-binding properties of peptide 
47/301. The scrambled peptide (372) bound to DNA almost as efficiently as the 
native sequence (Figure 31 and Table 9). Unfortunately, the HPLC-purified 
preparation of peptide 372 was found by FAB-MS analysis to contain several species 
of different Mrs. These are almost certainly deletion peptides, resulting from the 
incomplete coupling of several residues during the synthesis of this peptide. A firm 
conclusion cannot therefore be drawn from this experiment, but it gives a preliminary 
indication that the sequence of peptide 301/47 is immaterial and that the observed 
DNA binding is entirely attributable to its amino acid composition. Such a 
conclusion would not rule out the possibility of residues 234-243 of UL42 playing a 
role in the DNA-binding of the protein. A similar scrambled sequence containing the 
15 amino acid residues of peptide 47 was synthesised, but was found to be very 
poorly soluble, and so the experiment to confirm this conclusion was not repeated.
An investigation of the DNA-binding properties of a UL42 mutant protein with 
residues 234-243 deleted or altered should determine whether this epitope constitutes 
a major DNA-binding determinant. This experiment has not been done, but 
sequences immediately adjacent to this epitope have been mutated: neither the 
deletion of residues 242-250, nor the replacement of A2 4 2  by a 5-amino acid 
insertion, had any effect on the DNA- or Pol-binding properties of UL42 (Digard et 
al, 1993b).
7. Pol C-terminal peptides
As the experiments described in this thesis were nearing completion, evidence 
became available to us that the extreme C-terminus of Pol is crucial for the interaction 
with UL42 (Digard et al, 1993a; Stow, 1993; see Introduction, 4.4.4). The 
prediction that peptides from this region of Pol could inhibit the interaction had been
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tested in a preliminary experiment, which showed that a peptide corresponding to 
residues 1194-1223 of Pol inhibited processive synthesis by Pol-UL42 (Don Coen, 
personal communication). To further investigate this finding, two peptides were 
synthesised and tested (Figure 33a and b). Peptide 384 (residues 1209-1235) 
corresponded to the residues deleted by Nigel Stow, and peptide 386 (residues 
1194-1223) to the peptide found by Don Coen to be inhibitory. Tested at a 
concentration of 200jxM, the peptides had no detectable effect on Pol-UL42 
processivity (Figure 33b). This result is at variance with that communicated by 
Coen.
On the evidence of the available data, there are several alternative possible 
interpretations of the lack of inhibition by the Pol C-terminal peptides:
(i) If the extreme C-terminal -30 residues of Pol are an essential component of the 
Pol-UL42 interface (Digard et al, 1993a; Stow, 1993), then the lack of 
inhibition by the Pol peptides indicates that the nature of the Pol-UL42 
interaction is such that it cannot be disrupted by a peptide corresponding to the 
region of interaction on one of the proteins.
(ii) The lack of inhibition by the Pol peptides is consistent with the finding of 
Tenney et al (1993) — published after the completion of the experiments 
described here — that the C-terminal 40 residues of Pol may not be essential for 
the interaction of Pol and UL42 (Introduction 4.4.4).
(iii) Some of the data from the mutagenesis studies suggest that the physical 
interaction of Pol and UL42 may not be essential for their functional interaction. 
A mutant Pol with a four-amino-acid insertion at residue 1216 is not co- 
immunoprecipitated with UL42, but it is fully functional in vivo, as tested by its 
ability to complement a pol null mutant (Digard et al, 1993a). Similarly, deletion 
of the C-terminal 40 residues of Pol results in a mutant protein which cannot be 
co-immunoprecipitated with UL42, but which can be stimulated by UL42 to the 
same extent as the full-length protein, as tested by its activity on an activated 
DNA template (Tenney et al, 1993). The lack of inhibition by the Pol peptides is 
consistent with this idea.
Whilst inhibition of UL42-stimulated processivity would have provided further 
evidence that the extreme C-terminus of Pol interacts with UL42, the observed lack 
of inhibition by the Pol peptides does not contribute to resolving the controversy 
over the Pol-UL42 interface.
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8. Strength of complex formation
A clearer understanding of whether it is possible to disrupt the Pol-UL42 complex 
requires not only the identification of the regions of the proteins involved in the 
interaction, but also the determination of the strength of that interaction. When 
equimolar amounts of purified Pol and UL42 proteins were co-incubated for 1 hour 
at 37°C and then subjected to gel filtration chromatography, all of the protein was 
eluted in the form of the heterodimeric complex, which is indicative of a strong 
interaction (John Gottlieb, personal communication).
E. coli ribonucleotide reductase (RR), like the HSV RR, is disrupted by peptides 
corresponding to the C-terminal 19 or more amino acid residues of the small subunit 
(R2) (Climent et al, 1991). The intrinsic dissociation constant, for a single 
molecule of R2 binding to R1 is 13p.M , and the inhibition constant, Ki, for a 30- 
residue peptide is 15-18|iM, suggesting that no other parts of R2 contribute to its 
binding to R1 (Climent et al, 1992). Moreover, it is believed that the C-terminus of 
R2 is a rather flexible region, since it could not be resolved by X-ray crystallography 
(Nordlund et al, 1990), and this suggests that it could be effectively mimicked by an 
inherently flexible peptide. A Kd of 13|iM does not indicate a very strong 
association between the subunits — very strong complexes are considered to have 
Kd values below 10_7M (Suelter, 1985). The overall binding affinity of R1 for R2 is 
increased to 0.18|iM (Climent et al, 1992) by the dimeric nature of the subunits. It 
may be, therefore, that the characteristics of the RR subunit interface render it 
particularly susceptible to this type of inhibition by subunit dissociation.
It is interesting in this regard that the Pol-UL42 interface is also proposed to consist 
of the C-terminus of one of the proteins, since protein termini are often more flexible 
than internal sequences (Karplus-Schulz, 1985). However, one would predict that if 
the affinity of Pol and UL42 were orders of magnitude greater than that of R1 and 
R2, then the Pol-UL42 complex would not be susceptible to a similar dissociation.
9. Future work
Consideration of some of the questions outlined above, and of the difficulties of 
unambiguously interpreting results obtained using co-immunoprecipitation, identifies 
the need for a more quantitative method of detecting the physical association between 
Pol and UL42. Relatively large amounts of both Pol and UL42 proteins are now 
available, prepared by Mary Murphy, from insect cells infected with recombinant 
baculovirus vectors (Stow, 1992). This has allowed the development of an enzyme-
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linked immunosorbent assay (ELISA): Pol protein is bound to the plastic surface of 
a microtitre well; after removal of the unbound protein and blocking of unoccupied 
sites on the plastic, UL42 is added; this is followed by a UL42-specific MAb, 
Z1F11, which in turn is bound by protein A coupled to horseradish peroxidase 
(HRP); finally, the addition of a colorimetric substrate allows the quantitative 
detection of the bound HRP. The MAb Z1F11 (Schenk et al, 1988) reacts with an 
epitope of UL42 (residues 363-369) which is not required for its interaction with Pol 
(Murphy et al, 1989; Digard et al, 1993b; Introduction 4.4.4), and therefore would 
not interfere with Pol-UL42 complex formation.
Such an assay can be used to answer the following types of questions, which would 
advance the understanding of the Pol-UL42 interaction and of its potential as an 
antiviral target:
How is the Pol-UL42 interaction affected by the presence of DNA?
Is the affinity of Pol and UL42 increased by the formation of a ternary complex
with the DNA template-primer?
Can any of the UL42 peptides disrupt the physical association of Pol and
UL42?
Which C-terminal sequences of Pol are involved in the interaction with UL42?
This last question can be addressed by testing in the ELISA
(i) whether C-terminally truncated Pol proteins can form a complex with UL42;
(ii) whether peptides covering a more extensive region of the Pol C-terminus 
are able to disrupt the Pol-UL42 interaction;
(iii) whether antisera raised against Pol C-terminal sequences are able to disrupt 
the Pol-UL42 interaction.
What are the relative strengths of interaction with UL42 of full-length and of
C-terminally truncated Pol?
Given the existing evidence for the involvement of the C-terminus of Pol in the 
interaction with UL42, another line of investigation would be to chemically cross­
link the Pol C-terminal peptides to the UL42 protein and thus attempt to identify the 
regions of UL42 which contribute to the interface.
Many of the interactions that are likely to exist between the replication proteins of 
HSV-1 have yet to be identified and characterised. The interaction between Pol and 
UL42 has been studied more extensively than any other interactions between the 
seven essential replication proteins. The cloning and heterologous expression of 
UL5, UL8, UL9, UL29 and UL52 (Stow, 1992), allows their purification in 
relatively large amounts, and the production of reagents — MAbs and polyclonal 
antibodies of high specificity — essential for investigating their interactions.
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A library of random peptide sequences, generated using the fusion phage system 
(Parmley & Smith, 1988), could be screened for sequences which disrupt protein 
interactions. The R1-R2 interaction would provide a suitable model system for 
subsequent investigation of interactions between replication proteins. Such an 
approach, however, may identify inhibitory sequences unrelated to the sequence of 
the ligand under investigation (Scott & Smith, 1990; Christian et al, 1992).
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